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General introduction
General introduction
“It is the common wonder of all men, how among so many millions of faces, there 
should be none alike,” wrote Sir Thomas Browne in Religio Medici published in 1643. 
Ever since, people have been intrigued by the development of the human head and 
face and its biodiversity. Nowadays, we know that both nurture and nature, like cellular 
and molecular pathways, play a key role in this craniofacial development. If the cellular 
and/or molecular pathways are disturbed by gene mutations and/or teratogens during 
the embryonic period, a malformation can occur.1 The term malformation is derived 
from the Latin words malus meaning “bad” or “wretched,” and formare meaning “to form, 
to shape.”1
The aim of this thesis is to explore the genetic alterations that cause craniofacial 
malformations.
14845-goos-layout.indd   13 13/11/2017   19:20
14
Chapter 1
Craniofacial malformations
Craniofacial malformations can be subdivided in craniosynostosis, craniofacial clefts 
and facial dysostosis. 
Craniosynostosis occurs in 1:2,100-2,500 live births,2-4 and the prevalence is 
reported to be rising.5 It is characterized by the premature fusion of calvarial sutures. 
This fusion restricts the normal growth of the skull, brain and face (Figure 1.1). Therefore, 
surgical correction is often needed within the first year of life.6 Craniosynostosis can 
occur isolated, without any additional anomalies, or as part of a syndrome often caused 
by a genetic alteration. A genetic cause is implied if coronal or multiple suture synostosis 
is observed, if a patient shows symptoms of growth or developmental retardation, and/
or if a patient shows other congenital anomalies. 
Figure 1.1. Craniosynostosis. From left to right: normal calvarial sutures; sagittal suture synostosis 
leading to a scaphocephalic head shape; metopic suture synostosis leading to a trigonocephaly; 
left coronal suture synostosis leading to left-sided plagiocephaly; bicoronal suture synostosis 
leading to a brachycephalic head shape and right lambdoid suture synostosis leading to left-
sided occipital plagiocephaly.
Craniofacial clefts are very rare, they occur in approximately 1 per 400,000 births.7 
Just like in clefts of the lip and palate (CLP), a fusion defect occurs of various embryologic 
facial prominences that frequently manifests as an epithelially lined fissure. Also, 
these craniofacial clefts can occur due to failure of mesodermal penetration or due to 
disturbances of outgrowth of bone centres (for example in the mandible).8 However, in 
contrast to CLP, all facial parts and all tissues of the face can be affected in craniofacial 
clefts. The severity of the malformation differs, depending on the involved facial 
structures and the extend of the cleft. Often, the classifications of Tessier9 and Van der 
Meulen10 are used to describe the cleft (Figure 1.2). A genetic cause is implied if the cleft 
occurs in the midline and -just like in craniosynostosis- if a patient shows symptoms 
of growth or developmental retardation, and/or if a patient shows other congenital 
anomalies.
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Figure 1.2. Tessier classification. Every line indicates one of the possible craniofacial clefts 
(Journal of Maxillofacial Surgery 1976). 
The incidence of facial dysostosis ranges from 1 per 50,000 live births for Treacher 
Collins syndrome11 to for example 3 per 1,000,000 for Nager syndrome in Finland.12 
Facial dysostoses are caused by underdevelopment of the structures derived from 
the first and second pharyngeal arches leading to malar and mandibular hypoplasia, 
dysplastic ears and eyelids, hearing loss and cleft palate.11 A subdivision can be made 
into mandibulofacial dysostosis (without limb anomalies), and acrofacial dysostosis 
(with limb anomalies).11 These disorders can be further subdivided in many subtypes. A 
genetic cause is identified in many of these subtypes.  
The anatomy of the human head 
As discussed previously, in case of a craniofacial malformation, the normal anatomy of 
the head is disrupted. As one might say that the head is the most complex structure of 
the body,13 the normal anatomy will be described first.   
The human skull can be subdivided in two major parts: 
1. the viscerocranium (or splanchnocranium). This is phylogenetically the oldest part of 
the head, representing the skeleton of the face, surrounding the oral cavity, the pharynx 
and the upper respiratory system. And 2. the neurocranium, surrounding the brain. The 
neurocranium, can be divided in two as well: a. the chondrocranium (or cranial base) 
and b. the dermatocranium (or cranial vault).14
The cranial vault consists of five principal bones (the paired frontals, paired 
parietals and the unpaired occipital).14 Between the cranial bones, fibrous joints are 
found consisting of mesenchymal cells, that are called sutures.14 Hence, there are six 
primary sutures: the paired coronal and paired lambdoid sutures, and a single metopic 
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and sagittal suture.14,15 The sutures allow temporary deformation and compression 
during partition, and serve as growth sites during development.16 If one of these sutures 
is fused prematurely, it is regarded as craniosynostosis.
The cranial base consists of eight paired cartilages on the ventral surface of the 
brain forming three fossa in which the brain rests. Cartilaginous joints are located 
between some of the bones, called synchondroses. These synchondroses are important 
growth centres of the craniofacial skeleton.14 
The viscerocranium consists of several bones: two inferior nasal conchae, two 
lacrimal bones, one mandible, two maxillae, two nasal bones, two palatine bones, one 
vomer and two zygomatic bones.14 Sometimes, the hyoid bone, the ethmoid bone 
and the sphenoid bone are also considered as part of the viscerocranium. As in the 
cranial vault, sutures are located between the bones of the face.14 Disrupted fusion and 
outgrowth of progenitors of the facial bones play a key role in the development of facial 
clefts.
Embryology of the head and face
To understand the development of craniofacial malformations, it is essential to 
understand the development of the face and skull. This development begins early in 
embryonic life and continues until adolescence.17 
Development of the embryo
It all starts with fertilization; a sperm and egg cell fuse and their pronuclei subsequently 
fuse to form a zygote.17,18 The zygote divides with a cleavage division of one per day. 
Reaching the morula stage (16 cells) at day three and a stage of compaction at day 
4.17 During this process, the embryonic genome becomes activated.17,18 Then cavitation 
occurs; a blastocoel forms within the embryo. The embryo becomes a blastocyst with 
an inner cell mass, which will form the body of the embryo, and a trophoblast, the outer 
epithelial layer.17 Just before implantation in the endometrium of the uterus (day 6/7), 
the cells of the inner cell mass become arranged in an epithelial configuration.17 The 
main upper (dorsal) layer of cells is known as the epiblast and the lower (ventral) layer is 
called the hypoblast or primitive endoderm, leading to a bilaminar disk.17 Gastrulation 
starts at the beginning of the third week. During gastrulation a primitive streak is formed 
in the epiblast at the caudal end of the bilaminar embryo.17 Cells migrating through 
the primitive streak form the mesoderm and endoderm, and the remaining epiblast 
becomes ectoderm.17 At the anterior end of the primitive streak, the primitive node is 
formed, that eventually will give rise to the notochord.17 Cranial to the notochord the 
oropharyngeal membrane comes into existence.17 The primitive streak and notochord 
act as the primary inductors of the nervous system. The neural plate is formed and, after 
14845-goos-layout.indd   16 13/11/2017   19:20
17
General introduction
further shaping, neurulation occurs;17 the neural plate is folded laterally to form a neural 
groove.17 Opposing sides of the thickened epithelium of the neural groove fuse to form 
the neural tube that will give rise to the brain.17 
Development of the face
The development of the face occurs predominantly during the 5th and 8th week of 
development.14 
Very early, the brain is the dominant component of the craniofacial region.17 
Beneath the brain, the face is represented by the stomodeum, the primitive mouth.14,17 
The stomodeum is sealed off from the primitive gut by the oropharyngeal membrane, 
which breaks down by the end of the first embryonic month.17 At week four of 
gestation, the facial development is centred around the stomodeum.14,17,19 Surrounding 
the stomodeum, several prominences constitute the building blocks of the face: the 
unpaired frontonasal prominence in the rostral midline, the paired maxillary (more 
rostrally) and the paired mandibular processes (more caudally) originating from the first 
pharyngeal arch.14,17,19 
On either side of the frontonasal prominence, nasal placodes develop into 
horseshoe-shaped structures, each consisting of a nasomedial process and a nasolateral 
process.17 Subsequently, nasal pits begin to form that deepen until they break through 
into the oral cavity.14 
The mandibular and maxillary processes fuse. Subsequently, the maxillary processes 
fuse to the nasomedial processes to form the upper lip and jaw.14,17 The region of fusion 
of the nasomedial and maxillary processes is marked by an epithelial seam, the nasal 
fin that will form the nasolacrimal duct and lacrimal sac.14,17 The maxillary processes 
contribute to the maxilla (upper jaw), sides of the face and lips and the secondary 
palate.14,20 
The frontonasal prominence is displaced cranially, contributing to the forehead, 
bridge of the nose, primary palate, philtrum and upper lip.14,17,20 The nasomedial 
processes merge in the midline forming the intermaxillary segment, which gives rise to 
the philtrum of the lip, the premaxillary component of the upper jaw and the primary 
palate, the tip and crest of the nose, and a part of the nasal septum.14,17 The nasolateral 
processes form the alae of the nose.14,20 
The mandibular prominences form the mandible (lower jaw), including the caudal 
parts of the cheeks, the lower lip and chin.17,20 
When the basic facial structures take shape, they are invaded by cells associated 
with the first and second pharyngeal arches, that form several facial muscles.14 The 
remaining three pharyngeal arches produce small bones and cartilages of the ear and 
pharyngeal apparatus. 11,14 
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Development of the skull
The development of the skull starts between day 23 and 26 of human embryological 
development, when ossification centres destined to become bones of the cranial vault 
begin to form.21
Bones can develop either via endochondral ossification or intramembranous 
ossification. In endochondral ossification, chondroblasts form a cartilaginous model that 
is converted into bone by osteoblasts.14,15,22 Intramembranous ossification, on the other 
hand, occurs when bone is formed directly without passing through a cartilaginous 
stage.14,15,23
The bones of the cranial base, that underlie the brain, are formed via endochondral 
ossification.14 The synchondroses serve as important growth sites.14 
The majority of the bones of the facial skeleton (e.g. nasals, maxillae, premaxillae, 
zygomatic, mandible) and all cranial vault bones (e.g. frontal, parietal, and squamous 
temporal) are primarily formed by intramembranous ossification.14 The bones begin as 
ossification centres (a single ossification centre in, for example, the zygoma, and two 
or more ossification centres in the cranial vault bones). The ossification centres of the 
cranial vault fuse and growth occurs at the sutures from the edges of two opposing 
bones.16,24,25 Studies have shown that the expanding brain and dura mater play an 
important role in this growth.15,26-28 In humans, the biggest growth occurs in the first 
two years of life. At the age of seven, the growth of the neurocranium stops almost 
completely while the bones of the facial skeleton grow throughout puberty.14
Origin of cells
The tissues of the vertebrate head and face are derived from endoderm, mesoderm, 
ectoderm and cranial neural crest cells.19 The mesoderm and neural crest contribute to the 
facial mesenchyme.19  The mesodermal component gives rise to the voluntary muscles 
and endothelial cells while the neural crest-derived mesenchyme forms the majority of 
the facial skeleton.19,29,30 The pharyngeal arches are consisting of an outer ectodermal 
layer and an inner endodermal layer. In between these two layers are mesodermal cores 
which are initially surrounded by neural crest-derived mesenchyme19,31-35 The cranial 
vault has a mixed origin. In mice and presumably in humans as well, the frontal bone is 
formed from neural crest, the parietal bones are formed by mesoderm.19,29,30 The sutures 
contain mesenchymal stem cells36 and in the coronal sutures these stem cells originate 
from cephalic paraxial mesoderm.37 The cranial base is also mixed; the anterior cranial 
base is largely derived from neural crest, while the posterior cranial base is formed by 
paraxial mesoderm.19,38-40  
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It was the best of times, it was the worst of times, it was the 
age of foolishness, it was the epoch of belief: deoxyribonucleic 
acid41
Deoxyribonucleic acid (or DNA) codes for the information that is needed to synthesize 
proteins. The way the information is coded in DNA is extremely clever; 1. it is very 
densely stored, 2. it is three-dimensionally stored, and 3. it often remains readable 
over millennia.42-44 These remarkable characteristics of DNA have led to more and more 
research concerning data storage in DNA. Now, one can store the opening sentence of 
“A Tale of Two Cities” 41 (and the header of this chapter) and even an entire book in DNA.44 
DNA exists of two polymers of nucleotides.45 Nucleotides exist from deoxyribose 
(a sugar with five C-atoms), a nitrogenous base (attached to C1’ of the sugar) and a 
phosphate group (attached to C5’).45 The nucleotides bind via phosphodiester bonds, 
forming a polynucleotide.45 The nitrogenous bases of two polynucleotide strands bind 
by hydrogen bonds and Van der Waals forces.45 Adenine binds to Thymine (two hydrogen 
bonds) and Guanine binds to Cytosine (three hydrogen bonds). This phenomenon is 
called base pairing.18,45 The two connected polynucleotide strands are coiled around a 
common axis and form a double helix.45 These double helices are wind around histones 
and non-histone proteins, forming the nucleosome.45 Without the nucleosome the DNA 
would be too long to fit in the nucleus.45 
In the nucleus the DNA is organized into chromosomes. Humans have 22 pairs of 
autosomal chromosomes and one pair of sex chromosomes (XX for females or XY for 
males).18 From each pair of chromosomes, in principle, one chromosome is inherited 
from the mother and one from the father.45 
Mitochondria
Besides the DNA in the nucleus (called genomic DNA), there is also DNA present in the 
mitochondria (called mitochondrial DNA). These organelles are located in the cytoplasm 
of the cell. The mitochondrial DNA codes for only 37 genes and is usually inherited 
completely from the mother.46 
Coding DNA
The genomic DNA of humans comprises of approximately 3.2 billion base pairs.45 
Specific segments of the genome, called genes, contain the information for proteins.18,45 
Less than 5% of the 3.2 billion base pairs give rise to genes. People used to consider the 
remaining base pairs as “junk DNA”.18 However, more and more we start to learn that this 
so-called junk DNA encodes regulatory elements.47,48
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Most genes contain regions coding for proteins, called exons. In most genes, these 
exons are interrupted by noncoding regions, called introns.18 Two consecutive processes 
are used to convert the coding information of the exons into proteins. First, the protein 
RNA polymerase starts at the transcription start site (5’ of the gene) to transcribe the 
gene resulting in an unstable heteronuclear RNA.18,45 RNA processing takes place and 
the introns are removed by splicing.45 Single-stranded messenger RNA (mRNA) moves 
out of the nucleus to the ribosomes. The ribosomes translate the mRNA into proteins, 
linking various amino acids via multiple steps.18,45 Three nucleotides (=one triplet) 
encode one amino acid. In human proteins, 20 different amino acids are used to build 
the proteins from the messenger RNA molecules.18,45 
Splice sites
Within the intron, a donor site (5’end of the intron) and an acceptor site (3’end of the 
intron) are required for splicing. Comparison of many genes resulted in the observation 
that there is a consensus sequence around the splice donor (-gt) and splice acceptor 
site (ag-).49,50 Mutations in the consensus sequence can lead to extension of the exon, 
exon skipping, or retaining of (part of ) the intron when the splice site becomes useless 
or a cryptic splice site is being preferred. Cryptic splice sites are sites in the genome that 
contain the consensus sequence, but are normally not used as a splice site or are used 
only at a low frequency.51 Also, alternative splicing is seen, which means that the same 
gene can be spliced in several ways resulting in different proteins. 
Expression
In principle, all cells from an organism contain the same DNA coding information. 
However, each cell type shows its own protein expression pattern which can also vary in 
time of development (an osteoblast expresses different proteins than a cell of the skin, 
and the osteoblast expresses different proteins in early embryological stages than later 
in life). Several factors, like transcription factors or external signals, play a key-role in this 
expression pattern.18,45
Mitosis
Most eukaryotic cells are diploid.18 Which means that a nucleus contains two copies 
of each chromosome.18 Before a cell can divide into two new cells, the DNA must be 
replicated resulting in two identical replicas of the original DNA.18,45 Several control 
mechanisms, like proofreading and mismatch repair, prevent and/or correct mistakes. 
This all happens in the Synthesis phase (S) of the cell cycle, consisting of a prophase, 
metaphase, anaphase and telophase.18 In the Mitotic phase (M), the nucleus divides and 
the cell splits in two.45 Hence, the replicated chromosomes separate, with each daughter 
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cell getting a copy of each chromosome during cell division.18 The S and M phase are 
separated by a G1 and G2 phase, in which mRNA and proteins are synthesized and the 
cell grows.18,45   
Meiosis
Meiosis is a special type of cell division forming germ cells (sperm or egg cells).45 
It comprises of two rounds, each round containing a prophase, a metaphase, an 
anaphase and a telophase.18 Meiosis I separates homologous chromosomes.18,45 Meiosis 
II separates sister chromatids. Leading to the formation of 4 haploid germ cells.18,45 The 
four germ cells are genetically different from each other and from the parental cell, due 
to recombination. Fusion with a germ cell of another individual generates a diploid 
zygote.18,45
What if it goes wrong: heritable diseases
During meiosis, chromosome pairs are divided over daughter cells. Although the 
chromosomes appear alike under the microscope, they may be slightly different 
at specific base pairs (alleles).18 This variation can cause heritable traits leading to a 
specific phenotype. Hence, the genotype is the genetic information that an individual 
carries, the phenotype is any characteristic of an organism caused by the genotype and 
environmental factors.45,52,53 
Variation 
Approximately 3,000,000 nucleotides per genome differ from the reference genome, 
at least 20,000 of these differences are located within the coding regions.53,54 These 
variants can be common, present in more than 1% of the population, or rare, occurring 
in less than 1% of the population. 
Variants can exist of substitutions meaning that a certain nucleotide is changed 
into one of the other nucleotides.18 If this change is common it is also called a Single 
Nucleotide Polymorphism (SNP), and if it is a rare change, theoretically, it’s called a Single 
Nucleotide Variant (SNV).53 However, this terminology is often used interchangeably. 
SNPs are the most common cause of genetic variation.53,55 If the variant leads to a 
substitution of the encoded amino acid into another amino acid, it is called a missense 
mutation. If it leads to a premature stop-codon, it is called a nonsense mutation.18  
A nucleotide can also be deleted or inserted.18 These small “indels” are the second 
most common cause of genetic variation.53,56 If an indel is not a multiple of 3 bp in 
length it can cause a shift of the reading frame (frameshift)57 leading to the possible 
introduction of a stop codon or nonsense mediated decay.18 Nonsense mutations and 
indels combined are called truncating mutations. 
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Variants that do not alter the encoded amino acid are called synonymous variants.53 
Occasionally, these synonymous changes alter transcription because a cryptic splice 
site is created and this phenomenon can result in a non-functional protein. A good 
example of this phenomenon has been described for a synonymous sequence change 
in FGFR2. Using RNA analysis it was shown that the synonymous sequence change was 
a pathogenic mutation, confirming the diagnosis.58 
Besides of the small indels, deletions and insertions can also occur on a much larger 
scale.57 These large variants are called Copy Number Variation (CNV).53 Also, structural 
variants can occur, like inversions and translocations.53 
Inheritance
The current theory concerning the classical division of heritable traits was initially 
postulated by George Mendel. However, more and more traits are identified that are 
not inherited in accordance to these so-called Mendelian inheritance patterns. The 
following inheritance patterns are known:
Autosomal dominant
Inheritance of one affected allele can cause a certain trait. Usually one of the parents is 
affected. An autosomal dominant disorder can affect and be transmitted by both males 
and females. There’s a 50% chance to transmit the trait to the next generation. Many 
of the craniosynostosis-syndromes show an autosomal dominant inheritance pattern.46 
Non-penetrance and clinical variability can play a key role in the presentation of these 
diseases. Reduced penetrance means that a person carries a mutation without showing 
any signs of the disease46 (this is the case in for example TCF12-related craniosynostosis; 
many of the parents do not suffer from craniosynostosis although they do carry the 
mutation).59  Variability means that people with the same mutation have a varying 
severity of the disease46 (in for example families with Crouzon syndrome the expression 
of the disease can vary from exorbitism in one member, to severe pansynostosis with 
increased intracranial pressure in the other). 
Autosomal recessive
Both alleles, so both the paternal and the maternal allele, need to carry a pathogenic 
mutation to cause the disease.46 This can be a. homozygous recessive: the alleles 
are exactly the same, as is seen in IL11RA-related craniosynostosis60 or b. compound 
heterozygous: the alleles are different, like in Burn-McKeown syndrome61 or Carpenter 
Syndrome.62 Usually parents are asymptomatic carriers. It can affect and be transmitted 
by all sex. There is a 25% risk that a subsequent child is affected.46
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X-linked dominant
The inherited trait is located on the X-chromosome and causes a disease in males 
and in females. Females are usually more mildly affected compared to males due to X 
inactivation. A female carrier of the pathogenic mutation has a 50% chance to transmit 
the trait. In case of an affected male, all his daughters but none of his sons will be carrier 
of the pathogenic mutation.46 A remarkable example of an X-linked dominant disorder 
is craniofrontonasal syndrome. This syndrome is caused by pathogenic mutations in 
EFNB1, located on the X-chromosome. In contrast with the expected, females are more 
severely affected than males, due to cellular interference.63  
X-linked recessive
The inherited trait is located on the X-chromosome and pathogenic mutations in these 
X-linked genes will result in a phenotype in carrier males (who are hemizygous, meaning 
that they have only one X chromosome with the pathogenic mutation) and in a female 
who is homozygous for the pathogenic mutation, or in case of skewed X-inactivation. 
The mother is usually an asymptomatic carrier.46 
Y-linked
The trait is located on the Y-chromosome. So, only males can be affected. All sons of an 
affected father are affected.46 
Mitochondrial
Mitochondrial DNA is transmitted solely by the ovum. Therefore, mutations in this DNA 
are only transmitted from mother to child. All sexes can be affected.46 
Parental imprinting
One of the copies of a gene is silenced or “switched off”. This is a normal phenomenon. 
But if a variant is located on the other allele (which is “on”), a trait can occur.46  This is seen 
in Prader-Willi and Angelman syndrome.64
Mosaicism
The mutation is not present in all cell types. For example, a mutation can be present 
in buccal cells, but not in blood cells. Therefore, a mutation can be easily missed, since 
DNA diagnostic testing is often performed on DNA derived from blood.46 An example of 
mosaicism is described in ZIC1-related craniosynostosis.65
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Chromosomal abnormalities: 
- Numerical: an abnormal number of chromosomes can occur. Well-known is trisomy 
21 causing Down syndrome. Trisomy 18 (Edwards syndrome) and trisomy 13 (Patau 
syndrome) occur less frequently. 
- Structural abnormalities vary from deletions (part of the chromosome is missing), 
duplications (part of the chromosome is duplicated), inversions (part of the 
chromosome is inverted), insertions (part of the chromosome is inserted in another 
chromosome), rings (part of the chromosome is forming a ring structure) and 
translocations (parts of two chromosomes are rearranged; exchanging material 
from one chromosome to another). Structural abnormalities can be balanced, 
which means that  the normal amount of chromosomal material is present in a 
germ cell, or unbalanced, resulting in one germ cell having extra chromosomal 
material, while the other one is missing chromosomal material.18,46 
Complex
A certain trait is caused by a combination of multiple different variants at different 
locations.
De novo mutations
Mutations can be inherited, but can also occur de novo, which means that the mutation 
is not present in one of the parents, but has arisen in the proband during meiosis. Note 
that germline mosaicism cannot be excluded. The de novo mutation rate is estimated 
between 1x10-8 and 3x10-8 per base per generation,66-71 corresponding to approximately 
74 novel SNVs per genome per generation,72 the indel mutation rate has been estimated 
to be approximately 4x10-10 per position (3 novel indels per genome per generation),73 
CNVs larger than 100kb are estimated to occur de novo in approximately one out of 
every 50 individuals.72,74 The mutation rates have been shown to vary throughout 
the genome,68,75 across families,67,68,70 and to depend on paternal age.67,76 If a de novo 
mutation occurs, the risk of a second child with the same mutation is very low, in the 
affected child, however, it will act exactly the same as an inherited mutation. 
Examining the DNA
There are more than 2,500 human genes described that cause a disease if a mutation is 
present.77 Over the years, different molecular techniques have been developed to study 
the genetic causes of heritable diseases.
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Karyotyping
Karyotyping is one of the oldest tools to identify chromosomal aberrations. The 
techniques stains chromosomes in metaphase which are then analysed using light 
microscopy. So cells have to be cultured to obtain an adequate number of dividing cells 
in metaphase. With the development of chromosome banding techniques, a resolution 
of 5-10 Mb can be achieved.46 
Traditional sequencing
In 1977, two papers have been published that changed the world of genetic research.78 
Maxam and Gilbert and Sanger, Nicklen and Coulson described methods for DNA 
sequencing.78-80 Since the publication of these papers, the latter has been used 
extensively for research and diagnostic purposes.78 This dideoxy-sequencing or Sanger 
sequencing technique has also been used to generate the first data of the human 
genome in 2001.81,82 
The technique starts by annealing a primer to single stranded template DNA which 
is then amplified by Polymerase Chain Reaction (PCR).78 The 3’-OH end of the primer 
serves as the starting point for synthesis of a new DNA strand.78 A DNA polymerase 
catalyses the incorporation of dNTPs (dATP, dCTP, dGTP and dTTP) and ddNTPs (ddATP, 
ddCTP, ddGTP and ddTTP).78 If a ddNTP is incorporated, synthesis terminates.78 The 
reaction products are separated by size by subjecting them to polyacrylamide gel 
electrophoresis.78 The traditional dideoxy-sequencing method uses radioactive labelled 
dNTPs to visualize them (hence referred to as radioactive Sanger sequencing).78 The 
radioactive labels have been replaced by fluorophores, paving the way for automated 
DNA sequencing.78,83 Other developments that have contributed to the increased 
throughput of dideoxy sequencing are the use of a set of four chain-terminating 
ddNTPs carrying different fluorophore groups,84 thermal cycle sequencing85 and 
capillary sequencing, using capillary electrophoresis instead of polyacrylamide gel 
electrophoresis.78,86-88  
This method has become the gold standard for examining the DNA at the resolution 
of single nucleotides.53 It has the potential to detect all kinds of genomic variation 
in a single experiment. However, disadvantages are the low throughput,53 the use of 
synthetic primers and the possibility of false negative results due to SNPs underneath 
the primer.78
Fluorescent in situ hybridisation (FISH)
In 1982 a molecular cytogenetic technique has been developed in which fluorescently 
labelled DNA probes are hybridized to metaphase spreads or interphase nuclei 
enabling the detection of aneuploidy and chromosomal rearrangements using light 
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microscopy.78,89 Locus-specific probes can be applied to detect specific micro-deletion 
syndromes and sub-telomere region-specific probes have been developed to detect 
chromosomal imbalances at the telomeres. One of the limitations of FISH is the inability 
to detect small deletions.78
Microarray
In 1983 the first concepts of the microarray technique have been described.90 This 
technique can assay large amounts of biological material (DNA for example). It is based on 
measuring differences between fluorescent signals of patient DNA compared to control 
DNA.78 Patient and control DNA are labelled using fluorescent dyes and hybridized onto 
a microarray chip that contains a collection of microscopic spots of DNA sequences 
(Bacterial Artificial Chromosome clones or oligonucleotides).53,78 For each spot, the ratio 
of the fluorescent signals of patient and control DNA is measured.53,78 So, relative gains 
and/or losses of DNA can be detected.53,78,91,92 The oligonucleotide-based arrays have a 
resolution of 1 kb.93 Therefore, the microarray technique has replaced karyotyping for 
most implications. However, because a ratio is used, balanced genomic rearrangements 
such as inversions remain undetected94 and the location of additional copies on the 
genome remains unknown.53,78,95  
Multiplex ligation-dependent probe amplification (MLPA)
MLPA is a method by which up to 60 different sequences can be targeted in a single 
semi quantitative polymerase chain reaction-based assay.96,97 Each MLPA probe consists 
of two parts that can be ligated to each other when hybridized to a target sequence.98 
The two parts of the probe differ in length.98 The short part contains a target-specific 
sequence (21–30 nucleotides) at the 3’ end and a common 19 nucleotide sequence, 
identical to the labelled PCR primer, at the 5’  end.98 The long part contains a 25–43 
nucleotide target-specific sequence at the 5’ phosphorylated end, a 36 nucleotide 
sequence that contains the complement of the unlabelled PCR primer and is common 
to all probes at the 3’ end, and a stuffer sequence of variable length in between.98 It is 
only when the two parts of the probe are both hybridised to their target that they can be 
ligated into a single probe, containing both the forward and reverse primer sequence.97 
PCR amplification of the ligation products follows. Following the PCR, the resulting 
amplification products are separated by sequencing electrophoresis.97 An MLPA probe 
set is designed so that the length of each of its amplification products is unique.97 
Applications include the detection of exon deletions/duplications, detection of 
trisomies, characterisation of chromosomal aberrations, SNP and mutation detection; 
DNA methylation analysis and relative quantification of mRNA.97 The MLPA reaction 
is fast, relatively inexpensive, and easy to perform, and the equipment needed for 
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MLPA analysis is present in most molecular biology laboratories.96 Limitations are the 
sensitivity to contaminants, the complicated development of the probes, and the 
inability to investigate single cells or detect unknown point mutations.97 
Next generation sequencing
With the increasing need of sequencing complete genomes instead of single genes, 
new massive parallel sequencing techniques have been developed.78 This so-called 
next generation sequencing has the ability to sequence millions of DNA fragments in 
a highly parallel fashion, and the potential to detect all kinds of genomic variation in 
a single analysis.53,78 Different techniques have been developed. Well-known platforms 
are those of Roche (the “traditional” 454 pyrosequencing),99,100 Illumina HiSeq101,102 and 
Life Technologies (SOLiD and Ion Torrent semiconductor sequencing).78,103 Nowadays, 
these companies offer benchtop sequencers and revolutionary developments resulted 
in faster and cheaper equipment and chemistry. 
Currently, whole exome sequencing is mostly applied. This means that the complete 
coding region of the human genome is sequenced. But, with the improving throughput, 
whole genome sequencing is more and more applied, which means that both the 
coding regions and non-coding regions are sequenced. One of the leading companies 
that offers whole genome sequencing is Complete Genomics, a BGI Company. 
Whole genome sequencing
Since whole genome sequencing by Complete Genomics Inc., a BGI company (CGI) 
has been used in many of the studies described in this thesis, this technique will be 
explained in more detail. CGI uses a technique called sequencing by ligation to sequence 
the whole genome and the mitochondrial DNA at high coverage (≥80x) as described by 
Drmanac et al.104 
Genomic DNA (gDNA) is fragmented by type IIS restriction enzymes and directional 
adapters are inserted, resulting in circles of DNA.104 The circles are replicated with Phi529 
polymerase,105 leading to hundreds of tandem copies of single-stranded DNA.104 These 
long copies consolidate; they ball up to small particles of DNA that are referred to as 
DNA nanoballs.104 These DNA nanoballs are approximately 200 nanometres in diameter. 
They contain both genomic DNA sequence and adapter sequence. A genomic library 
(the collection of total genomic DNA from a single organism) contains millions of DNA 
nanoballs that together represent the complete genome. 
The DNA nanoballs are adsorbed to a silicon chip of 25 by 75 mm.104 The silicon is 
photolithographically etched (the same technique that is used in the semiconductor 
industry) to create a grid pattern of small spots of ~300 nm.104 One DNA nanoball sticks 
to one spot. When the silicon chip is filled with DNA nanoballs it is called a DNA nanoball 
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array. One array contains up to 180 billion bases of genomic DNA. The DNA array will 
now be sequenced. An anchor probe binds to the adapter sequence (still present in the 
DNA nanoball). A ligase enzyme then attaches one of four possible fluorescent-labelled 
probes to the anchor (corresponding to an A, T, C or a G), depending on the sequence 
being read in the fragment. By imaging the fluorescence during each ligation step, the 
sequence of nucleotides in each DNA nanoball can be determined. This technique is 
called combinatorial probe anchor ligation sequencing (cPAL).104
cPAL is based on unchained hybridisation and ligation technology.103,106,107 Via this 
technique, up to 10 bases adjacent to each of eight anchor sites can be read, resulting 
in a total of 31- to 35-base mate-paired reads (62 to 70 bases per DNA nanoball).104 After 
sequencing, the reads are mapped to a human genome reference and assembled as 
described by Carnevali et al.108 A custom software suite (SOM) employing both Bayesian 
and de Bruijn graph techniques is used for this purpose.104 For every genomic location 
it’s determined if there is a diploid reference, a variant or a no-call present.104 Detected 
variants include single nucleotide polymorphism (SNPs), indels, substitutions, copy 
number variants (CNVs, up to 50 bps), structural variants (SVs), and mobile element 
insertions (MEIs)(see also http://www.completegenomics.com/customer-support/).
Getting rid of the noise: filtering
By whole genome sequencing, a huge amount of data is generated; per patient sample 
1.9 Tb. Hence, storage and data management ask more and more attention, especially 
since the costs of data storage grow out of proportion. To identify the genetic cause of 
a certain trait (i.e. craniofacial malformations) in this “Big Data” also clever data analysis 
methods are needed. The variants need to be filtered in a structured approach. The 
approach used in many of the studies described in this thesis is described below. 
Inheritance pattern
First of all, the variants need to be present according to the correct inheritance pattern 
based on the family pedigree. 
If a proband is affected, but the parents of the proband are not affected, the following 
inheritance patterns are tested: de novo, dominant with reduced penetrance, recessive 
(both homozygous and compound heterozygous) or, in case of a male proband, 
X-linked. If a proband is affected, and one of the parents as well, the tested inheritance 
pattern is: dominant, and, if applicable, X-linked. If a proband is affected and the parents 
are consanguineous: homozygous recessive.
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Minor allele frequency
The patients in our cohort show craniofacial malformations, which are very rare. 
Therefore, one might expect that the genetic cause should be very rare as well. This 
assumption implies that variants should be discarded that occur in a public database 
and have a minor allele frequency of >1%. Databases that are used for filtering are 
dbSNPv37, the Wellderly cohort,109 Public60,110 ExAC,111 Exome Variant Server,112 Genome 
of the Netherlands (GoNL)70,76 and 1000 Genomes.113
Predicted effect of the variant
Looking at the remaining variants, the pathogenicity can be scored based on in silico 
prediction programs and conservation of the affected nucleotide and amino acid.
In silico prediction programs
In silico prediction programs try to discriminate between pathogenic and benign variants 
by predicting the deleteriousness of a nonsynonymous variant. This deleteriousness is 
based on the predicted effect of the variant on the sequence homology, the damage it 
may cause to the protein structure and function and on the evolutionary conservation. 
RNA in silico prediction programs are used to predict the effect on splicing (of both non-
synonymous and synonymous variants). Used programs are SIFT,114 Polyphen,115 LRT,116 
Mutation Taster,117 FATHMM,118 Radial SVM LR,119 VEST3120 and CADD raw/phred.121
Conservation
DNA sequences between different species are highly similar. For example, chimpanzees 
and humans share more than 98% of their DNA sequence.45,122,123 By comparing different 
species, many evolutionary conserved regions are identified both at DNA and protein 
level. That is, regions that are highly similar in a large amount of species. If a variant 
occurs in such a region, theoretically, one might expect it to be more harmful.  Programs 
that can be used are GERP++109 and PhyloP. 124 
Evaluation of the gene
Occasionally, a mutation is identified that has been described previously as a cause of 
a craniofacial malformation. However, often other variants occur in genes associated 
with craniofacial malformations. To identify known craniofacial malformation genes 
more easily, manually curated lists with “known cranio genes” are generated based 
on literature and the POSSUMweb database (Pictures of Standard Syndromes and 
Undiagnosed Malformations, Murdoch Children’s Research Institute, Royal Children’s 
Hospital, Melbourne, Australia). Also, a list containing all genes that are associated with 
a “craniofacial” phenotype in the Mouse Genome Database (at the Mouse Genome 
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Informatics website, The Jackson Laboratory, Bar Harbor, Maine, USA) and a list with all 
the genes that do not have a loss-of-function variant in Exome Variant Server112 are used 
to evaluate the mutated gene. 
If a pathogenic variant is identified in a gene that is not in one of these lists, a 
thorough literature search is performed to evaluate the function of the gene, its pathway 
and, if available, functional data. 
Validation cohorts
If a new candidate gene is identified, repeated occurrence of variants in that specific 
candidate gene across multiple families indicates a stronger association. Hence, re-
sequencing the gene in other clinically similar patient samples might result in the 
identification of multiple families with variants in the gene. 
Why tell me, why
Identification of the genetic cause is critical for genetic counselling. But it can also have 
implications for clinical management. 
A precise molecular diagnosis is essential for genetic counselling
Based on the molecular diagnosis, a legitimate recurrence risk for a following pregnancy 
can be given. Also, more clarity about heredity can be given to the proband when he or 
she enters the reproductive phase. 
If a child is born with craniosynostosis, for example, and tested negative with 
appropriate gene-specific tests and the parents are clinically not-affected, an empiric 
recurrence risk of 5-7% is given to the parents (2% for sagittal and metopic synostosis, 
5% for unicoronal synostosis and 10% for bicoronal and multisuture synostosis).125,126 
It is estimated that a proband with non-syndromic sagittal, metopic or unicoronal 
synostosis has a risk of ~5% of passing the disease on while probands with bicoronal or 
multisuture synostosis have a ~30-50% risk.125 Since the most common genetic causes 
of other craniofacial malformations like Treacher Collins syndrome are dominant, the 
proband is often told that he/she has a risk of 50% of passing the disease further on. 
These numbers affect reproductive decision-making significantly, and can lead to the 
wish of preimplantation genetic diagnosis or not having children.
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The molecular diagnosis has implications for clinical management
By increased knowledge of the association between the genotype and the phenotype, 
clinical management can be ameliorated. When a genetic cause is known, patients 
can be screened for associated symptoms earlier. Muenke syndrome, for example, is 
associated with sensory hearing deficits that can lead to speech- and language delay. 
Patients with a p.Pro250Arg mutation in FGFR3, the genetic cause of Muenke syndrome, 
should be monitored for hearing deficits so therapy can be offered early and speech- 
and language delay will be prevented. 
What we know now
Craniofacial malformations can be subdivided in craniosynostosis, craniofacial clefts 
and facial dysostosis. During embryological development, the normal anatomy of the 
craniofacial region is disturbed. This disruption of the normal development can be 
caused by alterations in the genetic code. Thanks to genetic research we now know: 
Craniosynostosis
That monogenic and chromosomal factors play a role in the aetiology of 
craniosynostosis.125,127,128 Over 100 human syndromes are reported to be associated 
with craniosynostosis.129 Since the identification of a mutation in MSX2 as a cause of 
craniosynostosis-Boston type in 1993,130 mutations in at least 57 genes are identified 
in syndromic craniosynostosis.127 However, a genetic cause can be identified in only 
~24% of the cases,59 with mutations in FGFR2,131-134 FGFR3,135-137 TWIST1,138,139 TCF12,59 
ERF140 and EFNB163,141 occurring most frequently. In clinical practice, patients with 
craniosynostosis are now tested for mutations in FGFR2, FGFR3 and TWIST1 and, if 
applicable, any of the 57 craniosynostosis genes as described by Twigg et al. To exclude 
chromosomal abnormalities, an array comparative genomic hybridisation analysis 
(aCGH) is undertaken (replacing karyotyping).
Craniofacial clefts
In contrast to craniosynostosis, only a small number of genetic causes have been 
identified in craniofacial clefts. This might be due to the very low incidence of these 
malformations. Until now, at least 11 genes and 2 genomic deletions are associated with 
craniofacial clefts. Remarkably, an overlap is seen with genes causing craniosynostosis. 
Mutations in for example EFNB163 cause a phenotype consisting of craniosynostosis and 
craniofacial clefting and mutations in TWIST1 (personal communication) cause either 
craniosynostosis or craniofacial clefting.142 If a patient presents with craniofacial clefting 
and a genetic cause is suspected, EFNB1, ALX3 and/or SHH can be tested and an aCGH 
analysis is undertaken. 
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Facial dysostosis
Patients with facial dysostosis can be affected symmetrically, which is the case in the 
Treacher-Collins like syndromes. But asymmetrical appearance also occurs, which 
is the case in hemifacial microsomia. Although hemifacial microsomia occurs much 
more often, familial occurrence is only rarely seen and genetic causes have not been 
described.  On the other hand, in case of the Treacher-Collins like syndromes, at least 
eight genes have been identified to be mutated. If a patient presents with a Treacher-
Collins like syndrome, these genes are tested and an aCGH analysis is undertaken. 
Table 1.1. Overview of diagnostic tests.
Craniosynostosis Craniofacial clefts Facial dysostosis
FGFR2 EFNB1 TCOF1
FGFR3 ALX3 POLR1A
TWIST1 + MLPA SHH POLR1C
aCGH aCGH POLR1D
Any of the 57 craniosynostosis 
genes as described by Twigg et 
al.127 can be added based on the 
phenotype
EFTUD
SF3B4
DHODH
aCGH
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What we want to know
Although many craniofacial malformations have been attributed to external factors 
like teratogens, foetal head constraint or bad luck, we now know that at least a part 
can be attributed to genetic alterations. In this era of rapidly developing genetic 
sequencing techniques, it seems a good time to study the genetic causes of craniofacial 
malformations further.
 
The aim of this thesis is to study genetic alterations that cause craniofacial malformations 
by addressing the following objectives:
1. Improve our knowledge on genes previously known to be causing craniofacial 
malformations. 
Focusing predominantly on: 
- FGFR2:  a. identification of new mutations in FGFR2 (chapter 2)
 b. identification of synonymous mutations as a cause of Crouzon 
syndrome (chapter 3)
- EFNB1: expanding the general phenotype of patients with craniofrontonasal 
syndrome (chapter 4)
2. Identification of new craniofacial genes by next generation sequencing
Focusing predominantly on: 
- TCF12: a. identification of mutations in TCF12 as a frequent cause of coronal 
craniosynostosis (chapter 5)
 b. identification of rearrangements in TCF12 as a cause of TCF12-related 
craniosynostosis (chapter 6)
- ZIC1: identification of gain-of-function mutations in ZIC1 as a cause of 
coronal craniosynostosis and learning disability (chapter 7)
- TXNL4A: identification of mutations in TXNL4A as a cause of Burn-McKeown 
syndrome and choanal atresia (chapter 8)
3. Assess next generation sequencing as a diagnostic tool in craniofacial 
malformations
Diagnostic value of exome and whole genome sequencing in craniosynostosis 
(chapter 9)
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Methods 
Patient selection
Based on clinical description, facial photographs and imaging (CT, MRI and/or invasive 
intracranial pressure measurements etc.), patients were selected that had coronal or 
multiple suture synostosis, or any other form of craniosynostosis in combination with an 
affected family member or in combination with growth or developmental retardation 
and/or other congenital anomalies. Also, patients with craniofacial clefts were selected 
if the cleft occurred in the midline and -just like in craniosynostosis- if family members 
were affected, and/or if a patient showed symptoms of growth or developmental 
retardation, and/or other congenital anomalies. Lastly, patients with facial dysostosis 
were selected. 
The clinical phenotype of the probands was evaluated by a Plastic Surgeon and a 
Clinical Geneticist and appropriate genes were tested negative prior to whole genome 
sequencing. Overall, this accounted for dideoxy sequencing of FGFR2, FGFR3, TWIST1. 
MLPA of TWIST1 and/or array comparative genomic hybridisation (aCGH) in case 
of craniosynostosis; EFNB1, ALX3, SHH and/or aCGH in case of craniofacial clefts; and 
TCOF1, POLR1A, POLR1C, POLR1D, EFTUD, SF3B4, DHODH and/or aCGH in case of facial 
dysostosis. 
In general, whole genome sequencing was performed on trios (i.e. DNA of the 
proband and its parents). In case of other affected family members, this DNA was also 
included (see Table 10.3 for patient characteristics, tested genes and included family 
members).  
Ethical approval was given by the board of the Medical Ethical Committee for 
whole genome sequencing (MEC-2012-140) and for retrospective data analyses (MEC-
2013-547). Informed consent was received from the study participants or their legal 
representatives. A total of 317 samples was included.
Whole genome sequencing and data analysis
DNA was extracted from whole blood samples. Prior to shipment of the DNA, the quality 
of the DNA samples was measured by PicoGreen® (ThermoFisher Scientific, Waltham, 
MA, USA) and gel electrophoresis. At least 5 µg of DNA (50-200 µl of 75-300 ng/µl DNA) 
per patient was shipped to Complete Genomics, a BGI Company (Mountain View, CA, 
USA). There, internal quality control measurements and, to exclude sample swaps, a 
gender check and 96-SNP genotyping assay were performed. 
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Whole genome sequencing at high coverage (≥80x) as described by Drmanac et 
al.104 was performed subsequently. Mapping of the reads and calling of the variants was 
performed as described by Carnevali et al.108 Reads were mapped using GRCh37/hg19 
and dbSNP build 130. Data were analysed using cga tools version 1.6.0.43 and Spotfire 
7.0.0 (TIBCO Software Inc., Boston, MA, USA).
Output files 
The data were given per sample in a so-called ‘Var-file’. A ‘List variants-file’ was extracted 
from the Var-files of the trio. Frequencies in the Wellderly cohort were added [Scripps 
Wellderly Genome Resource, The Scripps Wellderly Study, La Jolla, CA [December, 
2015]], funding provided by Scripps Health and NIH/NCATS UL1 TR00114), genes were 
annotated and occurrence of the variant in the family was added (‘Test variants’), 
contributing to the ‘Small variants-table’ (see Figure 1.3 for an overview of these output 
files and first filtering steps).
Identity by sequence (IBS)
To check the family relationship of the samples of a trio, a so-called IBS script (Complete 
Genomics) was run using the small variant table. Also, the samples were checked for 
regions of homozygosity using the Var-files. In that way, consanguinity of the samples 
and uniparental disomy could be visualized. 
Identification of variants
De novo
Lists of de novo variants (SNVs and indels) were generated using the ‘CallDiff script’ 
(Python script kindly provided by Complete Genomics) as described by Gilissen et al.143 
Roughly, this script compared the variant file of the proband to the variant files of the 
father and the mother to identify if a variant was truly de novo. Two confidence scores 
were provided per variant (one for the comparison with the father and one for the 
comparison with the mother). Using these confidence scores, the authenticity of the de 
novo variants were ranked. 
Dominant
The above mentioned analysis for de novo variants was performed using the CallDiff 
script. All the below mentioned analyses were performed using the ‘Multiple genome 
analysis script’, also provided by Complete Genomics. To analyse dominant inheritance, 
the mat_het (for variants inherited from the mother) and pat_het files (for variants 
inherited from the father) were used.
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var
Wellderly frequency
List	variants
Test	variants
Gene	annotation
Small	Variants	Annotated IBS
Homozygosity
UPD
Small	Variants	Annotated	Filtered
PAV,	SPL
Homozygous	recessive
Mat	Het;	Pat	Het	=>	compound	heterozygous
X-linked
De	novo
Inheritance	(Well	0,	0.01,	0.02)
Candidate	genes Check	
father-
proband
Spotfire file
Proband NOT 0	or	00
Well	<10%
Combine	all	families
Figure 1.3. Overview of output files and first filtering steps of the Multiple genome analysis 
script. IBS = Identity by sequence, Mat Het = Inherited from the mother, Pat het = Inherited from 
the father, PAV = Protein affecting variant, SPL = Splice site variant, UPD = Uniparental Disomy, Var 
= Var-file, Well = Wellderly.
Recessive 
The mat_het and pat_het files were also used to analyse recessive inheritance. Variants 
were selected that fit into the correct inheritance pattern (both homozygous variants as 
well as compound heterozygous variants). 
X-linked
X-chromosomal variants in females and males were analysed using the Small Variants-
table. 
Copy number variation and structural variation
Detection of copy number and structural variants was done by discordant mate-pair 
analysis. Junctions were sequenced, e.g. adjacent regions in the sequenced genome 
that are not adjacent in the reference genome (due to tandem duplications, distal 
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duplications, deletions, inversions, translocations and complex events). Variants were 
filtered based on inheritance pattern and a Complete Genomics baseline frequency of 
0. The called structural variants were ranked on mate pair count. The variants with a 
mate pair count >10 were manually curated.  
Mode of inheritance
If a phenotype was seen only in the proband, a de novo inheritance pattern was tested. 
Based on the findings in TCF12 and ERF,59,144 we know that reduced penetrance might also 
be possible, therefore a dominant inheritance pattern was also tested. Furthermore, an 
autosomal recessive inheritance pattern, a compound heterozygous inheritance pattern 
and in males an X-linked inheritance pattern was also tested for SNVs and CNVs/SVs. If 
one of the parents was also affected, a dominant inheritance pattern and (if applicable) 
an X-linked inheritance pattern was tested. Additionally, based on the phenotype, an 
overall comparison of the findings of the unrelated families was performed (cohort 
analysis). 
Generation of gene lists involved in craniofacial malformations (cranio 
genes)
To classify genes as known cranio genes we used several gene lists. 
1. Manually curated lists of genes that are described to be causative for the appropriate 
phenotype. 
2. All genes associated with the appropriate phenotype in the POSSUMweb database 
(Pictures of Standard Syndromes and Undiagnosed Malformations, Murdoch 
Children’s Research Institute, Royal Children’s Hospital, Melbourne, Australia).
3. All genes that were associated with a “craniofacial” phenotype in the Mouse 
Genome Database (Mouse Genome Informatics website, The Jackson Laboratory, 
Bar Harbor, Maine, USA).
4. All genes without loss-of-function variants in Exome Variant Server.112
5. All genes with a de novo mutation in the Deciphering Developmental Disorders 
(DDD).145
Annotation of variants
A custom in-house bioinformatics pipeline was created in Tibco Spotfire to annotate 
ANNOVAR data, Public60110 and 1000 Genomes113 data to the output of the Multiple 
Genome Analysis Script. The annotated information is shown in Table 1.3.
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Validation of candidates
All putatively causative variants were confirmed. SNVs were validated by dideoxy 
sequencing. PCR amplification was carried out in a total volume of 25 µl using Invitrogen 
(Life Technologies Ltd, Paisley, UK) or Takara master mix (Takara Bio Inc., Otsu, Shiga, 
Japan). PCR products were purified using Agencourt AMPure (Agencourt, Beckman 
Coulter Inc., Brea, CA, USA). Direct sequencing was performed using Big Dye terminator 
version 3.1 (Applied Biosystems, Foster City, CA, USA). Dye terminators were removed 
using Agencourt CleanSeQ (Agencourt) and loaded on an ABI 3130XL Genetic Analyzer 
(Applied Biosystems). The sequences were analysed using SeqPilot version 4.1.2 build 
507 (JSI Medical Systems Gmbh, Kippenheim, Germany).
Candidate pathogenic CNVs and SVs were validated using breakpoint spanning 
PCRs or deletion specific PCRs (as described by Goos et al.146). For breakpoint spanning 
PCRs, primer sequences were chosen to be located ~100-200 base pairs from the 
predicted junction. For deletion specific PCRs, one forward and one reverse primer were 
designed outside the deletion. The third primer was designed in the deleted region in 
such a way that the PCR product resulting from the mutant allele was smaller than the PCR 
product produced from the wildtype allele. The amplification reactions were performed 
according to standard procedures. Products were electrophoresed on agarose gels. To 
confirm the exact position of the breakpoints, the PCR products were sequenced. PCR 
products were purified with ExoSAP-IT (USB, Affymetrix, Cleveland, OH, USA). Dideoxy 
sequencing of both strands was performed using Big Dye terminator version 3.1 
(Applied Biosystems, Foster City, CA, USA) as recommended by the manufacturer. Dye 
terminators were removed using SephadexG50 (GE Healthcare, Pittsburgh, PA, USA) and 
loaded on an ABI 3130XL Genetic Analyzer or ABI 3730 (Applied Biosystems). 
Classification system
A classification system based on five classes was used to classify the candidate variants.147 
Class 1: benign
Class 2: likely benign
Class 3: variant of unknown significance (VUS)
Class 4: likely pathogenic
Class 5: pathogenic
 In figure 1.4 the classification flowchart is shown.
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Table	1.4.	Classification	flowchart.	
	
	
	
No	 Yes	
Class	3	
Frameshift	or	nonsense	 Intron	 Silent	 In-frame	del/dup	 Missense	
±	2	bp	
±	3	and	30	bp		
MAF	0.01	and	>200	chromosomes	
Splice	site	prediction	programs	
Class	1	
A. Effect	on	splicing	>	Translation	to	in-frame	
protein	not	possible:		 Class	5	
B. Effect	on	splicing	>	Translation	to	in-frame	
protein	possible:	 Class	4	
A. Effect	on	splicing	>	Translation	to	in-frame	
protein	not	possible:		 Class	5	
B. Effect	on	splicing	>	Translation	to	in-frame	
protein	possible:		 Class	4	
A. Effect	on	splicing:		 Class	3	
B. No	effect	on	splicing:		 Class	2	
A. Effect	on	splicing:		 Class	3	
B. No	effect	on	splicing:		 Class	2	
A. Effect	on	splicing:		 	 Class	3	
B. No	effect	on	splicing	
a. HGMD	link:		 	 Class	4	
b. 5	in	silico	prediction	programs	give	
data	>	4	programs	give	a	neutral	
result:		 	 Class	2	
c. 3	or	4	in	silico	prediction	programs	
give	data	>	3	programs	give	a	
neutral	result:		 	 Class	2	
d. All	other	missense	changes:	
	 	 	 Class	3	
Figure 1.4. Classification flowchart. Del = Deletion, Dup = Duplication, MAF = Minor allele 
frequency.
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Confirmation of pathogenicity
1. When a previously described pathogenic mutation was observed, the identified 
variant was assumed to be pathogenic. 
2. If a mutation was observed in a previously described gene with a phenotype similar 
to our patient, the phenotype of the patient was re-evaluated for the syndrome 
(like the ANKRD11 mutation) and if applicable assumed to be pathogenic.
3. If variants were identified in the same gene in more than one case with a similar 
phenotype, this observation was suggestive that the sequence change had a 
pathogenic effect. Especially if the sequence changes were present in a highly 
conserved domain. In these cases, repeated occurrence of candidate genes 
across multiple cases was checked in the 317 samples. To confirm pathogenicity, 
candidate genes were screened in our patient test cohort and a replication cohort 
in Oxford. Genes were inserted in GeneMatcher to identify similar cases in other 
cohorts (https://genematcher.org/). And, if possible, the biological consequence of 
a candidate was validated. 
Pathogenic mutations
The pathogenic mutations were described according to HGVS nomenclature148 and 
submitted to the Leiden Open Variation Database (http://www.lovd.nl).
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Table 1.3. Annotated information. 
Variant Chromosome position
aVariant type Snp
Sub
Del
Ins 
aReference and allele sequence
aVarScore and VarFilter
aComponent Coding sequence
Splice site (acceptor/donor)
Intron
UTR
Promoter region
aImpact Missense
Nonsense
Frameshift
Delete
Insert
Disrupt
Nonstop
Nonstart 
aTranscript
aNucleotide position
aProtein position
Inheritance
Frequency in variant databases adbSNPv37
aWellderly109
bExAC111
bExome Variant Server112
bGoNL70,76
cPublic60110
c1000 Genomes113 
Predicted effect bIn silico prediction SIFT114
Polyphen115
LRT116
Mutation Taster117
FATHMM118
Radial SVM LR119
VEST3120
CADD raw/phred121
bConservation GERP++109
PhyloP124
Del = Deletion, Ins = Insertion, SNP = Single Nucleotide Polymorphism, Sub = Substitution, UTR = Untranslated region. aData 
from Complete Genomics, bdata from Annovar, cdata from sequencing projects. 
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Abstract
Craniosynostosis is a congenital anomaly that can occur as an isolated condition 
or as part of a syndrome. Although several genes are known to cause syndromic 
craniosynostosis, only 24% can be attributed to known genes. Therefore, it is likely that 
more mutations and other genes are involved. We present the identification of a novel 
point mutation in fibroblast growth factor receptor 2 (FGFR2), c.812G>T, p.(Gly271Val). 
Furthermore, we describe a mutation that has been identified just recently c.1851G>C, 
p.(Leu617Phe). In addition, we describe findings from a sequence analysis of all coding 
exons and exon/intron boundaries of FGFR2 performed on 124 patients with syndromic 
craniosynostosis.
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Introduction
Craniosynostosis, characterized by the premature fusion of calvarial sutures, can occur 
as an isolated condition or as part of a syndrome. Previously, a syndrome was diagnosed 
based on the patient’s clinical appearance. For example, the distinct features in Apert 
syndrome, particularly, of the hands and feet, were easily recognizable, whereas 
differentiation between other syndromes, like Saethre-Chotzen and Muenke, was 
more difficult. In the last 20 years, genetic tests have been developed to confirm the 
genetic aetiology of many syndromes. Nowadays, the genetic causes of most common 
syndromes have been described and a causal mutation is identified in about 24% of 
patients with craniosynostosis.59
Several craniosynostosis syndromes are caused by mutations in fibroblast growth 
factor receptor 2 (FGFR2). For example, the mutations first described cause a clinical 
appearance similar to Crouzon syndrome (CS);133 however, mutations in FGFR2 are also 
known to cause isolated craniosynostosis, Pfeiffer,149 Apert,131 and Beare-Stevenson cutis 
gyrata syndrome.150 In addition, cases are described in which phenotypically different 
craniosynostosis patients have exactly the same genotype.149,151,152 In particular, the 
distinction between Crouzon, Pfeiffer, and Jackson-Weiss syndrome appears to be 
irrelevant, although the diagnosis ‘Pfeiffer syndrome’ is most often used for the more 
severe presentation of the non-Apert FGFR2 mutations. Consequently, the diagnosis 
of a syndrome is shifting from a solely clinical diagnosis towards a molecular one. In 
clinical practice, patients with craniosynostosis are now tested for mutations in FGFR2, 
FGFR3, and TWIST1. Usually, a limited number of exons of FGFR2 are tested.
Here, we present the identification of a novel point mutation and a point 
mutation that has been described recently in FGFR2 in these exons. In addition, we 
analysed all coding exons and exon/intron boundaries in 124 patients with syndromic 
craniosynostosis to gain more information on mutations in other FGFR2 coding regions.
Patient 1
A Caucasian boy was born as the first child of non-consanguineous phenotypically 
normal parents; at birth the mother was 28 and the father 31 years old. The boy was 
born at 40 weeks of gestation and weighed 3,580 g. The pregnancy was uncomplicated. 
During neonatal examination, a severe scaphocephalic head shape was observed 
(Figure 2.1). Physical examination showed scaphocephaly with clear frontal bossing 
and exorbitism, and a head circumference of 43 cm (+2.24 SD). The upper and lower 
extremities showed broad first digits and partial syndactyly of the second and third toes. 
No symptoms of obstructive sleep apnoea (OSA) were diagnosed. A clinical suspicion of 
Crouzon/Pfeiffer syndrome was raised, due to the peri-orbital features. Bicoronal and 
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sagittal suture synostosis were seen on skull radiographs and confirmed by 3D-CT at age 
3 months. No intracerebral anomalies were seen. At age 8 months, the boy underwent a 
supra-orbital advancement and fronto-parietal remodelling.
Over time, restricted growth of the maxilla became clear and resulted in dental 
crowding, with a narrow and retruded maxilla. At age 9 years, the skull growth stagnated 
and the boy developed papilledema. Intracranial pressure (ICP) measurements showed 
borderline elevated ICP with two plateaus higher than 25 mmHg and a mean value of 
13 mmHg during sleep. The CT scan showed signs of elevated ICP, wide lateral ventricles 
and narrowed basal cisterns. An MRI scan showed widened third and lateral ventricles, 
scalloping of the skull, narrowed corpus callosum, deficient periventricular white matter, 
and a Chiari I malformation. Furthermore, a holocord syrinx, reaching to the caudal 
cone, and sacral arachnoid cysts were seen. Because of the borderline ICP, papilledema, 
and the Chiari I malformation a biparietal expansion with distraction was performed at 
age 10 years.  The papilledema disappeared. The boy did not develop clinical signs of 
Chiari I malformation or holocord syrinx.
He had a normal development, with an IQ of 114. Since the clinical phenotype 
resembled Crouzon/Pfeiffer syndrome, genetic testing was performed for mutations 
in FGFR2. A heterozygous point mutation was found at c.812G>T, p.(Gly271Val) 
(see Supplementary Figure 2.1 for the sequence electropherogram). This mutation 
was not found in the parents, indicating that the mutation arose de novo. Paternity 
testing confirmed the family relationship. This mutation was not found in 378 control 
chromosomes. To determine whether this variant had been identified in other individuals, 
we checked our in-house Huvariome database153 consisting of 290 genomes, and the 
Exome Variant Server (EVS). The variant was not present in either database. According 
to the 1000 Genomes (1000G) database,154 another variant had been described in the 
COSMIC database155,156 at the same location [c.812G>A, p.(Gly271Glu) COSM29823] in 
a malignant melanoma sample (MAF = 0.001). This single-nucleotide polymorphism 
(SNP) was identified as probably damaging.
The p.Gly271Val variant was entered in Polyphen-2,115 SIFT,157 MutationTaster117 and 
Align GVGD,158 and results ranged from possibly damaging to disease causing (Table 
2.1). Furthermore, the nucleotide and amino acid were highly conserved. Combining 
these results, this variant was very likely to be the mutation causing the phenotype of 
this patient.
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Figure 2.1. Facial photographs of Patient 1. A-C: pre-operatively at age 2 months. D-F: post-
operatively at age 10 years.
Patient 2
A male patient aged 39 years with craniofacial features resembling Crouzon/Pfeiffer 
syndrome returned to our clinic. He wanted to know whether his condition was caused 
by a genetic alteration. At first referral (age 20 years) the patient had not received 
surgical treatment for his craniofacial disorder. He presented with mild retrusion of 
the forehead, low frontal hairline, exorbitism, mild orbital dystopia, a narrow maxilla, 
maxillary hypoplasia with mild malocclusion and small incisors, syndactyly of the 
third and fourth fingers, and camptodactyly of both fifth fingers. No information was 
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available regarding the presence of craniosynostosis, but the patient had no obvious 
abnormal head shape. On genetic testing, the same c.812G>T, p.(Gly271Val) mutation 
in FGFR2 was identified.
Patient 3
A boy of African descent was born after an uncomplicated pregnancy at 40 weeks 
gestation with a birth weight of 3,580 g. An abnormal head shape was seen immediately 
after birth. Physical examination showed scaphocephaly with frontal bossing, a palpable 
ridge over the sagittal suture, and a head circumference of 52 cm (+5.68 SD). The eyes 
had some scleral show as a result of the hypoplastic infra-orbital rim. No hand or foot 
deformities were observed. Skull radiographs suggested synostosis of the sagittal 
suture. This was confirmed on 3D-CT. Besides slightly enlarged peripheral cerebrospinal 
fluid spaces, no intracranial abnormalities were seen. The boy underwent a fronto-
biparietal remodelling of the skull at age 11 months with uneventful recovery. At age 3 
years he underwent orchidopexy because of bilateral undescended testicles. When the 
boy was 8 years old, he presented clinical features of OSA and exorbitism. Moreover, he 
had maxillary hypoplasia. Therefore, at age 10  years he underwent Le Fort III osteotomy, 
combined with external distraction. He had delayed development with an IQ of 77.
Because of the mild exorbitism and maxillary hypoplasia the clinical diagnosis of 
CS was suggested. Therefore, genetic testing of FGFR2 was performed. A heterozygous 
point mutation was found at c.1851G>C, p.(Leu617Phe) (Table 2.1). The DNA of both 
parents tested negative for the variant. Paternity tests confirmed the family relationship. 
The variant was not present in the Huvariome, 1000G, or the EVS database. The in 
silico programs predicted a probably damaging or even a disease-causing effect. The 
nucleotide was weakly conserved, but the amino acid was highly conserved. Combining 
these results, this SNP was very likely to cause the phenotype of our patient. During 
preparation of this case report, this mutation was also identified by Suh et al.159
Sequencing coding exons and exon/intron junctions
Previously, patients were tested by Single Strand Conformation Polymorphism (SSCP) 
or sequence analysis for mutations in a limited number of exons of FGFR2. However, 
in several patients no mutation in FGFR2 was found, even though such a mutation 
was suspected. Therefore, we decided to analyse all coding exons and the exon/intron 
junctions of FGFR2 (NM_000141.4) of 124 patients with syndromic craniosynostosis 
(Supplementary Table 2.1 presents detailed information). Patients were selected if they 
had fusion of the coronal sutures or of more than one suture, if they had a positive 
family history, or if they had other congenital anomalies or psychomotor disability 
(Supplementary Table 2.2 presents the clinical features of the tested patients). By 
expanding the analysis, we found two previously described mutations, i.e. c.314A>G, 
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p.(Tyr105Cys) and c.755C>G, p.(Ser252Trp), and four unclassified variants (UVs). Table 
2.1 presents a summary of these variants. An extensive overview of the clinical features 
of these patients is presented in Supplementary Table 2.3.
Discussion
It is established that all FGFRs originate from the same ancestral gene.160 They code for 
a group of transmembrane-receptor proteins crucial for early embryonic development. 
Similar to FGFR1 and FGFR3, FGFR2 comprises three extracellular immunoglobulin-like 
domains (IgI, IgII, and IgIII), a single-pass transmembrane segment, and a split tyrosine 
kinase (TK1/TK2) domain.160-162 The p.Gly271Val mutation is located in the IgIIIa domain, 
and the p.Leu617Phe mutation is located in the TK domain.
The clinical features of our three patients resemble Crouzon/Pfeiffer syndrome. 
The regions in which the mutations are located harbour other pathogenic missense 
mutations causing CS.162-164 Both mutations described here arose de novo. The mutations 
were not seen in the EVS, the Huvariome, or in the 1000G Database and the majority of 
the in silico data predicted a disease-causing effect (Table 2.1). Furthermore, because 
both amino acids were highly conserved, the mutations were considered disease-
causing mutations.
On sequence analysis of FGFR2, two previously described mutations and four 
UVs were found. Three of the UVs (i.e. c.1084+8C>T, c.1531G>A and c.2190C>T) were 
also found in the DNA of the clinically unaffected fathers. Because most families with 
syndromic craniosynostosis showed an autosomal dominant mode of inheritance, the 
decision as to whether or not a variant present in a parent is pathogenic has often been 
based on the phenotype. However, the findings of Sharma et al.59 of substantial non-
penetrance in a dominant form of craniosynostosis argue against this approach.
Three UVs were not present in the EVS, or in the Huvariome, whereas the c.2190C>T, 
p.(=) variant was present in the 1000G database. The c.23T>G, p.(Ile8Ser) variant was 
present in the EVS, the Huvariome, and in the 1000G database. According to five 
prediction programs, no variant had an effect on RNA splicing. The predictions of the 
in silico programs, if applicable, varied from benign to tolerated. The nucleotides were 
weakly conserved. The amino acid was weakly conserved for the c.23T>G, p.(Ile8Ser) 
variant and moderately conserved for c.1531G>A, p.(Ala511Thr). Combining these data, 
the UVs were considered non-pathogenic.
It was estimated that 94% of FGFR2 mutations occur in IgIIIa (exon 8; NM_000141.4) 
or IgIIIc (exon 10), or in the intron sequence flanking IgIIIc165 (as cited in Kan et al.162) 
The p.Tyr105Cys variant is one of the few pathogenic mutations outside these mutation 
hotspots.166 Although we found few variants by expanding the analysis to all coding 
exons and the exon/intron junctions, we did find the p.Tyr105Cys variant in the IgI 
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domain. In contrast, an FGFR2 mutation screen in 259 craniosynostosis patients by Kan 
et al. revealed mutations in seven additional exons.162 These authors claim that, since 
mutations are identified outside the hotspots, a more extensive search for mutations 
is justified; with the revolutionary developments in genetic research this will become 
cheaper and easier. However, the present study again demonstrates that pathogenic 
mutations predominantly occur in the well-conserved functional regions.
Web resources
EVS: NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: http://evs.
gs.washington.edu/EVS/) [May, 2013]).
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Abstract
Mutations of fibroblast growth factor receptor 2 (FGFR2) account for a higher proportion 
of genetic cases of craniosynostosis than any other gene, and are associated with a wide 
spectrum of severity of clinical problems. Many of these mutations are highly recurrent 
and their associated features well documented. Crouzon syndrome is typically caused 
by heterozygous missense mutations in the third immunoglobulin domain of FGFR2.
Here we describe two families, each segregating a different, previously unreported FGFR2 
mutation of the same nucleotide, c.1083A>G and c.1083A>T, both of which encode 
an apparently synonymous change at the Pro361 codon. We provide experimental 
evidence that these mutations affect normal FGFR2 splicing and document the clinical 
consequences, which include a mild Crouzon syndrome phenotype and reduced 
penetrance of craniosynostosis.
These observations add to a growing list of FGFR2 mutations that affect splicing and 
provide important clinical information for genetic counselling of families affected by 
these specific mutations.
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Introduction
Craniosynostosis defines the premature fusion of the cranial sutures and has an overall 
prevalence of 1 in 2,100–2,300 live births.2,3 Nearly one quarter of craniosynostosis 
has a genetic aetiology;59,128 there is considerable genetic heterogeneity and frequent 
phenotypic overlap between different syndromes. Genes encoding three members of 
the fibroblast growth factor receptor family (FGFR1, FGFR2 and FGFR3) are commonly 
mutated in individuals with craniosynostosis. Heterozygous mutations in FGFR2, which 
are frequently recurrent, account for ~28% of genetic cases59 and cause Crouzon,133,134 
Pfeiffer,149,167,168 Apert,131 Beare-Stevenson150 and bent bone dysplasia169 syndromes. All 
involve synostosis of the coronal and other cranial sutures, a distinctive “crouzonoid” 
craniofacial appearance (comprising hypertelorism, exorbitism, prominent nose, and 
midface hypoplasia), but differ in the presence and extent of abnormalities of the hands 
and feet, other skeletal manifestations and dermatological features.125,170
FGFR2, like the other members of the FGFR family, comprises an extracellular 
ligand-binding region (composed of three immunoglobulin-like domains), a single 
transmembrane peptide and a cytoplasmic tyrosine kinase domain. Mutually exclusive 
alternative splicing of exons IIIb and IIIc gives rise to epithelial and mesenchymal isoforms 
(FGFR2b and FGFR2c) respectively.171 These alternative extracellular domains interact 
with different repertoires of fibroblast growth factors (FGFs) to regulate downstream 
processes such as proliferation, differentiation and cell migration.172
Here we describe two families heterozygous for the same, previously unreported 
apparently synonymous variant in FGFR2 [p.(Pro361Pro)], although caused by differing 
nucleotide substitutions. The mutation carriers in both families exhibit features of mild 
Crouzon syndrome, and a minority required craniofacial surgery. We propose that 
this variant is in fact pathogenic and demonstrate the generation of abnormal cDNA 
products resulting from incorrect splicing of exon IIIc in the mutant allele. This finding 
highlights the challenges posed in interpreting such synonymous variants when 
providing genetic counselling for affected families.
Case presentations
Family 1
Individual III-1 (Figure 3.1A) was born after a normal pregnancy and was referred for 
craniofacial assessment at 2 years of age because prominent eyes and a head tilt. Her 
father II-1 (Figure 3.1B), grandmother I-1 and two deceased uncles were all said to have 
a similar appearance with prominent staring eyes, but had not required any surgery. She 
had an occipitofrontal circumference (OFC) of 50 cm (+1.1 SD) and was noted to have 
a mildly crouzonoid appearance, with slight exorbitism and midface retrusion. In view 
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of the mild crouzonoid features, sequencing of FGFR2 exons IIIa and IIIc was requested. 
This demonstrated a heterozygous c.1083A>G, p.(Pro361Pro) variant within exon IIIc, 
which was also present in II-1 and I-1.
Computed tomography (CT) of the skull of individual III-1 at the age of 2.8 years 
demonstrated right lambdoid and occipitomastoid synostosis, all other major cranial 
sutures being patent. Ophthalmological review identified slightly reduced visual acuity 
and a latent divergent squint with slight left hypophoria. The patient is now 4 years old 
and has not undergone any surgical intervention, as she has a good overall head shape 
with no major midface retrusion, is making good developmental progress, and has no 
features to suggest significant intracranial restriction.
Family 2
The male proband (III-2 in Figure 3.1C), born after an uneventful pregnancy, was referred 
for craniofacial assessment at the age of 3 months. Physical examination showed a mild 
cloverleaf skull with temporal bulging and reduced OFC (36 cm; −2.2 SD), hypertelorism, 
and severe exorbitism mainly at the infra-orbital level. Skull X-ray and CT showed 
pansynostosis and multiple craniolacunae, with no intracerebral anomalies.
Owing to the severe peri-orbital features and the absence of deformations of the 
upper and lower extremities a clinical diagnosis of Crouzon syndrome was suggested. 
The patient’s mother, grandmother and several cousins were reported to show mild 
facial features also suggestive of this diagnosis.
The proband underwent fronto-orbital advancement at the age of 5 months. Since 
the occiput was still severely flattened and both lambdoid sutures were fused, occipital 
craniotomy and remodelling was performed at the age of 12 months. Clumsiness 
and motor delay were first noted aged 18 months; psychological testing at the age 
of 12.8 years gave scores for non-verbal intelligence of 80 (SON-R) and visual-motor 
integration of 81. Clonidine was prescribed due to high distractibility and he underwent 
special education. During childhood, the exorbitism increased requiring further orbital 
advancement and cranial vault remodelling at the age of 8 years. Several deciduous and 
permanent teeth were extracted because of Class III malocclusion and dental crowding.
Genetic testing of FGFR2 was performed, identifying the heterozygous point 
mutation c.1083A>T, p.(Pro361Pro) (Figure 3.2A). This variant was also present in his 
mother II-1.
Independently of these events, a second patient (III-1) was referred to the same 
clinic at the age of 10 years with a scaphocephalic head shape. He had previously 
undergone vault remodelling at the age of 16 months owing to bicoronal synostosis. 
At the time of referral, he had an occipito-frontal circumference of 48.5 cm (−2.8 SD), 
hypertelorism and severe exorbitism. In addition, he had mild maxillary hypoplasia and 
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both second premolars of the lower jaw were absent. Ophthalmic examination showed 
myopia with divergent strabismus of the right eye associated with reduced visual 
acuity. A monobloc procedure without distraction (Le Fort III and an advancement of 
the forehead) was performed.
Figure 3.1. Pedigrees and facial features of individuals with FGFR2 mutations. A: pedigree 
of Family 1; solid symbols represent clinically confirmed craniosynostosis and hatched 
symbols represent individuals with a similar crouzonoid appearance but without confirmed 
craniosynostosis. *Confirmed heterozygosity for c.1083A>G. B: facial appearance of II-1 from 
Family 1 aged 33 years. C: abbreviated pedigree of Family 2; notation of symbols as in part A. 
†Confirmed heterozygosity for c.1083A>T. D: facial appearance of III-1 from Family 2 aged 8.75 
years (left) and 43 years (right).
Due to the severe peri-orbital features a diagnosis of Crouzon syndrome was 
suggested. Analysis of FGFR2 identified the heterozygous point mutation c.1083A>T, 
p.(Pro361Pro). His father, grandmother and great-grandmother had a similar 
craniofacial appearance. Based on the pedigree analysis, it is evident that III-1 and III-2 
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are third cousins and that the FGFR2 mutation present in these two branches is identical 
by descent (Figure 3.1C). Apart from III-1 and III-2, none of the other affected family 
members had undergone craniofacial surgery.
Materials and methods
Ethics approval for the study was obtained from NRES Committee London - Riverside 
(09/H0706/20) and the Medical Ethical Committee of the Erasmus University Medical 
Centre Rotterdam (MEC-2013-547). Venous blood was collected into PAXgene Blood 
RNA tubes (Qiagen) from individuals II-1 (Family 1) and III-1 (Family 2), and RNA was 
extracted according to the associated protocol. cDNA was synthesized using the 
Fermentas RevertAid First-Strand Synthesis kit with random hexamer primers according 
to the manufacturer’s instructions.
cDNA was amplified using a forward primer in FGFR2 exon IIIa 
(5’-TCGGAGGAGACGTAGAGTTTGTCTGC-3’) used in combination with a 
reverse primer in exon 11 (encoding the transmembrane (TM) domain; 
5’-TGTTACCTGTCTCCGCAGGGGGATA-3’). DNA bands were cut out and gel purified 
using the Q-Spin gel extraction kit (Geneflow). Dideoxy sequencing was carried out on 
the resulting DNA products. The resulting cDNA products were numbered according to 
NCBI Reference Sequence: NM_000141.4.
Results
The synonymous variants c.1083A>G and c.1083A>T occur at the −2 position of the 
5’ (donor) splice site of FGFR2 exon IIIc (Figure 3.2A). The neural network splice site 
predictor (http://www.fruitfly.org/seq_tools/splice.html) generates a score for the wild 
type donor of 0.88, which is reduced to 0.37 by the A>G transition, and to 0.19 by the 
A>T transversion. In these circumstances, use of a cryptic splice site (score 0.84) within 
exon IIIc, 51 nucleotides upstream from the end of the exon, is expected based on 
analysis of a previous mutation c.1084+3A>G.173 This would lead to an in-frame deletion 
of 17 amino acids.
Amplification of cDNA from individuals heterozygous for either the FGFR2 
c.1083A>G or the c.1083A>T variants demonstrated the presence of two additional 
bands, not present in the wild type control, at ~430 bp and 330 bp (Figure 3.2B). 
Sequencing of the normal 479 bp product from these individuals showed complete 
absence of the mutant allele (illustrated in Figure 3.2C for II-1 from Family 1), indicating 
that both mutations abolish use of the normal exon IIIc donor splice site. Sequencing 
of the ~430 bp product confirmed that the cryptic splice donor within exon IIIc was 
preferred in the mutant allele (Figure 3.2D), while the ~330 bp product demonstrated 
complete skipping of exon IIIc (Figure 3.2E).
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Figure 3.2. Genomic context and consequences of FGFR2 mutations. A: schematic 
representation of genomic region affected by c.1083A>G and c.1083A>T mutations (not to scale). 
IIIa, IIIb and IIIc denote exons of FGFR2 encoding the third immunoglobulin-like domain; note 
that physiological skipping of exon IIIb normally occurs in blood mRNA. TM, exon encoding 
transmembrane domain. Sequencing of genomic DNA demonstrates heterozygosity for 
c.1083A>G (II-1, Family 1) or c.1083A>T (III-2, Family 2) mutation at the −2 position from the 
end of exon IIIc (indicated by dashed red line; the upper line in each trace shows the wild type 
sequence). Below the cartoon is shown the genomic sequence around the cryptic donor splice site 
within exon IIIc (marked with red asterisk). B: amplified cDNA corresponding to c.1083A>G and 
c.1083A>T mutations (same individuals as for genomic analyses), demonstrates two additional 
smaller products (indicated with white arrows D and E), in addition to the normal (C) product. 
C: in the cDNA product coincident with the wild type band (II-1, Family 1), the mutant allele at 
the penultimate position of exon IIIc is not represented, indicating complete skipping of normal 
splicing. D and E: the consequences for splicing of the mutant allele (sequence traces illustrated 
are from III-1, Family 2) are either to activate the cryptic splice donor site within exon IIIc (D) or to 
skip exon IIIc completely (E).
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Conclusions
In humans there is a consensus sequence around the 5’ splice donor site: A, C or T, AG / 
gtaagt (where / indicates the exon-intron boundary). Mutations of the consensus A at 
the penultimate nucleotide of the exon have been associated previously with loss of 
splicing at the donor site.140,174 Other mutations near the FGFR2 exon IIIc splice donor 
site have also been described (Table 3.1), all associated with a mild Crouzon phenotype. 
It is likely that the p.(Ala362Ser) substitution175 in fact exerts its pathogenic effect via the 
G>T transversion at the −1 position in the exon, rather than as a missense substitution, 
but this was not tested experimentally.
In the cases reported here, the wild type splice donor site is abolished by the A>G 
or A>T mutations at the −2 position from the intron, leading to the cryptic site being 
preferred. The apparently greater amount of mutant cDNA products associated with the 
A>T mutation appears to correlate both with the greater predicted disruption of the 
splice site and with the more severe phenotype in clinically affected individuals from 
Family 2 compared with Family 1. However, since the A>G mutation did not support 
use of the normal exon IIIc donor splice site (Figure 3.2C), other explanations for these 
differences are possible, such as differing proportions of cell types in the blood samples 
analysed, and/or differences in genetic background.
Utilisation of the cryptic donor would lead to an in-frame deletion of the last 17 
amino acids of exon IIIc (p.Gly345_Pro361del), including four residues that form specific 
contacts with the ligand FGF2.176 However as craniosynostosis-causing FGFR mutations 
function in a constitutively active dominant manner,177 it is also likely that in these 
individuals a mutant protein is formed which is prone to forming covalently-linked 
dimers,177 leading to variable features of Crouzon syndrome.
Our case reports document the range of phenotypic consequences associated with 
these particular mutations. Whilst a mild crouzonoid phenotype was generally evident, 
only a minority of individuals developed overt craniosynostosis requiring calvarial 
surgery. Orthodontic problems may also occur but these were not fully documented 
in our study. The causes of the clinical variability are unknown, although one potential 
factor may be the extent of intrauterine foetal head constraint.178
In conclusion, mutations near the FGFR2 exon IIIc splice sites should be carefully 
evaluated as to whether they may be pathogenic, even if they are synonymous or 
outside the canonical AG/GT splice acceptor/donor sequences. In particular, the 
mutations described here are associated with variable Crouzon syndrome features and 
affected families should be counselled as such.
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Table 3.1. Summary of mutations affecting correct splicing of the FGFR2 exon IIIc donor site.
Mutation Protein Proposed effect
Experimental 
demonstration
Reference
c.1032G>A p.(Ala344Ala) Activation of cryptic 
splice site
Yes Reardon et al. 1994;133 Li et al. 
1995;179
Del Gatto & Breathnach 1995 180
c.1083A>G p.(Pro361Pro) Loss of normal donor 
site with use
of alternative cryptic 
splice site
Yes This study
c.1083A>T p.(Pro361Pro) As above Yes This study
c.1084G>T p.(Ala362Ser) Annotated as missense 
but likely
to affect splicing
No Everett et al. 1999 175
c.1084+3A>G - Loss of normal donor 
site with use
of alternative cryptic 
splice site
Yes Kan et al. 2004 173
c.1084+3A>C - Loss of normal donor 
site with use
of alternative cryptic 
splice site
No Cornejo-Roldan, Roessler & 
Muenke 1999;181
Kress et al. 2000 182
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Abstract
Craniofrontonasal syndrome (CFNS) is an X-linked developmental malformation, 
caused by mutations in the EFNB1 gene, which have only been described since 2004. A 
genotype-phenotype correlation seems not to be present. As it is of major importance 
to adequately counsel patients with EFNB1 mutations and their parents, and to improve 
diagnosis of new patients, more information about the phenotypic features is needed. 
This study included 23 patients (2 male, 21 female) with confirmed EFNB1 mutations. 
All patients underwent a thorough physical examination and photographs were taken. 
If available, radiological images were also consulted. Hypertelorism, longitudinal 
ridging and/or splitting of nails, a (mild) webbed neck and a clinodactyly of one or more 
toes were the only consistent features observed in all patients. Frequently observed 
phenotypic features were bifid tip of the nose (91%), columellar indentation (91%) and 
low implantation of breasts (90%). In comparison with anthropometric data of facial 
proportions, patients with CFNS had a significantly different face in multiple respects. 
An overview of all phenotypic features is shown. Patients with EFNB1 mutations have a 
clear phenotype. This study will facilitate genetic counselling of parents and patients, 
and contribute to the diagnostic and screening process of patients with suspected 
CFNS.
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Introduction
Craniofrontonasal syndrome (CFNS), also known as craniofrontonasal dysplasia, was 
identified as a specific subpopulation of frontonasal dysplasia, first delineated in 
a study by Cohen in 1979.183 Subsequently, many other studies have focused on the 
manifestation of this syndrome. Most commonly depicted phenotypic features were 
coronal synostosis,183-193 hypertelorism,183,186-196 bifid nasal tip,183,186,187,190-192,194,195 frizzy 
and curly hair190-193,197 and longitudinal ridging and splitting of nails.185,186,188,190,191,193-195 
It became clear that the majority of CFNS patients were female. In addition, the female 
patients appeared to be affected more severely than male carriers, who showed only 
few mild signs or no clear features at all. A genetic basis was likely, because families with 
multiple affected members were reported.184-186,188-191,194 However, there seemed to be a 
genetic paradox, as all daughters of affected males displayed severe signs of CFNS, but 
no male-to-male transmission was seen and affected males portrayed only mild or no 
signs. Therefore, multiple modes for inheritance were proposed; germline mosaicism, 
autosomal dominant with sex-influenced expression, X-linked dominant and metabolic 
interference.184-186,188-191
The mystery was unravelled by a combination of results of multiple studies.63,198,199 
The disease locus was finally claimed to be within Xq13.1 and loss of function mutations 
in EFNB1 were proven to cause CFNS.63,141,192,200-210 EFNB1 encodes ephrin-B1, which 
is a transmembrane ligand for Eph receptor tyrosine kinases. Because of random 
X-inactivation heterozygous females are uniquely mosaic and by consequence a cell 
either does or does not produce a functional protein. These proteins are important for 
cell-cell contact, migration and pattern formation in the developmental process of the 
embryo.211 The random pattern of expressing and non-expressing patches therefore 
leads to an abnormal sorting in cells, and in addition to ectopic tissue boundaries 
between these zones. The term for this process is called ‘cellular interference’.192 In 
hemizygous males, all cells are unable to produce a functional protein, and therefore this 
phenomenon cannot occur. Normal boundaries are probably maintained through an 
alternative mechanism,205 which could be via an ephrin redundancy205 and promiscuity 
of the ephrin ligand/receptor system.192 An explanation for the few severely affected 
males reported in literature188-190,212 could be a mosaicism in these patients, in which the 
wild type to mutant ratio should be similar to that in heterozygous CFNS females.23,206,213 
Additional mechanisms were recently added to the phenotypic manifestation. Not only 
cellular interference, but also an impaired signalling capacity of ephrin-B1 and improper 
regulation of gap junctional communication could be responsible for the pathogenic 
process in CFNS expression.204,208 A genotype-phenotype correlation has not been 
proven, and previous studies suggest that this is unlikely.206
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Taken together, around 20% of the patients screened for CFNS did not display a 
mutation in the EFNB1 gene.201,203,205 Multiple explanations have been proposed, one of 
which is misdiagnosis of some of the included patients.205 Studies following the discovery 
of the causal gene predominantly describe the location of new mutations, combined 
with a brief outline of phenotypic features of small families or cohorts.63,141,200,202,207,209,210 
Detailed overviews of phenotypic features of large cohorts of possible CFNS patients 
do exist,185,186,188-192,194,210 but it is not clear what proportion of these patients carry an 
EFNB1 mutation. The reports in the older literature could therefore cause confusion by 
reporting patients who might be improperly classified as CFNS patients.
As it is of major importance to adequately counsel patients with EFNB1 mutations 
and/or their parents and to improve diagnosis of new patients, more information about 
the phenotypic features of genuine CFNS patients with an EFNB1 mutation is needed.
Methods
Study population
This study was conducted at the Craniofacial Unit of the Department of Plastic and 
Reconstructive Surgery of the Erasmus MC, University Medical Centre in Rotterdam, 
The Netherlands. All patients with a diagnosis of CFNS based on a confirmed EFNB1 
mutation who were currently under treatment, or who were treated in the past, were 
included in this study. A total of 23 patients (21 female, two male) were selected. Seven 
of these patients have been described in prior clinical studies, and the mutations of 13 
patients have been published before.188,212,213
Design and procedure
A cross-sectional observational study was designed and conducted. Ethical approval 
was received from the board of the Medical Ethical Committee of the Erasmus MC, 
University Medical Centre Rotterdam (MEC-2006-121).
Complete series of standardized photographs of all patients were collected, 
combined with a review of the patient’s medical file and physical examinations. If 
available, radiological images were also consulted. However, as this was a retrospective 
study, not all images were still available and moreover could not always be used as a 
source of quantitative data. Patients were asked to participate for an extra physical 
examination and additional photographs to capture all bodily features. Some short 
questions on functioning and limitations of their body were asked as well. Patients or 
parents provided written consent for the use of patient images.
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Genotype-phenotype correlation
The EFNB1 gene was examined by DNA sequence analysis of all coding exons and exon/
intron boundaries. Rearrangements of EFNB1 (deletions or insertions) were sought by 
multiplex ligation-dependent probe analysis (MLPA). For each patient we classified the 
type of nucleotide change (point mutation, deletion or duplication) and the type of 
protein change (missense, nonsense or frameshift mutation). We also indicated in which 
exons (exons 1-5) the mutations were located and in which regions of the protein the 
mutations were located (signal peptide, receptor binding domain, ephrin (extracellular 
domain), transmembrane domain, cytoplasmic domain or PDZ domain).
Measurement of facial proportions
For calculation of facial proportions, standardized (frontal and profile) photographs 
of all patients were printed. Selected photographs had to be taken prior to major 
surgical interventions, so genuine dimension could be evaluated. As all evaluated facial 
proportions were ratios, no scaling or calibration problems existed. Calculated indexes 
were compared with values derived from anthropometric studies.214 As illustrated 
in Figure 4.1, chosen indexes were: Intercanthal Index (Intercanthal width/Biocular 
width); Upper Face Index (Upper face height/Face width); Nasal Protrusion-Nose 
Height Index (Nasal tip protrusion/Nose height); Nose-Craniofacial Height Index (Nose 
height/Craniofacial height); Nose-Upper Face Height Index (Nose height/ Upper face 
height) and Upper Lip-Upper Face Height Index (Upper lip height/Upper face height). 
Nomenclature of the mentioned indexes and measurements are directly derived from 
the referred anthropometric studies.214
Statistical analyses
As a measure of central tendency, percentages were calculated for categorical variables. 
For metric variables, the mean was used as measure of central tendency, and the 
standard deviation was used as a measure of dispersion. For statistical analysis, we used 
the Statistical Package for the Social Sciences (SPSS) for Windows, version 18.0 (Erasmus 
University Medical Centre, Rotterdam, The Netherlands).
Results
Twenty-three patients with classical features of CFNS and proven EFNB1 mutations 
(Table 4.1, variants reported in this study are submitted to the LOVD database http://
database.lovd.nl/shared/genes/EFNB1) were included in this study. The single patient 
excluded was a female originally suspected to have CFNS, but who had no identified 
EFNB1 mutation; in retrospect (with the findings of this study) she would clinically 
not be classified again as having CFNS. A total of 21 female and two male CFNS 
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patients were identified. Five patients refused to participate for the additional physical 
examination and photographs. The main reason for not participating was an emotional 
or psychological problem with their bodily features, and seeing ‘no use’ in participating. 
One patient could not be contacted. Patients who did not want to participate however, 
had had standardized photographs taken during their treatment at least of their face, 
and sometimes hands, feet and chest. Medical files were available for all selected 
patients. As a result, the denominator of some of the observed features was lower than 
the total of 23 patients. Other features (e.g. breast anomalies) could not be scored in all 
patients, because these individuals were either male or too young to have developed 
breasts. In addition, one of our patients was a baby aged 6 months, so many features 
could not be scored. In these cases of incomplete data, fractions are given instead of 
percentages.
Five patients were heterozygous for the familial mutation identified in the index 
patient of the family. Regarding the intrafamilial variability, the following most obvious 
features were found: concerning the patient who was a daughter of a carrier male with 
a very mild phenotype, no comparison could be made because the daughter obviously 
showed a very different phenotype. Concerning the affected mother and daughter pair, 
both patients were equally affected in facial and bodily features. The daughter, however, 
was born with several cardiac anomalies, dextroposition of the heart, two superior 
venae cavae, a bidirectional shunt and an atrial septal defect. The two affected sisters 
differed slightly in facial features, as one of the sisters had more pronounced epicanthic 
folds, whereas the other had a more obvious orbital dystopia. In addition, one of them 
had a coloboma of the iris, a strabismus sursoadductorius, and a difference in length of 
legs (asymmetrical lower limb shortness).
Overall, we scored 107 phenotypic variables in the cohort of 23 patients. We also 
checked the genotype of our patients and used four variables to describe the genotype 
(type of nucleotide change, type of protein change, involved exon, and region of protein 
affected). Many variables consisted of multiple possible values, leading to a large 
variation of both genotype and phenotype, and no genotype-phenotype correlation 
could be detected.
General features
The average age of patients at evaluation was 18.0 years (range 0.5-44 years) with 12 
adults (age 16 years and above). Analysis of the body mass index revealed that 28% (n 
= 5) were underweight and 11% (n = 2) were overweight. The span-length-ratio had a 
mean of 0.93 (range 0.77-0.99), indicating that in most patients their arm span was not 
equal to their total height, which is in contrast to the normal population.
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Figure 4.1. Anthropometric facial proportions. BW = Biocular width, CFH = Craniofacial height, 
FW = Face width, IW = Intercanthal width, NH = Nose height, NTP = Nasal tip protrusion, UFH = 
Upper face height, ULH = Upper lip height.
Skull and face
As can be seen in Table 4.2 and Figure 4.2, the facial features of CFNS patients differ 
significantly from the normal population (more than 2 SDs above the mean).214 As 
expected, the intercanthal distance is much greater. The upper face (base of the nose to 
height of the commissure of the mouth) is relatively small compared to the width of the 
face (lateral points of zygoma). Compared with the height of the nose, the protrusion of 
the tip is relatively high in patients. However, the height of the nose itself is significantly 
shorter, compared with both the total face as well as the upper face. In contrast, the 
upper lip is larger than normal.
Craniosynostosis was seen in 78% of all patients; 22% (n = 5) had a left-sided coronal 
synostosis, 4% (n = 1) had a right-sided coronal synostosis, 48% (n = 11) had a bilateral 
synostosis of the coronal suture and 4% (n = 1) had a bilateral coronal synostosis with 
synostosis of the sagittal suture. One patient had her craniosynostosis corrected abroad 
before her first presentation, and the exact type of synostosis was unclear. All patients 
with craniosynostosis needed a surgical correction. A very large anterior fontanelle with 
delayed closure was present in 6/18. Two patients had agenesis of the corpus callosum, 
with partial agenesis in another three patients. Facial asymmetry was seen in 19/22 of 
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all patients, with a degree ranging from mild to severe; three of these patients had no 
history of craniosynostosis. A diminished development of the maxilla was sometimes 
observed (4/22), at different ages and of variable degree. In addition, one patient had a 
groove in the middle of her alveolar ridge.
Hair
In our population, 65% (n = 15) of all patients had a widow’s peak, and 26% (n = 6) had 
a low anterior hairline. The hair itself was dry and with frizzy curls in 12/22, dry and 
with loose curls in 8/22, and 2/22 showed normal hair. Parents reported that hair usually 
changed around 6-12 months, from soft baby hair into dry curly hair.
Table 4.1. Overview of mutations in the EFNB1 genea.
Gender Nucleotide change Protein change Exon Protein region Inheritance
1 Female213 c.[=/-95T>C] p.? 5’UTR NA 2
2 Male212,213 c.[=/412–
399_1038+7004del]
p.? 3-5 Ephrin partially, TM and CY 3
3 Female c.1A>G (mosaic) p.0? 1 SP 3
4 Female203 c.30C>T p.(Lys11fs)b 1 SP 1
5 Female188,203 c.109T>G p.(Trp37Gly) 1 RBD 1
6 Female c.161C>T p.(Pro54Leu) 2 RBD 0
7 Female c.196delC p.(Arg66fs) 2 RBD 2 (daughter)
8 Female c.228C>G p.(Tyr76*) 2 RBD 1
9 Female203 c.233T>C p.(Leu78Pro) 2 RBD 2 (mother)
10 Female203 c.233T>C p.(Leu78Pro) 2 RBD 2 (daughter)
11 Female c.266G>A p.(Cys89Tyr) 2 RBD 1
12 Female c.324dupA p.(Arg109fs) 2 RBD 1
13 Female188,203 c.339G>C p.(Lys113Asn) 2 RBD 1
14 Female c.360C>A p.(Asn120Lys) 2 RBD 0
15 Female188 c.368G>A p.(Gly123Asp) 2 RBD 1
16 Female203 c.407C>T p.(Ser136Leu) 3 RBD 0
17 Female c.451G>A p.(Gly151Ser) 3 RBD 0
18 Female c.492_499+2del p.(Gly165fs) 3 Ephrin 1
19 Male188,213 c.496C>T (mosaic) p.(Gln166*) 3 Ephrin 3
20 Female188,203 c.496C>T p.(Gln166*) 3 Ephrin 2 (Sister)
21 Female188,203 c.496C>T p.(Gln166*) 3 Ephrin 2 (Sister)
22 Female c.543delC p.(Ser182fs) 4 Ephrin 1
23 Female203 c.564dupT p.(Val189fs) 4 Ephrin 1
CY = Cytoplasmic domain, Ephrin = Ephrin extracellular domain, NA = Not applicable, RBD = Receptor-binding domain 
(located in the ephrin extracellular domain), SP = Signal peptide, TM = Transmembrane domain, UTR = Untranslated region, 0 
= De novo, 1 = Sporadic, 2 = Familial, 3 = Mosaic.
Variants submitted to http://databases.lovd.nl/shared/genes/EFNB1.
aReference sequence: NG_008887.1.
bRNA analysis showed that this synonymous substitution creates a cryptic donor splice site.203
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Zone of the orbits and eyes
All patients, 100% (n = 23), displayed hypertelorism, with a variable degree from mild 
to severe. At the time of evaluation, six patients were still too young to undergo a 
correction of their hypertelorism, but will probably be operated on in the future. Two 
adults with a relatively mild form did not require surgical intervention, the other 15 
patients underwent a surgical correction. Orbital dystopia was seen in 10/22 of them, 
five of the patients had no history of craniosynostosis, in seven of them the orbital 
dystopia was evident before any surgical intervention. Downslanting of the palpebral 
fissures was present in 35% (n = 8), with variable severity, whereas an upslant of the 
palpebral fissures was present in 48% (n = 11), although usually only mild. Epicanthic 
folds were frequent, and were unilateral in 39% (n = 9) cases and bilateral in 39% (n = 9) 
cases. An interrupted hairline of the eyebrow was seen in 70% (n = 16) of patients. Rare 
observations were a coloboma of the iris (n = 1) and heterochromia of the iris (n = 1).
Table 4.2. Difference of facial proportions of CFNS patients compared with anthropometric 
means214 (expressed in average standard deviations from mean).
Intercanthal
Index
Upper 
Face
Index
Protrusion–
Nose Height
Index
Nose–Craniofacial 
Height
Index
Nose–Upper 
Face Height
Index
Upper Lip–Upper 
Face Height
Index
Patients 
<6 years
+5.3 SD -2.1 SD +1.7 SDa -3.4 SDb -4.0 SDb +5.1 SDb
Patients 
>6 years
+4.7 SD -1.5 SD +1.6 SD -1.6 SD -2.0 SD +2.8 SD
Total 
group
+5.0 SD -1.8 SD +1.7 SD -2.5 SD -3.0 SD +4.0 SD
aYoungest age of reference group is 6 years, difference probably slightly bigger if adequate reference would be available.
bYoungest age of reference group is 6 years, difference probably slightly smaller if adequate reference would be available.
Ocular function
Before a correction of the hypertelorism or orbital dystopia, a substantial number 
of ophthalmologic abnormalities were observed. The most common anomaly was 
strabismus (9/22), subdivided into divergent (n = 3), sursoadductorius (n = 4) and 
convergent (n = 2) types, sometimes in combination with a dissociated vertical deviation 
(n = 5). Nystagmus was also a common finding (9/22 patients): four had congenital 
nystagmus and four had latent nystagmus. Hypermetropia was present in three, two 
of them had a very high astigmatism and one had solitary high stigmatism. Amblyopia 
was identified in two and an absent oblique superior muscle was found in one patient.
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Figure 4.2. Patient displaying typical aberrant facial proportions.
Ears
Low set ears were a common finding, 52% (n = 12), whereas only two patients had an 
abnormal shape of the external ear.
Zone of the nose
Nearly all patients (91%, n = 21) displayed a bifid tip of the nose. The same can be said 
for an indentation in the columella, 91% (n = 21), although not all patients with a bifid 
tip also had this indentation. A broad nasal base, 70% (n = 16), and flat nasal bridge, 43% 
(n = 10), were frequently observed. One patient had a fistula in the dorsum of her nose 
with an intracranial connection.
Zone of the mouth, maxilla and mandible
A common observation was a tent-shaped mouth 39% (n = 9), and a mild keel-shaped 
maxilla in 35% (n = 8). Crowding of the teeth was seen in 23% (n = 5). Hypoplasia of the 
maxilla was reported in 4/22 patients, whereas 2/22 had a mandibular prognathism. 
A unilateral right-sided cleft lip and palate was seen in only one patient, whereas one 
other patient had a very mild notch in the midline of her upper lip.
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Zone of the neck, shoulders, chest and back
A true short and webbed neck was present in 12/18 patients and in addition a mild 
webbing or pseudo-webbing of the neck was present in the other 6/18 patients. 
Rounded and sloping shoulders, often rather narrow, were observed in 16/18. 
Sprengel’s deformity of the shoulders (defined as one shoulder blade that sits higher on 
the back than the other) was quite common as well (8/12). Three patients displayed an 
axillary pterygium; unilateral in two patients, bilateral in one. A low implantation of the 
breasts was seen in the majority of patients (19/21), and in addition most of them had 
asymmetrical heights of their nipples (11/19). Patients who were in their adolescence or 
adulthood also displayed an asymmetry of the breast volume (6/8). Looking at the chest 
wall itself, revealed a pectus excavatum in 11/17 patients, although mild in most cases. 
Four patients were affected with both breast asymmetry and a pectus excavatum. All 
of the above are illustrated in Figure 4.3. Scoliosis was diagnosed in 6/13 patients, but 
none of the patients needed surgery.
Upper extremity
All patients (100%, n = 23) had a longitudinal ridging and/or splitting of nails toward 
the end, although the number of digits affected and severity differed. Only two patients 
were born with an extra digit (9%), and only three had a complete or incomplete 
syndactyly (13%). A clinodactyly of one or more digits was frequent (74%, n = 17). A 
restricted range of motion of the arms, affecting either abduction or elevation above 
the head, was present in the majority of patients (15/17). This is probably due to the 
aberrant position of the clavicles, in combination with the earlier mentioned Sprengel’s 
deformity. The available radiological images of the chest revealed that patients had 
either an aberrant curvature of their clavicles and/or the angle of the clavicles with the 
sternum was bigger than normal. Either way, this resulted in a typical higher placement 
of the shoulders.
Lower extremity
As was observed in the hand, all patients (20/20) had a longitudinal ridging and/or 
splitting of toenails toward the end, whereas both the severity as well as the number of 
toes affected differed. Duplication of toes was seen in 4/20 patients and syndactyly in 
7/20 patients. Clinodactyly of at least one toe, was again a consistent finding (20/20), as 
illustrated in Figure 4.4. One patient had asymmetrical lower-limb shortness.
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Figure 4.3. Patient with typical chest and breast deformities.
Cardiac abnormalities
Three patients (13%) had problems affecting their heart. One had a patent ductus 
arteriosus, one had an atrial flutter of unknown origin immediately after birth and one 
had multiple cardiac problems: dextroposition of the heart, two superior venae cavae, a 
bidirectional shunt and an atrial septal defect.
Miscellaneous findings
Two patients had psoriasis and another single patient had an umbilical hernia, one male 
presented with cryptorchidism, another patient had a café-au-lait spot, one patient 
presented herself with a haemangioma and one patient had an episode with toddler’s 
hypoglycaemia.
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Figure 4.4. Patient displaying typical foot and toe deformities.
Discussion
Genuine CFNS patients, with proven EFNB1 mutations, have a clear and very 
distinguishable phenotype. However, a detailed overview of the phenotypic features of a 
large cohort of proven CFNS patients has not previously been presented in the literature. 
As expected, some of the previous reports can cause confusion by reporting patients 
who were possibly incorrectly diagnosed with CFNS. This probably explains the majority 
of the ~20% of apparent CFNS patients without an EFNB1 mutation.201,203,205 The results 
from this study make the diagnosis of some patients presented in literature therefore 
doubtful, based on their different facial proportions and dissimilar phenotype.189,196,210 
In other studies, some patients were classified as having frontonasal dysplasia, whereas 
they actually match the typical phenotype of CFNS.195,212,215
We included only three families with more than one affected member in this 
study. One of these comprised a father (a male carrier) and a daughter and therefore 
we could not draw any conclusions regarding intrafamilial variability. In the other two 
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families, the clinical features differed highly, suggesting that intrafamilial variability can 
be significant. A genotype-phenotype correlation seems to be unlikely, based on this 
intrafamilial variability and a previous study,206 and was not found in this study.
This study leads us to the conclusion that in CFNS patients with an EFNB1 mutation, 
consistent features exist: hypertelorism, a certain degree of longitudinal ridging and/
or splitting of nails of at least one digit or toe, a certain degree of webbed neck and 
a clinodactyly of one or more toes. In addition, abnormal facial proportions were 
observed in all patients.214 These proportions are reflected in a relatively small upper 
face compared with the width of the face, a very short nose, with a relatively high 
protrusion compared with its length and a relatively long upper lip, compared with the 
upper face. It must be stressed that the projection of the nose itself in comparison to 
the whole face is very small, but as the length is about the same as the projection, this 
ratio is relatively high.
Features that were present in most, but not all patients, can be regarded as ‘very 
suggestive’ of the diagnosis. These are: bifid tip of the nose (91%), indentation of the 
columella (91%), low implant of breasts (90%), rounded, sloping and often rather narrow 
shoulders (89%) with reduced range of motion of the shoulders (88%), facial asymmetry 
(86%), craniosynostosis (78%), clinodactyly of at least one digit (74%), aberrant form 
of eyebrow (70%) and broad nasal bridge (70%). Although similar features have been 
noted in previously published studies,186,188,190,191,193,194 it is not possible to compare 
frequency data directly because of differences in methodology.
Measurements of facial proportions are seldom reported, which is unfortunate. 
One study gave a description of the cranio-orbito-zygomatic region, based on CT-
scans compared with an age-matched control value. Besides the obvious increased 
interorbital distance, they also found a degree of horizontal midface retrusion 
demonstrated by a shortened zygomatic arch length and an expanded interzygomatic 
buttress distance, suggestive for a brachycephalic morphology.195 In addition, another 
study also described a short upper facial height190 and compared it to anthropometric 
measurements. However, the short upper facial height seemed to be present in only 
66% of their cases. A further study mentions midface hypoplasia,185 however, they do 
not support it with objective data or compare it to a normal reference group. These 
findings are in accordance to our data.
Hopefully, this study will facilitate the diagnosis of CFNS. Based on this study, new 
patients should be evaluated for facial proportions and hypertelorism, they should be 
checked for longitudinal ridging and/or splitting of nails of at least one digit or toe, for 
webbed neck, and for a clinodactyly of one or more toes. Furthermore, other bodily 
features should be compared with the ones given in this paper.
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It is likely that not all possible phenotypic features of CFNS are present within our 
population. A few other features that were not evaluated in this study are presented 
in the literature: myoclonus, poor hearing, pelvic kidney, bilateral vesico-ureteral 
reflux, hip girdle anomalies,193 median cleft lip/palate,190 asymmetric mandible.191 
Additional features that have been reported in other studies of patients with EFNB1 
mutations include: diaphragmatic hernia,63,141,201,207 dysplastic clavicles and clavicle 
pseudoarthrosis,63,190-194,200,203 accessory nipples,192 high arched palate,186,191-194,212 
uterus arcuatus,192 duplication of uterus, kidneys and ureters,192 and low posterior 
hairline.190,194,202 Furthermore, some studies state that CFNS patients have a normal 
intelligence,190,192,194,197 whereas others claim that some may have learning difficulties to 
a variable degree.185,186,192,203,212 In this study, intelligence was not measured.
One of the limitations of this study is the low number of males included. Although 
CFNS manifests particularly in females, and affected males express significantly less 
features, a clear phenotype of hemizygous males could not be given, as both of the 
two males evaluated carried mosaic mutations, and as a consequence were as severely 
affected as the females.32 On the other hand, we believe that the number of clinically 
evaluated CFNS patients with proven EFNB1 mutations in this study is unique in its size, 
and therefore adds value to the current literature. Future research could focus on the 
psychological and intellectual development and surgical impact.
14845-goos-layout.indd   79 13/11/2017   19:20
14845-goos-layout.indd   80 13/11/2017   19:20
C h a p t e r  5
Mutations in TCF12, encoding 
a basic helix-loop-helix partner 
of TWIST1, are a frequent cause 
of coronal craniosynostosis
Vikram P. Sharma,* Aimée L. Fenwick,* Mia S. Brockop,* Simon J. McGowan, Jacqueline A.C. 
Goos, A. Jeannette M. Hoogeboom, Angela F. Brady, Nu Owase Jeelani, Sally Ann Lynch, John 
B. Mulliken, Dylan J. Murray, Julie M. Phipps, Elizabeth Sweeney, Susan E. Tomkins, Louise C. 
Wilson, Sophia Bennett, Richard J. Cornall, John Broxholme, Alexander Kanapin, 500 Whole-
Genome Sequences (WGS500) Consortium, David Johnson, Steven A. Wall, Peter J. van der 
Spek, Irene M.J. Mathijssen, Robert E. Maxson,‡ Stephen R.F. Twigg,‡ Andrew O.M. Wilkie‡
* Equal contributors
‡ These authors jointly directed this work
Nature Genetics January 2013
14845-goos-layout.indd   81 13/11/2017   19:20
82
Chapter 5
Abstract
Craniosynostosis, the premature fusion of the cranial sutures, is a heterogeneous disorder 
with a prevalence of ~1 in 2,200.2,3 A specific genetic aetiology can be identified in ~21% 
of cases,128 including mutations of TWIST1, which encodes a class II basic helix-loop-helix 
(bHLH) transcription factor, and causes Saethre-Chotzen syndrome, typically associated 
with coronal synostosis.138,139,216 Using exome sequencing, we identified 38 heterozygous 
TCF12 mutations in 347 samples from unrelated individuals with craniosynostosis. The 
mutations predominantly occurred in individuals with coronal synostosis and accounted 
for 32% and 10% of subjects with bilateral and unilateral pathology, respectively. TCF12 
encodes one of three class I E proteins that heterodimerise with class II bHLH proteins 
such as TWIST1. We show that TCF12 and TWIST1 act synergistically in a transactivation 
assay and that mice doubly heterozygous for loss-of-function mutations in Tcf12 and 
Twist1 have severe coronal synostosis. Hence, the dosage of TCF12-TWIST1 heterodimers 
is critical for normal coronal suture development.
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Introduction
Our exome sequencing approach focused on bilateral coronal craniosynostosis 
(Figure 5.1) because of previous evidence that this pathological group is loaded with 
cases of monogenic aetiology.128 We examined the variant lists from the whole exome 
data217 of seven unrelated Individuals with bilateral coronal synostosis, negative for 
previously described mutations,125 for genes showing nonsynonymous changes in 
two or more samples. Two samples had different heterozygous frameshift mutations 
in TCF12 (encoding transcription factor 12; also known as HEB, HTF4 and ALF1);218-220 
one (family 19) had a single nucleotide deletion, and the other (family 30) had a four-
nucleotide deletion (details in Supplementary Table 5.1). The mutations were confirmed 
by dideoxy sequencing of the original DNA samples (primary sequence results for 
all families are shown in Supplementary Figure 5.1). In addition, a text search of the 
exome sequence data identified a new c.1468–20>A variant in TCF12 in a third sample 
(family 22), located 20 nucleotides upstream of the start of exon 17. This variant was 
predicted to generate a cryptic splice acceptor site that was confirmed experimentally 
(Supplementary Figure 5.2A). Thus, we had identified different heterozygous disruptive 
mutations of TCF12 in three of seven samples from individuals with bilateral coronal 
synostosis. We interrogated other exome or whole genome sequencing projects 
on craniosynostosis that we were undertaking concurrently: this analysis identified 
additional TCF12 mutations in two siblings with bilateral coronal synostosis and their 
clinically unaffected mother (family 20, which we had erroneously analysed assuming 
recessive inheritance) and in two unrelated individuals (from families 11 and 16) with 
clinical diagnoses of Saethre-Chotzen syndrome who did not have identified mutations 
in the TWIST1 gene.138,139,216
To confirm these findings and explore the clinical consequences of TCF12 mutations, 
we carried out dideoxy sequencing of TCF12 in individuals with different types of 
craniosynostosis in whom mutations had not previously been identified. In the initial 
panel of 287 unrelated samples, we identified 18 with pathogenic mutations in TCF12; 
all mutation-positive individuals had coronal synostosis. To replicate our findings, we 
sequenced an independent Dutch cohort of 50 samples with coronal synostosis and 
identified 14 additional mutations in TCF12. Overall, we observed a strong bias for 
mutations in TCF12 to occur in association with coronal synostosis (Table 5.1): 22 of 
69 (32%) bilateral coronal and 14 of 141 (10%) unilateral coronal cases had mutations, 
but none of 93 cases with isolated metopic, sagittal or lambdoid synostosis had TCF12 
mutations (P = 1 × 10−6, Fisher’s exact test). The remaining two cases positive for TCF12 
mutations had combinations of sagittal and either uni- or bilateral coronal synostosis, 
such that coronal synostosis was present in all 38 index subjects. In our extended Oxford
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To confirm these findings and explore the 
clinical consequences of TCF12 mutations, we 
carried out dideoxy sequencing of TCF12 in 
individuals with different types of craniosynostosis in whom mutations 
had not previously been identified. In the initial panel of 287 unrelated sam-
ples, we identified 18 with pathogenic mutations in TCF12; all mutation- 
positive individuals had coronal synostosis. To replicate our findings, 
we sequenced an independent Dutch cohort of 50 samples with coronal 
synostosis and identified 14 additional mutations in TCF12. Overall, 
we observed a strong bias for mutations in TCF12 to occur in association 
with coronal synostosis (Table 1): 22 of 69 (32%) bilateral coronal and 
14 of 141 (10%) unilateral coronal cases had mutations, but none of 
93 cases with isolated metopic, sagittal or lambdoid synostosis had TCF12 
mutations (P = 1 × 10−6, Fisher’s exact test). The remaining two cases 
positive for TCF12 mutations had combinations of sagittal and either 
uni- or bilateral coronal synostosis, such that coronal synostosis was 
present in all 38 index subjects. In our extended Oxford birth cohort3 with 
minimum 5-year follow-up (cases born in calendar years 1998–2006), 
we found TCF12 mutations in 4 of 402 subjects (1.0%; 95% confidence 
interval of 0.3–2.5%). Hence, mutations in TCF12 occur in a measurable 
fraction of craniosynostosis overall (Supplementary Fig. 3).
The mutations identified in TCF12 comprise 14 nonsense, 
15 frameshift, 7 splicing and 2 missense changes, suggesting a loss-
of-function mechanism (Fig. 2). This is consistent with previous 
reports12 of individuals with cytogenetically identified chromosome 15 
deletions (predicted to include TCF12 at 
15q21.3) in whom craniosynostosis was 
present, although no whole-exon deletions 
of TCF12 were detected in our subject panel 
using a multiplex ligation–dependent probe 
amplification (MLPA) assay. In cases with 
frameshift or splice-site mutations, analyses 
of mRNA extracted from various cell types 
showed lower expression of the mutant 
compared to the wild-type allele, consist-
ent with nonsense-mediated mRNA decay 
(Supplementary Fig. 2 and Supplementary 
Table 2). The mutations showed a clear 
enrichment in the 3′ half of TCF12, with all 
Figure 1 Phenotype associated with TCF12 or 
Tcf12 haploinsufficiency in humans and mice. 
(a,b) Clinical presentation of individuals with 
TCF12 mutations, showing facial appearance 
(left) and computed tomography (CT) images of 
the head (right). Written permission was obtained 
to publish the clinical photographs. (a) Bilateral 
coronal synostosis in the proband from family 
30: note the high forehead and brachycephaly 
at the age of 13 months. CT images at the age 
of 4 months show bilateral fusion of the coronal 
sutures associated with bony ridging (arrows).  
(b) Right unilateral coronal synostosis in the 
proband from family 35: at the age of 10 months, 
note the elevation of the right orbit and shifting 
of the midface and mandible to the left.  
CT images at the age of 4 months show complete 
fusion of the coronal suture on the right 
(arrowhead), an open coronal suture on the left 
(LC) and relative angulation of the metopic (M) 
and sagittal (S) sutures. (c–f) Severe bilateral 
coronal synostosis in EIIa-Cre; Tcf12flox/+; 
Twist1+/− combination mutants. Shown are 
representative images of postnatal day (P) 21 
skulls stained with Alizarin Red S (top), three-
dimensional µCT reconstructions (middle) and 
two-dimensional µCT images of sagittal slices 
(10 µm) through the coronal suture (bottom; the 
section planes are indicated by white lines in 
the three-dimensional images). Note the normal 
coronal sutures in the wild-type (c) and EIIa-Cre; 
Tcf12flox/+ (d) skulls, partial unilateral coronal 
synostosis in the Twist1+/− skull (e, arrow) and 
complete bilateral coronal synostosis in the 
EIIa-Cre; Tcf12flox/+; Twist1+/− skull (f, arrows). 
C, coronal suture; FB, frontal bone; L, lambdoid 
suture; PB, parietal bone. Scale bars, 1 mm.
a
c d e f
b S
S
M
M
S
PB
PB
L
FB
FB
Wild type Ella-Cre; Tcf12flox/+ EIIa-Cre; Tcf12flox/+; Twist1+/–Twist1+/–
PB
C
FB
C
C
M
LC
LC
table 1 Identification of TCF12 mutations in different categories of craniosynostosis
Non-syndromic Syndromic Combined
Total
TCF12 mutation  
positive Total
TCF12 mutation  
positive Total
TCF12 mutation  
positive
Metopic 32 0 14 0 46 0
Sagittal 32 0 7 0 39 0
Unilateral coronal 115 9 26 5 141 14
Bilateral coronal 28 5 41 17 69 22
Uni- or bilateral  
 lambdoid
8 0 0 0 8 0
Multisuture 19 1 19 1 38 2
Sutures not specified 2 0 4 0 6 0
Combined 236 15 111 23 347 38
Figure 5.1. Phenotype associated with TCF12 or Tcf12 haploinsufficiency in humans 
and mice. A and B: clinical presentation of individuals with TCF12 mutations, showing facial 
appearance (left) and computed tomography (CT) images of the head (right). Written permission 
was obtained to publish the clinica  photographs. A: bi ateral coronal synostosis in the proband 
from family 30. Note the high forehead and brachycephaly at the age of 13 months. CT images 
at the age of 4 months show bilateral fusion of the coronal sutures associated with bony ridging 
(arrows). B: right unilateral coronal synostosis in the proband from family 35: at the age of 10 
months, note the elevation of the right orbit and shifting of the midface and mandible to the 
left. CT images at the age f 4 months show complete fusion of the coronal suture on the right 
(arrowhead), n open coronal suture on the left (LC) and relative angulation of the metopic (M) 
and sagittal (S) sutures. C-F: severe bilateral coronal synostosis in EIIa-Cre; Tcf12flox/+; Twist1+/− 
combinati n mutants. Shown are representative images of postnatal day (P) 21 skulls stained 
with Alizarin Red S (top), three-dimensional μCT reconstructions (middle) and two-dimensional 
μCT images of sagittal slices (10 μm) through the coronal suture (bottom; the section planes are 
indicated by white lines in the three-dimensional images). Note the normal coronal sutures in the 
wild-type (C) and EIIa-Cre; Tcf12flox/+ (D) skull , partial unilateral coron l synostosis in the Twist1+/− 
skull (E, arrow) and complete bilateral coronal synostosis in the EIIa-Cre; Tcf12flox/+; Twist1+/− skull 
(f, arrows). C = Coronal suture, FB = Frontal bone, L = Lambdoid suture, PB = Parietal bone. Scale 
bars, 1 mm.
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birth cohort128 with minimum 5-year follow-up (cases born in calendar years 1998–
2006), we found TCF12 mutations in 4 of 402 subjects (1.0%; 95% confidence interval of 
0.3–2.5%). Hence, mutations in TCF12 occur in a measurable fraction of craniosynostosis 
overall (Supplementary Figure 5.3).
Table 5.1. Identification of TCF12 mutations in different categories of craniosynostosis.
Non-syndromic Syndromic Combined
Total
TCF12 mutation
positive
Total
TCF12 mutation
positive
Total
TCF12 mutation
positive
Metopic 32 0 14 0 46 0
Sagittal 32 0 7 0 39 0
Unilateral 
coronal
115 9 26 5 141 14
Bilateral coronal 28 5 41 17 69 22
Uni- or bilateral
lambdoid
8 0 0 0 8 0
Multisuture 19 1 19 1 38 2
Sutures not 
specified
2 0 4 0 6 0
Combined 236 15 111 23 347 38
The mutations identified in TCF12 comprise 14 nonsense, 15 frameshift, 7 
splicing and 2 missense changes, suggesting a loss-of-function mechanism (Figure 
5.2). This is consistent with previous reports221 of individuals with cytogenetically 
identified chromosome 15 deletions (predicted to include TCF12 at 15q21.3) in whom 
craniosynostosis was present, although no whole exon deletions of TCF12 were detected 
in our subject panel using a multiplex ligation–dependent probe amplification (MLPA) 
assay. In cases with frameshift or splice-site mutations, analyses of mRNA extracted 
from various cell types showed lower expression of the mutant compared to the wild-
type allele, consistent with nonsense-mediated mRNA decay (Supplementary Figure 
5.2 and Supplementary Table 5.2). The mutations showed a clear enrichment in the 
3’ half of TCF12, with all but one located between exons 10 and 19. The remaining 
mutation (c.526+1G>A), which caused skipping of exon 7 (Supplementary Figure 5.2D), 
is specific to the longer TCF12 transcript, as the alternative transcription start site222 
lies downstream of this position (exon 9A; Figure 5.2A). The two missense mutations 
(encoding p.Leu624Pro and p.Gln638Glu substitutions) affect highly conserved residues 
of the bHLH domain required for dimerization (Supplementary Figures 5.4A and 5.4B); 
mutations of other bHLH proteins often affect this region, with examples including 
alterations of the class I protein TCF4 (Pitt-Hopkins syndrome)223 and class II protein 
TWIST1.216 Using a transactivation assay with a reporter containing three E-boxes,224 we 
found that the combination of native TCF12 and TWIST1 proteins had a synergistic effect 
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on activation relative to the activity of either protein individually, but this effect was 
65–76% lower in the presence of the TCF12 missense mutations encoding p.Leu624Pro 
or p.Gln638Glu alterations (Supplementary Figure 5.4C).
Figure 5.2. Structure of TCF12 and the encoded protein showing the location of mutations 
identified in coronal synostosis. A: gene structure. The major transcript comprises 21 exons; 
inclusion or exclusion of exon 15 by alternative splicing generates proteins of 706 and 682 amino 
acids, termed HEBβ and HEBα, respectively. Alternative transcription starting at exon 9A generates 
a different protein (HEBAlt) of 512 amino acids.222 B: protein structure. Domains identified in the 
HEBβ protein (portion encoded by exon 15 shaded gray). Functional studies previously defined 
activation domains 1 and 2225 and the rep domain.226 Identical mutations identified in independent 
families are indicated (×2); note that mutations predicted to affect splicing are omitted from the 
protein schematic.
Of 36 families from which additional samples were available, the TCF12 mutation 
was shown to have arisen de novo in 14 (Supplementary Figure 5.1 and Supplementary 
Table 5.1), providing further evidence that the TCF12 mutations are causative of the 
coronal synostosis phenotype. In 23 of the families, cascade testing identified 34 
additional mutation-positive individuals, only 16 of whom had craniosynostosis or other 
relevant clinical features, indicating substantial (53%) non-penetrance (Supplementary 
Table 5.1; see Supplementary Figure 5.5 for representative clinical photographs). There 
was no evidence to implicate somatic mosaicism in any of the non-penetrant cases, but 
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preliminary analysis of haplotypes around TCF12 (which resides in a region of strong 
linkage disequilibrium) suggested that the allelic backgrounds of both non-mutant and 
mutant copies of TCF12 contribute to variability in the phenotype (data not shown). 
Of 14 mutation-positive relatives diagnosed with craniosynostosis involving specific 
sutures, 12 had coronal synostosis, and 2 had sagittal synostosis.
The clinical features associated with TCF12-related craniosynostosis are detailed 
(Supplementary Table 5.3), and representative subjects with bilateral coronal 
synostosis (Figure 5.1A) or unilateral coronal synostosis (Figure 5.1B) are shown. In 15 
probands (39%), a genetic cause was suspected because of a positive family history. 
In another seven probands (18%), clinical features (including dysmorphic appearance 
of the face and external ears and minor limb anomalies) were suggestive of Saethre-
Chotzen syndrome, which had been excluded by negative TWIST1 mutation testing. 
The remaining subjects (16/38 = 42%) presented sporadically with apparently non-
syndromic synostosis (Supplementary Table 5.1). No genotype-phenotype correlation 
was detected. For affected individuals recruited at Oxford, we compared the surgical 
trajectory128 of TCF12-positive individuals with those of individuals falling into other 
clinical and genetic categories. The individuals with TCF12 mutations had a more 
benign course compared with individuals with either p.Pro250Arg FGFR3 or TWIST1 
alterations (Supplementary Figure 5.6), and no individuals positive for TCF12 mutations 
were documented to have an interval onset of raised intracranial pressure after their 
initial surgical procedure(s). Most individuals had normal developmental attainment, 
but ten (14%) had developmental delay or learning disability, which in two cases was 
associated with autism (clinical features are summarized in Supplementary Table 5.4). 
Previous genetic data derived from homozygous mutant mice identified key roles for the 
orthologous Tcf12 gene in the development of the immune system,222,227 but we found 
no history of infection susceptibility in individuals heterozygous for TCF12 mutations, 
and there was no detectable reduction in monocyte, natural killer (NK), T-cell or B-cell 
subsets or lower amounts of immunoglobulin in 11 mutation-positive individuals.
Supporting our transactivation data (Supplementary Figure 5.4), it was 
previously reported that TCF12 forms heterodimers with TWIST1228 and that TWIST1 
haploinsufficiency causes Saethre-Chotzen syndrome.138,139,216 Our observation that 
haploinsufficiency of TCF12 in humans leads specifically to coronal synostosis suggests 
that the total quantity of TCF12-TWIST1 heterodimers is a critical factor in coronal suture 
development.
To test this hypothesis, we compared the phenotypes of the previously constructed 
individual heterozygous null mutant mice (EIIa-Cre; Tcf12flox/+ and Twist1+/−)227,229,230 
to that of the compound heterozygotes (EIIa-Cre; Tcf12flox/+; Twist1+/−). At three weeks 
of age, the EIIa-Cre; Tcf12flox/+ animals (n = 14) had normal coronal sutures, indicating 
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that the coronal suture is less sensitive to Tcf12 dosage in mice than in humans (Figure 
5.1C,D); Twist1+/− mice (n = 4) showed variable coronal synostosis, as previously reported 
(Figure 5.1E).139,231 However, the EIIa-Cre; Tcf12flox/+; Twist1+/− compound heterozygotes 
(n = 6), which were born at a frequency close to the expected Mendelian ratio (25%), 
consistently showed severe coronal synostosis (Figure 5.1F).
The discovery that haploinsufficiency of TCF12 causes coronal synostosis in 
humans and that severe bilateral coronal synostosis occurs in mice with 50% of the 
wild-type dosage of both the Tcf12 and Twist1 genes highlights the key role of TCF12 
acting with TWIST1, probably as a heterodimeric complex, in the normal development 
of the coronal sutures. The TCF12-TWIST1 heterodimer is likely to regulate specification 
of the boundary between the neural crest and cephalic mesoderm231,232 and/or inhibit 
osteogenic differentiation via actions on RUNX2233 and bone morphogenetic protein234 
or fibroblast growth factor receptor228 signalling.
URLs
ANNOVAR, http://www.biobase-international.com/product/annovar;
GBrowse2, http://gmod.org/wiki/GBrowse;
MRC-Holland, http://www.mrc-holland.com/;
PolyPhen-2, http://genetics.bwh.harvard.edu/pph2;
SAMtools, http://samtools.sourceforge.net.
Accession codes
All cDNA numbering of TCF12 follows NCBI reference NM_207037.1, starting with 
A of the ATG initiation codon (+1). We used NM_207040.1 to design primers to the 
alternatively spliced first exon (9A). The genomic reference sequence is available under 
accession NC_000015.9.
Supporting information
Samples
The clinical studies were approved by Oxfordshire Research Ethics Committee B 
(reference C02.143), Riverside Research Ethics Committee (reference 09/H0706/20) and 
the Medical Ethical Committee of the Erasmus University Medical Centre Rotterdam 
(MEC-2012-140). Written informed consent to obtain samples for genetics research was 
obtained from each child’s parent or guardian. The clinical diagnosis of craniosynostosis 
was confirmed by CT scan, and evidence of associated syndromic features was sought by 
clinical examination. Venous blood was obtained for DNA and RNA extraction (collected 
into PAXgene Blood RNA tubes (Qiagen) for the latter procedure). Fibroblast cultures were 
established from skin biopsies obtained from the scalp incision at the time of surgical 
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intervention. When clinically indicated, samples were tested for mutation hotspots in 
FGFR2, FGFR3 and TWIST1,125 and significant chromosome aneuploidy was investigated 
using aCGH; samples with identified mutations known to cause craniosynostosis were 
excluded. Seven samples from unrelated individuals with bilateral coronal synostosis 
were chosen for exome sequencing. These comprised five subjects who were clinically 
non-syndromic with negative family history, one subject who was clinically non-
syndromic but reported to have two children with coronal synostosis and one subject 
who was the only individual in the family affected with craniosynostosis but who had 
short thumbs that were also present in several additional family members from the two 
previous generations.
Exome sequencing
We used an Agilent SureSelect Human All Exon Kit (v.2; 44 Mb) to capture exonic DNA 
from a library prepared from 3 μg of each proband’s genomic DNA (extracted from whole 
blood). The enriched DNA was sequenced on an Illumina Genome Analyzer IIx platform 
with 51-bp paired-end reads. We generated between 3.98 and 4.56 Gb of sequence 
for each sample that, after mapping with Novoalign (Novocraft Technologies) to the 
hg19 genome and removal of artefacts using custom Perl scripts, resulted in an average 
coverage of exons of between 33- and 44-fold. Variants were called using SAMtools 
and annotated using ANNOVAR and PolyPhen-2. We removed all variants annotated in 
dbSNP132 and manually examined the gene lists for overlaps of two or more variants. 
Sequence data were visualized using GBrowse2.
Analysis of TCF12
After the identification of candidate TCF12 mutations in the exome sequence, we 
confirmed and extended this analysis by direct sequencing of genomic PCR amplification 
products, MLPA and analysis of cDNA products. Details of the oligonucleotides and 
experimental conditions are provided in Supplementary Table 5.5. Our initial screening 
panel mostly comprised samples recruited in Oxford128 and other craniofacial units 
within the UK, and the replication panel comprised samples obtained in Rotterdam, 
the Netherlands. PCR amplification was performed in a volume of 20 μl, containing 15 
mM Tris-HCl (pH 8.0), 50 mM KCl, 2.5 mM MgCl2, 100 μM each dNTP, 0.4 μM primers 
and 0.5 units of Amplitaq Gold polymerase (Applied Biosystems), with or without 10% 
DMSO, as indicated. Cycling conditions consisted of an 8-min denaturation step at 94 °C, 
followed by 35 cycles of 94 °C for 30 s, annealing at 65 °C (unless otherwise indicated in 
Supplementary Table 5.5) for 30 s and extension at 72 °C for 30 s, with a final extension at 
72 °C for 10 min. Amplification products were sequenced using the BigDye Terminator 
v3.1 cycle sequencer system (Applied Biosystems). All mutations were reconfirmed, 
either by restriction digestion of 5 μl of PCR product or by repeat dideoxy sequencing 
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of an independent PCR product. In addition to the mutations listed in Supplementary 
Table 5.1, we identified two previously unreported variants in single individuals that are 
currently of uncertain pathogenic significance, c.630T>G, p.(Ser210Arg) and c.982A>G, 
p.(Asn328Asp).
Copy-number variation was analysed by MLPA performed using synthetic 
oligonucleotide probes designed to TCF12 according to protocols available from MRC-
Holland. Fragments were analysed by capillary electrophoresis using an ABI 3130 
containing POP-7 polymer. Peaks were visualized using Gene Mapper v3.7 (Applied 
Biosystems). Normal MLPA results were obtained in 226 craniosynostosis samples 
negative for intragenic TCF12 mutations. For studies of splicing and mRNA stability, 
RNA was extracted from whole blood and fibroblasts using TRIzol reagent. cDNA was 
synthesized using the Fermentas RevertAid First-Strand Synthesis kit with random 
hexamer primers according to the manufacturer’s instructions. The microsatellites used 
to confirm sample relationships were D3S1311, D4S403, D5S2027, D6S1610, D7S519, 
D9S158, D10S548, D11S898, D13S1265, D14S280, D16S415 and D18S474.
Immune function tests
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by density 
gradient centrifugation in cell separation tubes (Sigma), washed three times in sterile 
PBS and rested overnight in RPMI 1640 medium supplemented with 10% FCS, 1% 
L-glutamine, 1% penicillinstreptomycin solution and 50 μM β-mercaptoethanol (all from 
Sigma) and 1% HEPES buffer (GibcoBRL). Monocytes, NK cells and naive, effector and 
memory T- and B-cell subsets were enumerated by flow cytometry of PBMCs stained 
with human-specific antibodies against CD3, CD4, CD19, CD14, CCR7, CD45RO, CD62L, 
CD16, CD56, CD25, IgD, IgM, CD10 and CD27 (Supplementary Table 5.6). Total IgM, IgA 
and IgG antibody titres were measured by ELISA.
Transactivation analysis of missense mutations
We obtained a full-length TCF12 cDNA clone (pCMV6-XL5, encoding HEBβ) from OriGene 
and synthesized the TWIST1 clone (pCMV-Twist) in house. The pCaSpeR-Tinman::lacZ 
(pTinE1/E2/E3) construct (containing three Tinman E-boxes comprising two 5’-CATGTG-3’ 
and one 5’-CATATG-3’) was used as a bHLH  protein-responsive reporter, and placZ 
(containing no E-boxes) was used as a control (both constructs were gifts from E.M. 
Füchtbauer).224 PCR mutagenesis was used to introduce the c.1871T>C and c.1912C>G 
mutations into the TCF12 cDNA using the primers indicated in Supplementary Table 5.5; 
mutated cDNAs were fully verified by sequencing.
The HT1080 human cell line was cultured in high-glucose DMEM (Invitrogen) 
supplemented with 10% FCS. Cells were transfected in triplicate with 1 μg of reporter 
plasmid, 1 μg each of TWIST1 and TCF12 constructs or the corresponding empty 
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expression vectors using Promega FuGENE 6 transfection reagent according to the 
manufacturer’s protocols. Transfections were carried out when cells were ~50% 
confluent in 6-well plates. Cells were harvested after 48 h, and β-galactosidase assays 
were performed in triplicate on 5 μl of cellular extract using the Galacto-Star system 
(Applied Biosystems). The missense mutations were modelled in Protein Workshop onto 
the structure of mouse E47/NeuroD1 (Protein Data Bank (PDB) accession 2QL2).235
Analysis of mouse mutants
The mouse mutants analysed were Tcf12flox (obtained on a mixed C57BL/6/129 
background as a gift of Y. Zhuang),227 EIIa-Cre (purchased from The Jackson Laboratory 
(B6.FVB-Tg(EIIa-cre) C5379Lmgd/J)229 and Twist1 (C57BL/6 background).230 The EIIa-
Cre transgene was detected using primers Cre-F and Cre-R (Supplementary Table 
5.5); Tcf12flox and Twist1 were genotyped as described.227,230 Heads of P21 mice were 
skinned and stained for mineralized bone with Alizarin Red S (80 mg/l in 1% KOH) for 
3 days. Skulls were then cleared and stored in 100% glycerol. P21 mouse skulls were 
scanned using a μCT system (SCANCO μCT 50, Scanco Medical AG) and analysed using 
Amira software (Visage Imaging). All scans were conducted at an energy setting of 70 
kVp, current intensity of 200 μA, integration time of 500 ms/projection, 0.24 degree 
rotational step (DRS) and a field of view (FOV) of 15.1 mm. Scans were performed at a 
10-μm isotropic resolution.
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Abstract
TCF12-related craniosynostosis can be caused by small heterozygous loss-of-function 
mutations in TCF12. Large intragenic rearrangements, however, have not been 
described yet. Here, we present the identification of four large rearrangements in TCF12 
causing TCF12-related craniosynostosis. Whole genome sequencing was applied on the 
DNA of 18 index-cases with coronal synostosis and their family members (43 samples in 
total). The data were analysed using an autosomal-dominant disease model. Structural 
variant analysis reported intragenic exon deletions (of sizes 84.9, 8.6 and 5.4 kb) in 
TCF12 in three different families. The results were confirmed by deletion-specific PCR 
and dideoxy-sequence analysis. Separately, targeted sequencing of the TCF12 genomic 
region in a patient with coronal synostosis identified a tandem duplication of 11.3 
kb. The pathogenic effect of this duplication was confirmed by cDNA analysis. These 
findings indicate the importance of screening for larger rearrangements in patients 
suspected to have TCF12-related craniosynostosis.
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Introduction
Craniosynostosis is a condition in which the calvarial sutures are fused prematurely. 
Fusion of the coronal sutures has the highest chance of having a specific genetic cause. 
In patients with coronal synostosis, mutations are often found in FGFR2 [MIM: 176943], 
FGFR3 [MIM: 134934], TWIST1 [MIM: 601622] and EFNB1 [MIM: 300035]. Recently, 
however, another disease gene for coronal synostosis, TCF12 [MIM: 600480], has been 
identified.59 The product of this gene is a member of the basic helix-loop-helix E-protein 
family and forms heterodimers with TWIST1.59,228
In 32% and 10%, respectively, of patients with bicoronal and unicoronal synostosis 
in whom other genetic testing was negative, a pathogenic heterozygous mutation 
could be identified in TCF12 by dideoxy-sequencing.59 In addition to coronal synostosis, 
patients can have craniofacial features suggestive of Saethre-Chotzen syndrome, and 
a minority has developmental delay and/or learning disabilities. On the other hand, 
a substantial proportion (>50%) of individuals heterozygous for a pathogenic TCF12 
mutation are non-penetrant.59
In patients with TCF12-related craniosynostosis, point mutations are predominantly 
found.59,236,237 A few patients with craniosynostosis and intellectual disability have been 
reported with large chromosome 15q deletions including TCF12.221,238,239 Recently, 
Le Tanno et al. have described a heterozygous de novo deletion of 3.64 Mb due to an 
unbalanced maternally inherited translocation in a patient with coronal craniosynostosis 
and intellectual disability.240 In addition, a 72-year-old patient has been identified with 
intellectual disability (without clear signs of craniosynostosis) and a TCF12 microdeletion 
of 84-121 kb, removing exons 19-21 and extending 3’ from the end of the gene.241 Gross 
rearrangements with both breakpoints lying within TCF12, however, have not been 
described to date; in the original report of TCF12 mutations, an assay for deletions using 
multiplex ligation-dependent probe amplification (MLPA) found no rearrangements in 
226 mixed craniosynostosis samples negative for intragenic TCF12 mutations.59
In this study, we describe the identification of three large inherited intragenic exon 
deletions in TCF12 using whole genome sequencing and one large inherited duplication 
using targeted TCF12 sequencing.
Within the framework of a broader study into the genetic causes of craniosynostosis, 
whole genome sequencing was applied to DNA of 18 Dutch index cases with coronal 
synostosis and negative testing for FGFR2, FGFR3 and TWIST1, and their family members 
(43 samples in total), by Complete Genomics, a BGI company (Mountain View, CA, 
USA), as described by Drmanac et al.104 The data were analysed using an autosomal-
dominant disease model. Structural variant analysis using a custom made Python 
script143 reported different large intragenic exon deletions of TCF12 in three families 
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(families 1, 2 and 3). The clinical features of the families are summarized in Table 6.1 and 
full subject descriptions and pedigrees are provided in the Supporting Information and 
Supplementary Figure 6.1 respectively.
A heterozygous 84,949 bp deletion was reported in family 1, starting at 
chr15:57478485 and ending at chr15:57563433 (c.391-5871_1746-1795del) in DNA of 
the index patient and his mother (using reference NM_207037.1 on GRCh37). Exons 7 
through 18 were deleted. In family 2, a heterozygous deletion of 8,580 bp was reported, 
starting at chr15:57560034 and ending at chr15:57568613 (c.1745+4562_1978+3153del) 
in DNA of the index patient, the clinically unaffected father and affected paternal aunt. 
The deletion removed exon 19. In family 3, a heterozygous 5,363 bp deletion was 
reported, starting at chr15:57571496 and ending at chr15:57576858 (c.1979-3147_*12-
1497del) in DNA of the index patient and his clinically unaffected mother. This deleted 
exon 20. The three deletions were not seen in control samples (i.e. Structural Variation 
Baseline Genome Set comprising 52 baseline genomes used by Complete Genomics 
and 588 Wellderly samples [Scripps Wellderly Genome Resource, The Scripps Wellderly 
Study, La Jolla, CA [December, 2015]], funding provided by Scripps Health and NIH/
NCATS UL1 TR00114).
Deletion-specific PCRs were designed to confirm the findings by whole genome 
sequencing (Figure 6.1A-E). In family 1, the mutant PCR product of 644 bp was present 
in II.2 and III.1 (Figure 6.1B lanes 2-4, and 6.1C). An analysis of the normal sequence 
showed that the proximal breakpoint resided in an AluJb element, whereas the distal 
breakpoint was located in a L1P2 repetitive element. The sequences of the breakpoints 
showed no significant similarity except for a shared 4 bp GAGC motif. In family 2, the 
mutant PCR product of 556 bp was present in II.1, II.2 and III.1 (Figure 6.1B lanes 5-8, 
and 6.1D). The proximal breakpoint was located in an MIRb element and the distal 
breakpoint in a HAL1 element. The sequences showed no significant similarity, except 
for a shared cytosine. In family 3, the mutant PCR product of 646 bp was present in 
II.2 and III.2 (Figure 6.1B lane 9-11, and 6.1E). The proximal breakpoint also resided in a 
HAL1 element; the distal breakpoint was not located in a repetitive element. However, 
an AluSz repeat was located 151 bp centromeric of the distal breakpoint and an MIRb 
789 bp telomeric. The sequences of the breakpoints showed no significant similarity. 
Amplification of patient cDNA of family 3 with primers located in exon 18 and 3’ UTR 
(exon 21) showed an extra smaller product, absent in control cDNA. Sequencing of the 
smaller-sized product indicated skipping of exon 20 (Supplementary Figure 6.2).
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Table 6.1. Clinical features of families harbouring TCF12 rearrangements.
Family 1 Family 2 Family 3 Family 4
cDNA position of 
rearrangement
c.391–5871_1746–
1795del
c.1745 + 4562_1978 
+ 3153del
c.1979–3147_∗12–
1497del
c.1746–1697_∗11 + 
65dup
Size of 
rearrangement (kb)
84.9 8.6 5.4 11.3
Exons involved 7-18 19 20 19 and 20
Type of 
rearrangement
Deletion Deletion Deletion Duplication
Gender of index 
patient
Male Female Male Male
Gestational age 
(weeks)
37+6 42+4 39+4 38
Birth weight 
(grams)
3,075 3,620 3,365 NA
Cranial suture 
fusion
RC BC All except M BC
Major craniofacial 
procedures
Fronto-supraorbital 
remodelling @ 10 
months
Supraorbital 
advancement @ 9 
months
Fronto-biparietal 
remodelling @ 8 
months,
parieto-occipital 
decompression @ 
2 years
FOAR @ 10.5 
months
Development Mild learning 
problems VIQ 82, 
PIQ 64, GIQ 74
Normal Normal Normal
Limbs Fifth finger 
camptodactyly
Normal Normal Fifth finger 
clinodactyly
Other major clinical 
features
Divergent 
strabismus,
recurrent 
infections,
febrile seizures
Myopia,
crowding of teeth, 
divergent growth 
pattern
Increased ICP Class II.1 
malocclusion,
small ears with 
prominent helical 
crura
Family history Mother LC Sister of father 
brachycephaly
Negative Flattened foreheads 
in maternal half-
brother and his 
daughter
Previous genetic 
diagnostics
Karyotyping, FGFR2, 
FGFR3, TWIST1, 
TCF12
FGFR2, FGFR3, 
TWIST1, TCF12
FGFR2, FGFR3, 
TWIST1
FGFR2, FGFR3, 
TWIST1, TCF12
Subjects sequenced II.1, II.2 and III.1 II.1, II.2, II.3 and III.1 II.1, II.2 and III.2 III.1
BC = Bicoronal, FOAR = Fronto-orbital advancement and remodelling, GIQ = Global IQ, LC = Left coronal, M = Metopic, PIQ = 
Performal IQ, RC = Right coronal, VIQ = Verbal IQ.
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In parallel to this work, targeted sequencing of DNA samples of 160 British unrelated 
subjects with craniosynostosis, including the coronal suture, and previously negative 
testing of the FGFR2, FGFR3, TWIST1 and TCF12 genes, was carried out by capturing 
the TCF12 genomic region (chr15: 57,029,979-57,670,037) using the SeqCap EZ Choice 
Library system (Roche-Nimblegen, Inc., Madison, WI, USA). Using analysis with Pindel,242 
a heterozygous tandem duplication was called in the index patient of family 4 (pedigree 
in Supplementary Figure 6.1D (II.1)).
Breakpoint spanning PCR (using primers orientated in opposite directions in the 
wild-type sequence, shown in Supplementary Table 6.1) showed a mutant PCR product 
from genomic DNA of both the index patient and his clinically unaffected mother 
(Figure 6.1F). Dideoxy-sequencing confirmed a tandem duplication of 11,331 base pairs, 
starting at chr15:57563531 and ending at chr15:57574861 (c.1746-1697_*11+65dup) in 
the DNA of the index patient of family 4. The duplication included TCF12 exons 19 and 
20.
An analysis of the normal sequence showed that the proximal breakpoint was 
located in an L1P2 repetitive element, whereas the distal breakpoint did not reside in a 
repetitive element. Further sequence analysis revealed the presence of an MER1A DNA 
sequence 678 bp centromeric of the distal breakpoint, and the presence of an AluSx 
element and a simple tandem repeat at 597 bp and 1,165 bp, respectively, telomeric 
of the distal breakpoint. The sequences of the breakpoints shared an AG dinucleotide 
(Figure 6.1G).
Amplification of patient cDNA with primers located in exon 18 and 3’ UTR (therefore 
spanning the duplication) showed only a single product corresponding to the wild-
type allele (data not shown). This suggested that the product from the duplicated allele 
might be expressed at a relatively low level, although bias in PCR amplification favouring 
the smaller wild-type product could not be excluded. We therefore designed a pair of 
primers in exon 19, orientated in opposite directions, predicted to generate a product 
only from the duplicated allele. Electrophoresis of PCR products revealed two relatively 
weak fragments in the patient cell line, absent in two controls (Figure 6.1I). Sequencing 
of the smaller-sized product indicated splicing from exon 20 to the duplicated exon 
19, whereas the larger product contained additional neo-exon sequence of 35 bp, 
originating from within the intron 18-19 sequence (Figure 6.1J).
In summary we have identified the first intragenic duplication and deletions within 
TCF12 in patients with craniosynostosis. These findings demonstrate the importance of 
screening, not only for point mutations and small indels in TCF12, but also for larger 
rearrangements. 
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Figure 1. Rearrangements identified in TCF12. A–E: Confirmation of deletions. A primer design. F1, forward primer; R1, reverse primer 1; R2,
reverse primer 2. F1+R1, wild-type allele (WT); F1+R2, mutant allele (). B: Results of mutation-specific deletion PCR analysis. Lane 1, negative
control. Lanes 2–4, family 1; wild-type fragment 1,455 bp, mutant fragment 644 bp; lane 2, II.1; lane 3, II.2; lane 4, III.1. Lanes 5–8, family 2; wild-type
fragment 1,107 bp, mutant fragment 556 bp; lane 5, II.1; lane 6, II.2; lane 7, II.3; lane 8, III.1. Lanes 9–11, family 3; wild-type fragment 1,303 bp, mutant
fragment 646 bp; lane 9, II.1; lane 10, II.2; lane 11, III.2. C–E: Electropherograms of dideoxy sequence analysis. C: Mutant allele in family 1, exons 7–18
deleted. D: Mutant allele in family 2, exon 19 deleted. E: Mutant allele in family 3, exon 20 deleted. Dashed lines indicate where deletions occurred.
F–J: Confirmation of duplication. F: PCR from genomic DNA confirming the presence of duplication in index patient of family 4 (III.1), which was
inherited from the index patient’s clinically unaffected mother (II.2). G: The sequence at the duplication breakpoint is sandwiched between the
normal proximal (above) and distal (below) sequences, with the electropherogram underneath (H). I: cDNA amplified from the index patient (III.1)
with primers specific to the mutant allele. Two different products were visible on the gel (but absent in two control cDNA samples). J: Sequencing
of these products indicated splicing from exon 20 to the duplicated exon 19 in the smaller-sized product (lower electropherogram). The larger
product (upper electropherogram) contains an additional 35 nucleotide neo-exon between exons 20 and 19. The normal stop codon in exon 20 is
highlighted.
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Figure 6. . Rearrangements identified in TCF12. A–E: confirmatio  of deletions. A primer 
design. F1, forward primer; R1, reverse primer 1; R2, reverse primer 2. F1+R1, wild-type allele (WT); 
F1+R2, mutant allele (Δ). B: results of utation-specific d letion PCR analysis. Lane 1, negative 
control. Lanes 2–4, family 1; wild-type fragm nt 1,455 bp, mu ant fragm nt 644 bp; lane 2, II.1; 
lane 3, II.2; lane 4, III.1. Lanes 5–8, fam ly 2; wild-type fragment 1,107 bp, mutant fragment 556 
bp; lan  5, II.1; lane 6, II.2; la e 7, II.3; lan  8, III.1. Lanes 9–11, fa ily 3; wild-type fragment 1,303 
bp, mutant fragment 646 bp; lane 9, II.1; lane 10, II.2; lane 11, III.2. C–E: electropherograms of 
dideoxy sequence analysis. C: mutant allele in family 1, exons 7–18 deleted. D: mutant allele in 
family 2, exon 19 deleted. E: mutant allele in family 3, exon 20 deleted. Dashed lines indicate 
where deletions occurred. F–J: confirmation of duplication. F: PCR from genomic DNA confirming 
the presence of duplication in index patient of family 4 (III.1), which was inherited from the 
index patient’s clinically unaffected mother (II.2). G: the sequence at the duplication breakpoint 
is sandwiched between the normal proximal (above) and distal (below) sequences, with the 
electropherogram underneath (H). I: cDNA amplified from the index patient (III.1) with primers 
specific to the mutant allele. Two different products were visible on the gel (but absent in two 
control cDNA samples). J: sequencing of these products indicated splicing from exon 20 to the 
duplicated exon 19 in the smaller-sized product (lower electropherogram). The larger product 
(upper electropherogram) contains an additional 35 nucleotide neo-exon between exons 20 and 
19. The normal stop codon in exon 20 is highlighted.
14845-goos-layout.indd   99 13/11/2017   19:20
100
Chapter 6
In patients with non-syndromic and syndromic bicoronal or unicoronal synostosis, 
FGFR2, FGFR3 and TWIST1 are often tested routinely for mutations. In approximately 
28% of the craniosynostosis patients (with any combination of sutures fused) having a 
genetic cause, a pathogenic mutation can be identified in FGFR2, in 19% of the patients 
in FGFR3, and in 16% in TWIST1. TCF12 intragenic mutations cause approximately 4% of 
these cases.59
To date, we have tested, by dideoxy-sequencing of TCF12, 105 Dutch syndromic and 
non-syndromic coronal craniosynostosis index patients with negative results for FGFR2, 
FGFR3 and TWIST1 testing. This led to the identification of 22 TCF12 mutation-positive 
index cases (including 14 cases that were previously described by Sharma et al.)59 We 
now report the identification of gross deletions of TCF12 in three out of 18 index cases 
that were analysed by whole genome sequencing (in five cases a mutation was found in 
another gene). Furthermore, we describe a gross TCF12 duplication in a further patient 
with coronal synostosis, using targeted sequencing of the TCF12 genomic region.
The identification of TCF12 deletions in two of the Dutch patients (families 1 and 
2) was a particular surprise, because these patients had been included in the negative 
MLPA analysis (zero positive from 226 samples) previously reported by Sharma et al. 
(2013).59 Re-examination of the raw MLPA data revealed that the analysis had not 
been performed correctly, and both deletions were in fact evident. Further scrutiny 
of the remaining MLPA data revealed an Oxford sample that harboured a deletion of 
exons 5-19, which was independently found in the TCF12 capture sequencing data 
(not shown). Hence, it is evident that TCF12 deletions contribute more frequently to 
coronal synostosis than previously thought; combining the results of whole genome 
sequencing (3/13) and the reanalysed MLPA dataset (1/95), 4 of 108 (3.7%) individuals 
with this diagnosis and previously negative for standard genetic testing, were found to 
have deletions. Overall, three out of 25 Dutch cases of TCF12-related craniosynostosis 
were caused by large, intragenic TCF12 rearrangements.
Analysing the breakpoint sequences, it appears that the rearrangements occur in, or 
in the proximity of, repeat sequences (family 1 AluJb SINE and L1P2 LINE element; family 
2 MIRb SINE and HAL1 LINE; family 3 HAL1 LINE and in proximity of AluSz SINE/MIRb SINE; 
family 4 L1P2 LINE and in proximity of MER1A/AluSx SINE). Furthermore, the sequences 
of the breakpoints show no significant similarity (family 1 four-nucleotide homology; 
family 2 one shared nucleotide; family 3 none; family 4 two shared nucleotides). The 
nonobligatory presence of terminal microhomology and repeat sequences indicates 
classical nonhomologous end joining as the most likely mechanism.243-245
All but one previously described pathogenic mutations are located in the 3’ half of 
TCF12 (exons 9-19).59 The first two deletions also include this region of the gene (family 
1 exons 7-18 and family 2 exon 19). The deletion in family 1 contains regions of TCF12 
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encoding the activation domain 2 and the rep domain. In family 2, the region encoding 
the functionally important basic helix-loop-helix domain is included.225,226,246 These 
domains are still present in the mutant alleles in families 3 and 4. cDNA studies indicate 
skipping of exon 20 in family 3 (Supplementary Figure 6.2). Although the duplicated 
allele in family 4 should retain the capacity to translate the full-length protein, the cDNA 
studies (Figure 6.1G) indicate that this transcript is likely unstable, causing functional 
haploinsufficiency. The rearrangements in families 3 and 4 are the first mutations 
described that lie 3’ of the region that encodes the bHLH domain.
While the deletion in family 1 is 10-fold larger than that in family 2 and removes 
two functional domains of TCF12, the clinical craniofacial features of the index patient 
of family 1 are not more severe than the features of the index patient of family 2. The 
index patient of family 1 has unicoronal synostosis, whereas the index patient of family 
2 and her aunt have bicoronal synostosis. The index patient of family 1, however, does 
have mild learning disability. The most severe phenotype in our study is seen in the 
index patient of family 3 (synostosis of almost all sutures and increased intracranial 
pressure), though the smallest deletion is present in this family. Although the index 
patient of family 4 has a duplication partially overlapping the deleted regions of both 
family 2 and the more severely affected family 3, he only shows bicoronal synostosis and 
minor anomalies like fifth finger clinodactyly. Clinodactyly and brachydactyly (present 
in his mother), have previously been described in association with TCF12 mutations.59,236 
Overall, the findings do not reveal any genotype-phenotype correlation.
The index patient of family 3 does not exhibit the classical clinical phenotype 
of TCF12-related craniosynostosis, since all vault sutures were fused except for the 
metopic suture. Only two patients have been described previously with synostosis of 
the coronal sutures combined with synostosis of the sagittal suture.59 Also, the patient 
had papilledema postoperatively, indicating increased intracranial pressure. To our 
knowledge, this is the first patient described with TCF12-related craniosynostosis and 
increased intracranial pressure postoperatively.
In conclusion, the clinical features of the index patients of family 1, 2 and 4 fit 
the phenotype of TCF12-related craniosynostosis as described by Sharma et al.59 The 
reduced penetrance described previously is seen in three of our families as well. Our 
study demonstrates that TCF12-related craniosynostosis can also be caused by large 
intragenic rearrangements and that there is no indication of a genotype-phenotype 
correlation. Therefore, mutation analysis of TCF12 should also include a search for larger 
rearrangements.
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Supporting information
Materials and methods
Ethical approval was given for whole genome sequencing by the board of the Medical 
Ethical Committee Rotterdam (MEC-2012-140) and for targeted TCF12 sequencing by 
the Oxfordshire Research Ethics Committee B (reference C02.143) and London Riverside 
Research Ethics Committee (reference 09/H0706/20). Informed consent was received 
from the study participants.
Within the framework of a broader study into the genetic causes of craniosynostosis, 
whole genome sequencing was applied on the DNA of 18 Dutch index-cases with coronal 
synostosis and negative testing for FGFR2, FGFR3 and TWIST1, and their family-members 
(43 samples in total), by Complete Genomics, a BGI company (Mountain View, CA, USA), 
as described by Drmanac et al.104 Data were analysed using cga tools version 1.6.0.43. 
An autosomal dominant disease model was tested. The analysis was restricted to novel 
non-synonymous variants, variants disrupting a splice site (±2 bp), and insertions or 
deletions in the coding sequence (±50 bp). Because there were no obvious mutations in 
known craniosynostosis genes (list of variants available on request), a structural variant 
analysis was performed using a custom-made Python script. Structural variant calling 
was performed using uniquely mapped discordant read pairs as described by Gilissen 
et al.,143 and filtering was based on scrutinizing regions with a known association with 
craniosynostosis. In three families, large intragenic exon deletions were identified in 
TCF12. Variants of family 1 and 2 were annotated using NCBI build 36.3/hg18 and dbSNP 
build 130, variants of family 3 were annotated using GRCh37/hg19. Annotations of the 
deletions of family 1 and 2 were lifted over to hg19 by using Human BLAT search on the 
UCSC website (Kent Informatics, Inc., Santa Cruz, CA, USA).
The deletions identified by whole genome sequencing were confirmed by deletion 
specific PCR. Primers used for the deletion PCR are given in Supplementary Table 6.1. For 
each specific deletion PCR, one forward and one reverse primer were designed outside 
the deletion. The third primer was designed in the deleted region in such a way that 
the PCR product resulting from the mutant allele was smaller than the PCR product 
produced from the wild-type allele.
In parallel to this, targeted sequencing of DNA samples of 160 British unrelated 
subjects with craniosynostosis, including the coronal suture, and previously negative 
testing of the FGFR2, FGFR3, TWIST1 and TCF12 genes, was carried out by capture of 
the TCF12 genomic region (chr15: 57,029,979-57,670,037) using the SeqCap EZ Choice 
Library system (Roche-Nimblegen, Inc., Madison, WI, USA). Samples were multiplexed 
and two pools of 80 samples were each run on a single lane of the HiSeq2500 platform 
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(Illumina, Inc., San Diego, CA, USA) run in rapid mode. The resulting data were aligned 
using Novoalign (http://www.novocraft.com/products/novoalign/) to the human 
reference genome GRCh37/hg19, and indels were detected by Pindel v0.2.4.242
The duplication was confirmed on genomic DNA by breakpoint spanning 
PCR (primers shown in Supplementary Table 6.1). The effect of the duplication and 
the deletion in family 3 were studied by cDNA analysis. RNA was extracted from a 
lymphoblastoid cell line obtained from individual III.1 (family 4) using Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) and the RNeasy kit (Qiagen Ltd., Crawley, UK). cDNA was 
synthesized using the RevertAid First Strand cDNA kit (Thermo Scientific Inc., Waltham, 
MA, USA), with random hexamer primers according to the manufacturer’s instructions.
All amplification reactions were performed according to standard procedures. 
Products were electrophoresed on agarose gels in TBE buffer. To confirm the exact 
position of the breakpoints, the PCR products were sequenced. PCR products were 
purified with ExoSAP-IT (USB, Affymetrix, Cleveland, OH, USA). Dideoxy-sequencing of 
both strands was performed using Big Dye terminator version 3.1 (Applied Biosystems, 
Foster City, CA, USA) as recommended by the manufacturer. Dye terminators were 
removed using SephadexG50 (GE Healthcare, Pittsburgh, PA, USA) and loaded on an ABI 
3130XL Genetic Analyzer or ABI 3730 (Applied Biosystems).
The pathogenic mutations were described according to HGVS nomenclature,148 
using reference NM_207037.1 consisting of 21 exons, protein coding from exon 2 
through 20, on GRCh37 and submitted to the Leiden Open Variation Database (http://
www.lovd.nl/TCF12).
Subject descriptions
Family 1
The index patient was a boy, born by caesarean section due to breech position at 37+6 
weeks of gestation, weighing 3,075 grams (Supplementary Figure 6.1A, III.1). He had 
non-consanguineous parents. Directly after birth, a progressive skull malformation was 
observed. Physical examination at the age of 4.5 months showed a frontal plagiocephalic 
head shape and a closed fontanel. The skull circumference was 42.5 cm (-0.41 SD). 
Apart from bilateral camptodactyly of the fifth fingers, no hand or foot anomalies were 
present. Skull radiographs and 3-dimensional computed tomography (3D-CT) showed 
synostosis of the right coronal suture. A fronto-supraorbital remodelling was performed 
at the age of 10 months. Furthermore, a tenotomy was performed at the age of 4 years 
because of divergent strabismus and an adenoidectomy was performed because of 
recurrent airway infections. In addition to this, he suffered from febrile seizures. He had 
mild learning problems (Verbal IQ 82, Performance IQ 64, Global IQ 74). Karyotyping 
was normal and FGFR2, FGFR3, TWIST1 and TCF12 were tested negative by dideoxy-
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sequencing. The family history was positive; his mother (II.2) was born with a left-sided 
plagiocephaly, requiring a surgical correction early in life. The DNA of subjects II.1, II.2 
and III.1 was sequenced.
Family 2
The index patient was a girl born as the third child of non-consanguineous unaffected 
parents at 42+4 weeks of gestation, weighing 3,620 grams (Supplementary Figure 6.1B, 
III.1). Physical examination at the age of 5 months showed a frontal brachycephalic head 
shape. The skull circumference was 41 cm (-0.87 SD). Her hands and feet were normal. 
Skull radiograph and 3D-CT showed bicoronal synostosis. At the age of 9 months, a 
supraorbital advancement was performed. Later, the girl was seen by an ophthalmologist 
because of myopia. Furthermore, she was seen by an orthodontist because of a divergent 
growth pattern and crowding of teeth. She had normal development. The family 
history was positive; a sister of the father (II.1) had an un-operated brachycephalic head 
shape. The father of the patient was clinically unaffected. Learning disabilities were not 
mentioned in the family. In the index patient, no mutations were found in FGFR2, FGFR3, 
TWIST1 and TCF12 by dideoxy-sequencing. The DNA of subjects II.1, II.2, II.3 and III.1 was 
sequenced.
Family 3
The index patient was a boy born as a second child at 39+4 weeks of gestation, weighing 
3,365 grams (Supplementary Figure 6.1C, III.2). Physical examination at the age of 6 
months showed an asymmetrical skull shape, with frontal bossing (predominantly on 
the left side), right-sided supra-orbital retrusion and an asymmetrical occiput. The skull 
circumference was 45 cm (+0.62 SD). Hands and feet were normal. Skull radiographs 
and 3D-CT showed premature fusion of all calvarial sutures, except for the metopic 
suture. Clinically, the patient was suspected to have Crouzon syndrome. A fronto-
biparietal remodelling was performed at the age of 8 months. At the age of 2 years, the 
patient had a skull circumference of 51 cm (+1.07 SD), a bony defect occipitally, and mild 
fingerprinting on the skull radiograph. No other symptoms of increased intracranial 
pressure were noticed. However, fundoscopy showed papilledema of 1.5-2 dpt. Thus, 
a parieto-occipital decompression was performed. During the subsequent four-year 
follow-up, papilledema was absent. The family history was negative. No mutations were 
found in FGFR2, FGFR3 or TWIST1. The DNA of subjects II.1, II.2 and III.2 was sequenced.
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Family 4
The index patient was a boy born at 38 weeks’ gestation following an uneventful 
pregnancy (Supplementary Figure 6.1D, III.1). At birth he was noted to have 
hypertelorism and brachycephaly. The head circumference was 43 cm at the age of 8 
months (-1.9 SD). At the age of 10.5 months a CT head scan showed bicoronal synostosis 
with a very shallow anterior cranial fossa and small facial skeleton, and a fronto-orbital 
advancement and remodelling procedure was performed. Physical examination at the 
age of 6 years revealed relatively small ears with prominent helical crura and marked 
bilateral 5th finger clinodactyly. He attended a normal school without additional help 
up to the age of 15 years. He was receiving treatment for Class II.1 dental malocclusion 
on a mild Class II skeletal base. His mother had a normal craniofacial examination but 
was noted to have generalized brachydactyly. A maternal half-brother and his daughter 
were reported to have flattened foreheads.
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Abstract
Human ZIC1 (zinc finger protein of cerebellum 1), one of five homologs of the Drosophila 
pair-rule gene odd-paired, encodes a transcription factor previously implicated in 
vertebrate brain development. Heterozygous deletions of ZIC1 and its nearby paralog 
ZIC4 on chromosome 3q25.1 are associated with Dandy-Walker malformation of the 
cerebellum, and loss of the orthologous Zic1 gene in the mouse causes cerebellar 
hypoplasia and vertebral defects. We describe individuals from five families with 
heterozygous mutations located in the final (third) exon of ZIC1 (encoding four 
nonsense and one missense change) who have a distinct phenotype in which severe 
craniosynostosis, specifically involving the coronal  sutures, and variable learning 
disability are the most characteristic features. The location of the nonsense mutations 
predicts escape of mutant ZIC1 transcripts from nonsense-mediated decay, which 
was confirmed in a cell line from an affected individual. Both nonsense and missense 
mutations are associated with altered and/or enhanced expression of a target gene, 
engrailed-2, in a Xenopus embryo assay. Analysis of mouse embryos revealed a localized 
domain of Zic1 expression at embryonic days E11.5–12.5 in a region overlapping the 
supraorbital regulatory centre, which patterns the coronal suture. We conclude that the 
human mutations uncover a previously unsuspected role for Zic1 in early cranial suture 
development, potentially by regulating engrailed 1, which was previously shown to be 
critical for positioning of the murine coronal suture. The diagnosis of a ZIC1 mutation 
has significant implications for prognosis and we recommend genetic testing when 
common causes of coronal synostosis have been excluded.
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Introduction
Among the varied causes of craniosynostosis (premature fusion of one or more sutures 
of the skull vault), a monogenic aetiology is most commonly identified in individuals 
with fusion of the coronal sutures, the major pair of transverse sutures crossing the 
vertex of the skull.128 Coronal synostosis, which can be present bilaterally (bicoronal) 
or unilaterally (unicoronal), affects approximately 1 in 10,000 children2 and is the type 
most commonly associated with an identifiable syndrome. Common monogenic 
disorders that characteristically present with coronal synostosis are Muenke [MIM: 
602849] and Apert [MIM: 101200] syndromes, caused by localized gain-of-function 
mutations encoded by FGFR3 [MIM: 134934] and FGFR2 [MIM: 176943], respectively; 
Saethre-Chotzen syndrome [MIM: 101400] (TWIST1 [MIM: 601622] haploinsufficiency); 
TCF12-related craniosynostosis [MIM: 600480 and 615314] (also a haploinsufficiency); 
and craniofrontonasal syndrome [MIM: 304110] (cellular  interference involving variants 
in the X-linked EFNB1 gene [MIM: 300035]).59,125
Even in the absence of an obvious syndromic diagnosis, a specific mutation can 
be identified in about 60% of individuals with bicoronal and 30% with unicoronal 
synostosis.59,128 The high monogenic load in coronal synostosis can be accounted for 
by the specific developmental origin of the coronal suture, which lies at an embryonic 
tissue boundary between neural-crest-derived frontal bone and mesoderm-derived 
parietal bone.29,30 Based on analysis of mouse models,127 coronal synostosis is frequently 
caused by disruption in the maintenance of the population of stem cells within the 
suture during early development (typically, embryonic days E12.5–14.5), caused, for 
example, by abnormalities in migration of neural crest cells232 or abnormal paracrine 
signalling through fibroblast growth factor receptors.247,248
An alternative possibility is that coronal synostosis could be caused by a primary 
failure of the suture to develop. Lineage tracing demonstrates that the cells of the future 
coronal suture originate from paraxial cephalic mesoderm at E7.5 and migrate laterally 
to locate above the developing eye.37 This region constitutes the supraorbital regulatory 
centre and during E11.5–E13.5, cells from this zone migrate apically to form and populate 
the coronal suture.24,30,37 One of the genes characteristically expressed by these cells is 
engrailed 1 (En1), a homolog of the Drosophila engrailed segment polarity gene. Mice 
with homozygous loss of En1 function have generalized calvarial bone hypoplasia and 
persistent widening of the sutural gaps, which is associated with a posterior shift in 
the boundary between cells of neural crest and mesodermal origin.37,249 An orthologous 
mutation has not yet been described in humans.
Here, we report an additional genetic aetiology for coronal synostosis, caused by 
heterozygous variants in the final exon of ZIC1 (zinc finger protein of cerebellum 1 [MIM: 
600470]), identified in four simplex case subjects and a three-generation pedigree. ZIC1, 
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located on chromosome 3q25.1, belongs to a family of five genes encoding Zn-finger 
transcription factors, which are arranged as one unpaired and two paired paralogs in the 
human and mouse genomes;250 ZIC genes are homologous to the Drosophila pair-rule 
gene odd-paired, which is required for activation of embryonic engrailed expression.251 
Vertebrate ZICs have important roles in multiple developmental processes, including 
neurogenesis, left-right axis formation, myogenesis, and skeletal patterning.252,253 
Heterozygous complete deletions of ZIC1 were previously associated with Dandy-Walker 
malformation (DWM; hypoplasia and upward rotation of the cerebellar vermis and cystic 
dilatation of the fourth ventricle [MIM: 220200]);254 we now show that mutations affecting 
the highly conserved C terminus of the protein, which are likely to be associated with 
a gain of function, lead to a distinct phenotype of coronal suture fusion and learning 
disability. In addition to its previously established importance for neurogenesis,255,256 
this work shows that ZIC1 is required for normal coronal suture development. We find 
that murine Zic1 is expressed in the supraorbital regulatory centre, suggesting that this 
gene acts at a very early stage of coronal suture development,127 potentially (reflecting 
a similar epistatic relationship to that in Drosophila) by regulating En1.
Subjects and methods
Subjects
The clinical studies were approved by Oxfordshire Research Ethics Committee B (reference 
C02.143), London Riverside Research Ethics Committee (reference 09/H0706/20), and 
the Medical Ethical Committee of the Erasmus University Medical Centre Rotterdam 
(MEC-2012-140 and MEC-2013-547). Written informed consent to obtain samples for 
genetics research was obtained from each child’s parent or guardian. Venous blood was 
used for DNA extraction and fibroblast cultures were established from skin biopsies 
taken from scalp incisions during surgical intervention. Intracranial pressures in subject 
1 were documented by 24–48 h direct recording with an intraparenchymal Codman 
Microsensor.257 The screening panel comprised samples from 307 individuals with 
syndromic or non-syndromic craniosynostosis. All DNA samples were previously tested 
for mutation hotspots in FGFR2, FGFR3, TWIST1, and TCF12.59,125 Significant chromosome 
aneuploidy in individuals with ZIC1 mutations was excluded by karyotyping and/or array 
comparative genomic hybridisation. Where necessary, correct biological relationships 
were confirmed by segregation analysis of a panel of 13 microsatellites (D1S2868, 
D3S1311, D4S403, D5S2027, D6S1610, D7S519, D9S158, D10S548, D11S898, D13S1265, 
D14S280, D16S415, and D18S474).
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Whole genome/exome sequencing and mutation screening of ZIC1
Whole genome sequencing of the male proband subject 1 and his parents was 
performed as part of the WGS500 clinical genome sequencing initiative.258 In brief, 3–5 
µg DNA was used to prepare libraries for 100 bp paired-end sequencing to generate 
a mean coverage of 30x using the Illumina HiSeq2000 platform. Sequence reads were 
mapped to the human reference GRCh37d5 using Stampy (v1.0.12–1.0.22) and variants 
called with Platypus (v.0.2.4).259,260 To identify de novo mutations, we prioritized variants 
within coding regions that were called as absent in both parents and in dbSNP135, 
generating a list of 203 variants in 177 genes, of which 39 were classified as protein 
altering. Visualization of the trio read alignments revealed a single bona fide change in 
ZIC1 (12 of 27 reads), which was absent in both the paternal (19 reads) and maternal (31 
reads) samples; the other 38 variants were either in fact present in one of the parents 
or were artefactual (Supplementary Table 7.1). Possible recessive inheritance was 
analysed with an in-house perl script to list homozygous, compound heterozygous, and 
hemizygous X chromosomal variants in subject 1, with a frequency cut-off of 0.003 in 
either 1000 Genomes or Exome Variant Server; variants in two genes fitted the criteria 
(Supplementary Table 7.1). Whole genome sequencing of genomic DNA from four 
subjects in family 5 (affected: 5:II.2, 5:III.3, 5:III.6; unaffected: 5:II.3) was performed by BGI 
Complete Genomics.104,108 Filtering based on a list of genes mutated in craniosynostosis 
identified a predicted missense substitution encoded by ZIC1, present only in the three 
affected individuals. Exome sequencing of subject 3 was performed on genomic DNA 
(extracted from whole blood) using an Agilent SureSelect Human All Exon Kit (v.5; 50 
Mb) on the Illumina HiSeq2000 platform. Reads were mapped to hg19 with Novoalign 
(Novocraft Technologies) and variants called with SAMtools and annotated by ANNOVAR.
To investigate further the significance of the ZIC1 mutations, primers were 
designed for amplification of genomic DNA (GenBank: NT_005612.17) and cDNA 
(GenBank: NM_003412.3), for multiplex ligation-dependent probe amplification 
(MLPA) analysis, and for deep sequencing (Supplementary Table 7.2, which provides 
details of experimental conditions). Variant screening of all three exons of ZIC1 was 
performed by dideoxy sequencing on PCR amplification products from genomic DNA 
by BigDye Terminator v3.1 (Applied Biosystems). Copy-number variation was analysed 
by MLPA using probes to each exon, according to the manufacturer’s instructions (MRC 
Holland). RNA was extracted from fibroblasts (Trizol, Invitrogen), cDNA synthesized with 
RevertAid first strand cDNA kit (Thermo Scientific), and the samples analysed by agarose 
gel electrophoresis after digestion with BfaI. To quantify the proportions of wild-type 
to mutant allele in cDNA, an amplification product spanning exons 2–3 was used as a 
template for PCR to add Ion Torrent P1 and A adapters, and the resulting product was 
purified with AMPure beads (Beckman Coulter). Emulsion PCR and enrichment were 
performed with the Ion PGM Template OT2 200 Kit (Life Technologies) according to the 
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manufacturer’s instructions and sequencing of enriched templates performed on the 
Ion Torrent PGM (Life Technologies) for 125 cycles with the Ion PGM Sequencing 200 
kit v2. Data were processed with Ion Torrent platform-specific pipeline software v.4.2.1.
was purified with AMPure beads (Beckman Coulter). Emulsion
PCR and enrichment were performed with the Ion PGM Template
OT2 200 Kit (Life Technologies) according to the manufacturer’s
instructions and sequencing of enriched templates performed on
the Ion Torrent PGM (Life Technologies) for 125 cycles with the
Ion PGM Sequencing 200 kit v2. Data were processed with Ion
Torrent platform-specific pipeline software v.4.2.1.
Xenopus Assays
All experiments using Xenopus were approved by the Institutional
Animal Care and Use Committee of Montana State University.
Xenopus full-length zic127 and zic1DC28 cDNA constructs were
described previously (zic1DC was originally termed oplDC). The
zic1DC2 construct was made by PCR amplification of the portion
of zic1 cDNA encoding the N terminus and zinc finger domains,
including four amino acids of the C-terminal region, followed
by cloning into the EcoR1 and Xba1 sites of pCS2þATG.27 The
human ZIC1 cDNA pCR4-Topo-ZIC1 (ThermoFisher) was sub-
cloned into pcDNA3 and six different nucleotide substitutions—
c.895G>T (p.Glu299*), c.1163C>A (p.Ser388*), c.1198G>C
(p.Gly400Arg), c.1204G>T (p.Glu402*), c.1240A>G(p.Thr414Ala),
and c.1309_1310GC>TA (p.Ala437*)—were introduced by PCR
mutagenesis using the primer sequences and experimental condi-
tions provided in Table S2. The human ZIC1 constructs were sub-
sequently digested with EcoR1 and Xba1 and ligated into the
pCS2þ plasmid. Capped sense RNAs for microinjection were syn-
thesized from the Xenopus and human pCS2þ constructs by SP6
transcription of NarI linearized plasmids. Xenopus laevis eggs were
collected and fertilized as previously described28 and embryos
were staged according to Nieuwkoop and Faber.29 Embryos at the
two-cell stage were injected into a single cell with 200 pg sense
RNA synthesized from cDNA constructs, together with 25 pg lacZ
RNA as tracer. After b-galactosidase staining,30 wild-type embryos
were bleached by exposing the embryos to fluorescent light in
hybridization buffer containing 1% H2O2. Expression of en-2 was
determined in neurula stage 15–17 albino and wild-type embryos
by in situ hybridization31 with digoxygenin-labeled antisense
RNA en-2 probe as described.32 An anti-digoxygenin alkaline phos-
phatase-conjugated antibody (Roche) and the alkalinephosphatase
substrateNBT/BCIP (Fisher Scientific)were used for color detection.
Embryos were scored double-blind to determine changes in en-2
expression in comparison to the uninjected side. Results using
wild-type and mutant constructs were compared by Fisher’s exact
tests with Bonferroni correction for multiple comparisons (n ¼ 9).
RNA In Situ Hybridization of Mouse Embryos
Experimental procedures were performed in accordance with
UK Animals (Scientific Procedures) Act, 1986 (PPL 70/7194).
For whole-mount embryo in situ hybridization, embryos were
dissected, fixed overnight in 4% paraformaldehyde in phos-
phate-buffered saline, and dehydrated through graded methanol
solutions. Non-radioactive RNA in situ hybridization was per-
formed as described33 before vibratome sectioning. RNA probes
for Zic134 and En135 were digoxygenin labeled with the In Vitro
Transcription kit (Roche Applied Science) followed by anti-digox-
ygenin-AP antibody (1:1,000) (Roche Applied Science) and NBT/
BCIP (Sigma) staining to detect the hybridization signals.
Results
Identification of ZIC1 Mutations
The proband (subject 1) presented at birth with severe
brachycephaly (Figure 1A), which was shown by three-
Figure 1. Clinical and Radiological
Phenotype of Individuals with ZIC1
Mutations
(A) Subject 1, age 7 weeks (left) and 8 years
(right).
(B) Subject 2, age 23 years.
(C) Subject 3, age 5 months.
(D) CT head scan of subject 3 (age
5 months) showing bicoronal synostosis,
a large wormian bone (arrow) in the posi-
tion of the anterior fontanelle, and an
ossification defect in the sagittal suture
(arrowhead).
(E) Subject 4, age 7 months.
(F) CT head scan of subject 4 (age
2.5 months). Note asymmetric skull shape
associated with bilateral coronal and right
lambdoid suture fusion (arrow). Sections
of the metopic and sagittal sutures remain
widely patent (arrowheads).
(G) MRI brain scan (T2 image) of subject 4,
age 16 months. Note short, broad corpus
callosum, peaked tentorium cerebelli
(arrow), and hypoplasia of the pons
(arrowhead), cerebellar vermis, and cere-
bellar hemispheres.
(H) Pedigree of family 5.
(I) Subject 5:III.6, age 2 months.
(J) MRI brain scan (T2 image) of subject
5:III.6, age 13 years. Abnormal features
show a similar pattern to those present in
subject 4.
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Figure 7.1. Clinical and radiological phenotype of individuals with ZIC1 mutations.
A: subject 1, age 7 weeks (left) and 8 years (right). B: subject 2, age 23 years. C: subject 3, age 
5 months. D: CT head scan of subject 3 (age 5 months) showing bicoronal synostosis, a large 
wormian bone (arrow) in the position of the anterior fontanelle, and an ossification defect in the 
sagittal suture (arrowhead). E: subject 4, age 7 months. F: CT head scan of subject 4 (age 2.5 
months). Note asymmetric skull shape associated with bilateral coronal and right lambdoid suture 
fusion (arrow). Sections of the metopic and sagittal sutures remain widely pate t (arrowheads). 
G: MRI brain scan (T2 image) of subject 4, ag  16 months. Note sh rt, broad corpus callosum, 
peaked tentoriu  cerebelli (arrow), and hypoplasia of the pons (arrowhead), cerebellar vermis, 
and cerebellar hemispheres. H: pedigree of family 5. I: subject 5:III.6, age 2 months. J: MRI brain 
scan (T2 image) of subject 5:III.6, age 13 years. Abnormal features show a similar pattern to those 
present in subject 4.
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Xenopus assays
All experiments using Xenopus were approved by the Institutional Animal Care and 
Use committee of Montana State University. Xenopus full-length zic1261 and zic1∆C262 
cDNA constructs were described previously (zic1∆C was originally termed opl∆C). The 
zic1∆C2 construct was made by PCR amplification of the portion of zic1 cDNA encoding 
the N terminus and zinc finger domains, including four amino acids of the C-terminal 
region, followed by cloning into the EcoR1 and Xba1 sites of pCS2+ATG.261 The human 
ZIC1 cDNA pCR4-Topo-ZIC1 (ThermoFisher) was subcloned into pcDNA3 and six 
different nucleotide substitutions— c.895G>T, p.(Glu299*), c.1163C>A, p.(Ser388*), 
c.1198G>C, p.(Gly400Arg), c.1204G>T, p.(Glu402*), c.1240A>G, p.(Thr414Ala), and 
c.1309_1310GC>TA, p.(Ala437*)—were introduced by PCR mutagenesis using the 
primer sequences and experimental conditions provided in Supplementary Table 7.2. 
The human ZIC1 constructs were subsequently digested with EcoR1 and Xba1 and 
ligated into the pCS2+ plasmid. Capped sense RNAs for microinjection were synthesized 
from the Xenopus and human pCS2+ constructs by SP6 transcription of NarI linearized 
plasmids. Xenopus laevis eggs were collected and fertilized as previously described262 
and embryos were staged according to Nieuwkoop and Faber.263 Embryos at the two-
cell stage were injected into a single cell with 200 pg sense RNA synthesized from cDNA 
constructs, together with 25 pg lacZ RNA as tracer. After β-galactosidase staining,264 
wild-type embryos were bleached by exposing the embryos to fluorescent light in 
hybridisation buffer containing 1% H2O2. Expression of en-2 was determined in neurula 
stage 15–17 albino and wild-type embryos by in situ hybridization265 with digoxygenin-
labelled antisense RNA en-2 probe as described.266 An anti-digoxygenin alkaline 
phosphatase-conjugated antibody (Roche) and the alkaline phosphatase substrate 
NBT/BCIP (Fisher Scientific) were used for colour detection. Embryos were scored 
double-blind to determine changes in en-2 expression in comparison to the uninjected 
side. Results using wild-type and mutant constructs were compared by Fisher’s exact 
tests with Bonferroni correction for multiple comparisons (n = 9).
RNA in situ hybridisation of mouse embryos
Experimental procedures were performed in accordance with UK Animals (Scientific 
Procedures) Act, 1986 (PPL 70/7194). For whole-mount embryo in situ hybridisation, 
embryos were dissected, fixed overnight in 4% paraformaldehyde in phosphate-buffered 
saline, and dehydrated through graded methanol solutions. Non-radioactive RNA in situ 
hybridisation was performed as described267 before vibratome sectioning. RNA probes 
for Zic1268 and En1269 were digoxygenin labelled with the In Vitro Transcription kit (Roche 
Applied Science) followed by anti-digoxygenin-AP antibody (1:1,000) (Roche Applied 
Science) and NBT/ BCIP (Sigma) staining to detect the hybridisation signals.
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Results
Identification of ZIC1 mutations
The proband (subject 1) presented at birth with severe brachycephaly (Figure 7.1A), 
which was shown by three-dimensional computed tomographic reconstruction (3D-
CT) to be caused by bicoronal synostosis. He required three major craniofacial surgical 
procedures (at the ages of 7 months, 2.4 years, and 4.8 years), the latter two because 
of raised intracranial pressure. In addition he had autistic traits and moderate-severe 
learning disability, features that are rarely associated with coronal synostosis. Genetic 
testing for mutations known to be associated with coronal synostosis was negative; his 
phenotype is summarized in Table 7.1 and more detailed descriptions of all subjects are 
provided in the Case Reports.
We undertook whole genome sequencing of the parent-child trio and analysed the 
data for variants consistent with either (1) autosomal or X-linked recessive inheritance or 
(2) a new dominant mutation (Supplementary Table 7.1). After filtering, variants in two 
genes were consistent with the recessive disease model, but these genes, CNGA3 [MIM: 
600053] and NEB [MIM: 161650], are associated with achromatopsia 2 [MIM: 216900] 
and nemaline myopathy 2 [MIM: 256030], respectively, disorders without a craniofacial 
phenotype, and thus were not considered further. The single dominant candidate was 
a heterozygous c.1163C>A mutation in ZIC1 (GenBank: NM_003412.3), predicting the 
nonsense change p.Ser388*. This variant was absent in the parental samples and was 
confirmed by dideoxy sequencing (Figure 7.2A).
The significance of this de novo ZIC1 mutation was initially uncertain. Contiguous 
heterozygous deletions of ZIC1 and its adjacent paralog ZIC4 were previously described 
in DWM,254 although a few deletion cases have lacked this characteristic phenotype.270 
Review of the CT scan in subject 1 showed no brain malformation, and on a later 
magnetic resonance imaging (MRI) scan, only minor abnormalities of configuration of 
the ventricles and corpus callosum were evident (not shown).
Nonsense mutations of ZIC1 have not previously been reported, but the location 
of the nucleotide substitution in the terminal (third) exon (Figure 7.2A) predicted that 
it would escape nonsense-mediated decay.271 We digested ZIC1 cDNA generated from 
scalp fibroblasts with the restriction enzyme BfaI, which cuts the mutant allele, and 
found that the expected mutant fragments were readily visualized (Figure 7.2B); we 
then used deep sequencing for accurate quantification and found that 7,175 of 13,088 
reads (55%) represented mutant alleles, confirming escape from nonsense-mediated 
decay (not shown). A prematurely truncated translation product could be associated 
with dominant-negative or gain-of-function mechanism, distinct from the previously 
described deletions.271 Support for a gain-of-function mechanism was provided 
by previously published work on the Xenopus zic1 ortholog, formerly known as opl 
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(odd-paired-like), in which it had been shown that a cDNA construct, zic1∆C, containing 
a shorter truncation missing the C-terminal 36 amino acids (see Figure 7.2C), had 
enhanced activity compared to full-length cDNA, in transactivation, and Xenopus animal 
cap, and other in vivo assays.261,272,273
To search for further evidence that ZIC1 mutations cause craniosynostosis, we 
screened a panel comprising 307 unrelated subjects with synostosis affecting any 
combination of sutures (including 45 and 112 with exclusively bilateral and unilateral 
coronal synostosis, respectively) and for whom no genetic diagnosis had been made. 
Initially we identified a single heterozygous nonsense mutation in this panel (subject 
2: c.1204G>T encoding p.Glu402*); neither parent had the mutation, indicating that it 
had arisen de novo (sample relationships were confirmed by microsatellite analysis). We 
did not identify any ZIC1 copy-number changes in this craniosynostosis panel by MLPA 
(data not shown). Later, we discovered by exome sequencing that a second individual 
included on the panel (subject 3) had the identical mutation, but present in mosaic state 
(see legend to Figure 7.2A for details). Strikingly, review of the phenotypes of subjects 
2 and 3 revealed that both had bicoronal synostosis with severe brachycephaly (Figures 
7.1B–D); in addition, both had learning disability, which was milder in subject 3 who had 
the mosaic mutation. Review of CT brain scans showed that subject 2 had agenesis of 
corpus callosum and dilated lateral ventricles, but neither subject 2 or 3 had DWM (not 
shown).
In an attempt to further replicate these findings, we examined DNA samples 
collected at a second craniofacial unit (Rotterdam), specifically where the combination 
of both coronal synostosis and significant learning disability was present. Only three 
samples were available for analysis, which reflects the rarity of this combination of 
phenotypes; remarkably, however, dideoxy sequencing showed that one of these 
samples harboured a heterozygous nonsense mutation in ZIC1 (c.1165C>T encoding 
p.Gln389*) at the codon adjacent to that affected in subject 1 (Figure 7.2A). This child 
had presented with bicoronal and unilateral lambdoid synostosis (Figures 7.1E and 
7.1F) and had significant learning problems (Table 7.1). An MRI scan identified several 
cerebral anomalies including a short corpus callosum, mildly enlarged lateral ventricles, 
peaked tentorium, hypoplastic pons, and cerebellum with prominent cerebellar folia 
and enlarged foramen magnum with signal void near the cervical cord (Figure 7.1G).
The final family (family 5) consisted of six affected individuals in three generations 
(Figure 7.1H). Two cousins (subjects 5:III.3 and 5:III.6) had bicoronal synostosis (Figures 
7.1I and 7.1J) and a further individual (subject 5:III.1, a half-brother of 5:III.3) had a DWM 
but no craniosynostosis (not shown). All three, and their respective mothers (5:II.2 
and 5:II.4), had mild learning disability. Whole genome sequencing of four individuals 
(subjects 5:II.2, 5:II.3, 5:III.3, 5:III.6) identified a heterozygous variant in ZIC1, c.1198G>C 
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encoding p.Gly400Arg, present in the three affected individuals (5:II.2, 5:III.3, 5:III.6) 
but not in the unaffected spouse (5:II.3). These results were confirmed by dideoxy 
sequencing, which showed that the variant was also present in 5:III.1 (the individual 
with DWM) and in 5:II.4 (the obligate transmitting mother) but not in her two unaffected 
children (5:III.4 and 5:III.5). This variant is absent from more than 120,000 alleles in the 
Exome Aggregation Consortium (ExAC). The combination of phenotypic features, the 
segregation of the variant, its location in the region where the previously identified 
nonsense mutations all clustered (Figure 7.2A), and absence in large databases of 
variation suggest that this variant is causative of the phenotype.
Functional consequence of ZIC1 mutations in Xenopus embryo assay
The function of the Xenopus zic1 ortholog has been studied in detail, where it was shown 
to act together with Pax3 as a key transcription factor required for the initiation of 
neural crest formation.274 In Xenopus embryos, a signalling cascade has been proposed 
in which inhibition of bone morphogenetic proteins (Bmps) activates zic1, which in 
turn activates members of the Wnt family including wnt1, which in turn activates the 
transcription factor engrailed-2 (en-2).261,272 A previously designed assay had shown 
that injection of zic1∆C RNA encoding a truncated ZIC1 into a single cell of 2-cell stage 
embryos led to increased en-2 expression in stage 15–17 Xenopus embryos, whereas 
injection of wild-type zic1 construct had no effect.261 We next examined the activity of 
human ZIC1 and various mutant constructs with this assay.
In initial experiments, we replicated the previously reported results of the Xenopus 
assay. Although very few (3%) embryos were disrupted by injection of the wildtype 
zic1 construct, this increased to 31% using the previously published zic1∆C. Moreover, 
a construct deleting almost the entire region C-terminal to the zinc fingers (zic1∆C2; 
Figure 7.2C) showed an even higher proportion (61%) of disrupted embryos (Figure 
7.3). Using constructs encoding human ZIC1, injection of full-length ZIC1 RNA yielded 
only 8% disrupted embryos, but this was increased to 79% and 68% with constructs 
corresponding to two of the observed truncations, p.Ser388* (subject 1) and p.Glu402* 
(subjects 2 and 3), respectively. Strikingly, a similar magnitude of effect (66%) was found 
with the most C-terminal truncation construct (p.Ala437*, which does not correspond 
to an observed mutation), highlighting the importance of the terminal 11 amino acids, 
which includes a 5-amino-acid motif (NEWYV) of unknown function that is conserved 
in human ZIC2, ZIC3 (isoform A), and ZIC5 (Figure 7.2C) but is not present in any other 
human protein. Two constructs encoding missense substitutions were studied with 
the same assay: p.Gly400Arg present in family 5 and p.Thr414Ala, corresponding to a 
rare SNP (dbSNP rs143292136), present in 104/121,380 alleles in ExAC, which we had 
identified in a child with bicoronal synostosis and her unaffected father (data not shown);
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and 5:III.5). This variant is absent frommore than 120,000
alleles in the Exome Aggregation Consortium (ExAC). The
combination of phenotypic features, the segregation of the
variant, its location in the region where the previously
identified nonsense mutations all clustered (Figure 2A),
and absence in large databases of variation suggest that
this variant is causative of the phenotype.
Functional Consequence of ZIC1 Mutations in
Xenopus Embryo Assay
The function of theXenopus zic1 ortholog has been studied
in detail, where it was shown to act together with Pax3 as
a key transcription factor required for the initiation of
neural crest formation.40 In Xenopus embryos, a signaling
cascade has been proposed in which inhibition of bone
Figure 2. Molecular Genetic Analysis of Individuals with ZIC1 Mutations
(A) Cartoon showing exon organization (white boxes denote non-coding regions) and previously identified conserved domains (Zic opa
conserved motif [ZOC], zinc finger N-flanking conserved region [ZF-NC], and five zinc fingers [1–5, blue boxes]) of human ZIC1.16 Also
indicated is the C-terminal NEWYVmotif conserved in all family members except ZIC4. Above the cartoon are the positions of the five
independent ZIC1 mutations described in this report, and dideoxy-sequence traces showing comparison of normal sequence (above)
and mutant sequence (below). Note, in the case of subject 3, the mutation was not evident in the DNA sample (sourced from scalp
fibroblasts; not shown) originally analyzed; however, in the exome sequence of DNA sourced from blood of the same individual,
63 of 183 (34%) reads showed the c.1204G>T mutation, which is also readily apparent on the dideoxy sequence. The relative heights
of mutant and wild-type peaks differ between samples from subject 3 and subject 2, who is constitutionally heterozygous for the iden-
tical mutation, corroborating that in subject 3 the mutation is present in high-level mosaic state.
(B) Agarose gel analysis of ZIC1 cDNA obtained from RNA extracted from scalp fibroblasts of subject 1 and digested with BfaI. The frag-
ments yielded by digestion of the mutant allele are indicated with asterisks.
(C) Amino acid sequence encoded by 30-terminal exon ofZIC1 and comparisonwith the paralogous human proteins ZIC2-ZIC5, showing
conservation including theNEWYVmotif (bracket). The endof thefifth zincfinger (Zn5) is shownabove the sequence, as are thepositions
of the four different pathogenic variants (red symbols) (triangle, nonsense; circle, missense) identified in this study. The positions
at which the Xenopus constructs zic1DC2 and zic1DC are truncated, relative to the human sequence, are indicated by blue arrows
(note zic1DC2 is equivalent to p.Gln389*). Additional human constructs tested in the Xenopus assay are indicated by green symbols.
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Figure 7.2. Molecular genetic analysis of individuals with ZIC1 mutations.
A: cartoon showing exo  organizati  (white box s de ote non-coding regions) and previously 
identified conserved domains (Zic opa conserved motif [ZOC], zinc finger N-flanking conserved 
region [ZF-NC], and fiv  zinc fingers [1–5, blue boxes]) of human ZIC1.252 Also indicated is the 
C-terminal NEWYV motif conserved in all family members except ZIC4. Above the cartoon are the 
positions of the five independent ZIC1 mutations described in this report, and dideoxy-sequence 
traces showing comparison of norm l sequence (above) and mutant sequence (b low). Note, 
in the case of subject 3, the mutation was not evident in the DNA sample (sourced from scalp 
fibroblasts; not shown) originally analysed; how ver, n the exom  sequ nce of DNA ourced 
from blood of the same individual, 63 of 183 (34%) reads showed the c.1204G>T mutation, which 
is al o re dily apparent on the dideoxy sequ nce. T e relative heights of mutant and wild-type 
peaks differ between samples from subject 3 and subject 2, who is constitutionally heterozygous 
for the identical mutation, corroborating that in subject 3 the mutation is present in high-level 
mosaic state. B: agarose gel analysis of ZIC1 cDNA obtained from RNA extracted from scalp 
fibroblasts of subject 1 and digested with BfaI. The fragments yielded by digestion of the mutant 
allele are indicat d with asterisks. C: amino acid sequ nce encoded by 30- erminal exon of ZIC1 
a d comparison with the paralo ous human proteins ZIC2-ZIC5, showing conservati  including 
the NEWYV motif (bracket). The end of the fifth zinc finger (Zn5) is shown above the sequence, 
as are the positions of the four different pathogenic variants (red symbols) (triangle, nonsense; 
circle, missense) identified in this study. The positions at which the Xenopus constructs zic1ΔC2 
and zic1ΔC are truncated, relative to the human sequence, are indicated by blue arrows (note 
zic1ΔC2 is equivalent to p.Gln389*). Additional human constructs tested in the Xenopus assay are 
indicated by green symbols.
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60% of embryos were disrupted in both cases. Although producing a slightly milder 
effect than the nonsense mutations, these results suggest that residues in the 
C-terminal domain in addition to the NEWYV motif contribute to function. Importantly, 
using a truncated control construct (p.Glu299*) missing the last three of the five zinc 
fingers, a much lower proportion of embryos (20%) was disrupted, which did not differ 
significantly from the full-length ZIC1 RNA (Figure 7.3C). This indicates that intact zinc 
fingers are required to induce consistently abnormal en-2 expression in this assay.
Zic1 expression in mouse embryos
Of note in the above experiments, the effect of the ZIC1 C-terminal mutants was to 
increase the expression of the Xenopus target gene en-2 (Figures 7.3B and 7.3C). 
Given previous evidence that the paralogous gene En1 is critical for early biogenesis 
of the murine coronal suture,37 we asked whether Zic1 might also be expressed in 
relevant cells. Although the neural pattern of Zic1 expression256,275 and loss-of-function 
phenotypes255,256 were previously described in the mouse, no evidence has linked Zic1 
expression to coronal suture development. Therefore, we analysed expression patterns 
of Zic1 in embryonic mouse heads between E11.5 and E17.5. Between E11.5 and E12.5, a 
distinct domain of Zic1 expression was observed in the supraorbital region and cephalic 
mesoderm, which appeared to precede and partly overlap En1 expression (Figure 7.4). 
By contrast, no Zic1 expression was observed in the calvaria at E14.5 and E17.5 (not 
shown).
Discussion
Given the homology to one of the classical early patterning genes of the Drosophila 
embryo, the function of the vertebrate Zic family has been the focus of sustained interest. 
Highlighting their importance for development, mutations in the related genes ZIC2 
[MIM: 603073] and ZIC3 [MIM: 300265] were previously described in holoprosencephaly 
[MIM: 609637]276 and X-linked visceral heterotaxy [MIM: 306955],277 respectively. In the 
case of ZIC1, the observation that heterozygous deletions in tandem with ZIC4 cause 
DWM254,270 has supported work in Xenopus261,272,274 and mouse,256,275 indicating key 
roles for the Zic1 ortholog in neurogenesis (in the mouse, deficiency of Zic1 and Zic4 
contribute additively to cerebellar hypoplasia).256 Our data now highlight a previously 
unsuspected subsidiary role for ZIC1 in early patterning events in the coronal suture.
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morphogenetic proteins (Bmps) activates zic1, which in
turn activates members of the Wnt family including
wnt1, which in turn activates the transcription factor
engrailed-2 (en-2).27,38 A previously designed assay had
shown that injection of zic1DC RNA encoding a truncated
ZIC1 into a single cell of 2-cell stage embryos led to
increased en-2 expression in stage 15–17 Xenopus embryos,
whereas injection of wild-type zic1 construct had no
effect.27 We next examined the activity of human ZIC1
and various mutant constructs with this assay.
In initial experiments, we replicated the previously
reported results of the Xenopus assay. Although very few
(3%) embryos were disrupted by injection of the wild-
type zic1 construct, this increased to 31% using the previ-
ously published zic1DC. Moreover, a construct deleting
almost the entire region C-terminal to the zinc fingers
(zic1DC2; Figure 2C) showed an even higher proportion
(61%) of disrupted embryos (Figure 3). Using constructs
encoding human ZIC1, injection of full-length ZIC1 RNA
yielded only 8% disrupted embryos, but this was increased
to 79% and 68% with constructs corresponding to two
of the observed truncations, p.Ser388* (subject 1) and
p.Glu402* (subjects 2 and 3), respectively. Strikingly, a
similar magnitude of effect (66%) was found with the
most C-terminal truncation construct (p.Ala437*, which
does not correspond to an observed mutation), high-
lighting the importance of the terminal 11 amino acids,
which includes a 5-amino-acid motif (NEWYV) of un-
known function that is conserved in human ZIC2, ZIC3
(isoform A), and ZIC5 (Figure 2C) but is not present in
any other human protein. Two constructs encoding
missense substitutions were studied with the same assay:
p.Gly400Arg present in family 5 and p.Thr414Ala, corre-
sponding to a rare SNP (dbSNP rs143292136), present in
104/121,380 alleles in ExAC, which we had identified in
a child with bicoronal synostosis and her unaffected father
(data not shown); 60% of embryos were disrupted in both
cases. Although producing a slightly milder effect than the
nonsense mutations, these results suggest that residues in
the C-terminal domain in addition to the NEWYV motif
contribute to function. Importantly, using a truncated
control construct (p.Glu299*) missing the last three of
the five zinc fingers, a much lower proportion of embryos
(20%) was disrupted, which did not differ significantly
from the full-length ZIC1 RNA (Figure 3C). This indicates
that intact zinc fingers are required to induce consistently
abnormal en-2 expression in this assay.
Zic1 Expression in Mouse Embryos
Of note in the above experiments, the effect of the ZIC1
C-terminal mutants was to increase the expression of the
Xenopus target gene en-2 (Figures 3B and 3C). Given previ-
ous evidence that the paralogous gene En1 is critical for
early biogenesis of the murine coronal suture,11 we asked
whether Zic1 might also be expressed in relevant cells.
Although the neural pattern of Zic1 expression20,41 and
loss-of-function phenotypes19,20 were previously described
in the mouse, no evidence has linked Zic1 expression to
coronal suture development. Therefore, we analyzed
expression patterns of Zic1 in embryonic mouse heads
between E11.5 and E17.5. Between E11.5 and E12.5, a
distinct domain of Zic1 expression was observed in the
supraorbital region and cephalic mesoderm, which ap-
peared to precede and partly overlap En1 expression
(Figure 4). By contrast, no Zic1 expression was observed
in the calvaria at E14.5 and E17.5 (not shown).
Discussion
Given the homology to one of the classical early
patterning genes of the Drosophila embryo, the function
of the vertebrate Zic family has been the focus of sustained
Figure 3. Analysis of Consequences of ZIC1 Mutations in Xeno-
pus Embryos
(A) Cartoon showing the structure and nomenclature of the cDNA
constructs used in the experiment. The five zinc finger domains
are highlighted in blue.
(B) Xenopus en-2 expression after microinjection of ZIC1 construct
RNA (right side of each embryo). Arrows indicate widened,
increased, or shifted en-2 expression in three representative
embryos.
(C) Quantification of effects of ZIC1mutations on en-2 expression.
The numbers of embryos used in each experiment are indicated in
parentheses. Statistical comparisons between full-length Xenopus
zic1 and human ZIC1 and between ZIC1 and ZIC1-p.Glu299*
were not significant (NS), whereas comparisons between all other
mutants and corresponding full-length constructs were highly
significant (p < 108).
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Figure 7.3. Analysis of consequences of ZIC1 mutations in Xenopus embryos. A: cartoon 
showing the structure and nomenclature of the cDNA constructs sed in the experiment. The 
five zinc finger domains are highlighted in blue. B: Xenopus en-2 expression after microinjection 
of ZIC1 construct RNA (right side of each embryo). Arrows indicate widened, increased, or shifted 
en-2 expression in three representative embryos. C: quantification of effects of ZIC1 mutations on 
en-2 expression. The numbers of embryos used in each experiment are indicated in parentheses. 
Statistical comparisons between full-length Xenopus zic1 and human ZIC1 and between ZIC1 and 
ZIC1-p.Glu299* were not significant (NS), whereas comparisons between all other mutants and 
corresponding full-length constructs were highly significant (p < 10-8).
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interest. Highlighting their importance for development,
mutations in the related genes ZIC2 (MIM: 603073) and
ZIC3 (MIM: 300265) were previously described in holo-
prosencephaly (MIM: 609637)42 and X-linked visceral
heterotaxy (MIM: 306955),43 respectively. In the case of
ZIC1, the observation that heterozygous deletions in
tandem with ZIC4 cause DWM18,36 has supported work
in Xenopus27,38,40 and mouse,20,41 indicating key roles for
the Zic1 ortholog in neurogenesis (in the mouse, defi-
ciency of Zic1 and Zic4 contribute additively to cerebellar
hypoplasia).20 Our data now highlight a previously unsus-
pected subsidiary role for ZIC1 in early patterning events
in the coronal suture.
The nonsense mutations of ZIC1 present in subjects 1 to
4 all arose de novo (post-zygotically in the case of subject 3,
who has an attenuated phenotype) and are associated with
consistent features comprising bicoronal synostosis, mod-
erate to severe learning disability, and subtle abnormalities
in brain anatomy including variable deficiency of the
corpus callosum and abnormal conformation of the ventri-
cles and posterior fossa. The progressive scoliosis in two of
these individuals is likely to be causally related to the mu-
tation, because vertebral and thoracic defects were also
observed in mouse mutants homozygous for the null mu-
tation in Zic1.44 In family 5, a heterozygous missense
Figure 4. Expression of Zic1 in E11.5–
E12.5 Mouse Embryos Analyzed by RNA
In Situ Hybridization and Comparison
with En1
Panels show comparison of Zic1 (A, B) and
En1 (C, D) expression at E11.5 (A, C) and
E12.5 (B, D). In each case the top panel
shows the whole embryo and plane of
sections 1, 2, and 3, which are illustrated
in the three respective lower panels
(e, eye; t, telencephalon; d, diencephalon;
m, mesencephalon; f, forebrain; circles
indicate relative position of the eye).
Note strong expression of Zic1 in supra-
orbital region (open arrow) at E11.5; other
areas of expression aremidbrain-hindbrain
boundary (closed arrow), neural tube, and
limb mesenchyme (A). At E12.5 Zic1
expression is seen mainly in the cephalic
mesenchyme, just posterior to the eye
(B). By comparison, at E11.5 the expres-
sion of En1 expression is relatively weak
in the supraorbital region (stronger expres-
sion is seen in the apical ectodermal ridge
of the limb and in the somitic mesoderm).
By E12.5 En1 expression has increased in
the cephalic mesoderm.
variant p.Gly400Arg, present in the
same C-terminal region of the ZIC1
protein, segregated through three
generations in six affected individ-
uals. The phenotype in this family
was variable, with two individuals
having documented bicoronal synos-
tosis and another a DWM. Associated learning disabilities
were less severe than in subjects with truncations. Interest-
ingly, MRI scans showed that several individuals from this
family not formally diagnosed with DWM nevertheless
had more subtle abnormalities in the conformation of
the posterior fossa (Figure 1J). Hence the cerebral features
were reminiscent of, but milder than, the malformations
described in the previous cases with contiguous ZIC1-
ZIC4 deletions. In contrast to many craniosynostosis
syndromes, no diagnostic limb anomalies were apparent
in any of the affected individuals.
In assessing the association of ZIC1 mutations with
craniosynostosis, two features are particularly striking:
the highly localized distribution of the mutations and
the severity of the phenotype. All five mutations predict
protein alterations within a 15-residue stretch encoded
by the final exon. The occurrence of distinct phenotypes
and/or patterns of inheritance associated with truncations
localized to the terminal exon is a well-recognized indi-
cation that escape from nonsense-mediated decay might
be responsible.37 Indeed, we were able to demonstrate
that the transcript carrying the nonsense mutation
was stable in a fibroblast cell line from the individual (sub-
ject 1) with the most N-terminal truncation (Figure 2B).
The qualitative difference in phenotype associated with
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Figure 7.4. Expression of Zic1 in E11.5–E12.5 mouse embryos analysed by RNA in situ 
hybridisation and comparison with En1. A-D: panels show comparison of Zic1 (A,B) and En1 
(C,D) expression at E11.5 (A,C) and E12.5 (B,D). In each case the top panel shows the whole 
embryo and plane of sections 1, 2, and 3, which are illustrated in the three respective lower panels 
(e = eye, t = telencephalon, d = diencephalon, m = mesencephalon, f = forebrain, circles indicate 
relative position of the eye). Note strong expression of Zic1 in supraorbital region (open arrow) 
at E11.5; other areas of expression are midbrain-hindbrain boundary (closed arrow), neural tube, 
and limb mesenchyme (A). At E12.5 Zic1 expression is seen mainly in the cephalic mesenchyme, 
just posterior to the eye (B). By comparison, at E11.5 the expression of En1 expression is relatively 
weak in the supraorbital region (stronger expression is seen in the apical ectodermal ridge of 
the limb and in the somitic mesoderm). By E12.5 En1 expression has increased in the cephalic 
mesoderm.
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The nonsense mutations of ZIC1 present in subjects 1 to 4 all arose de novo (post-
zygotically in the case of subject 3, who has an attenuated phenotype) and are associated 
with consistent features comprising bicoronal synostosis, moderate to severe learning 
disability, and subtle abnormalities in brain anatomy including variable deficiency of 
the corpus callosum and abnormal conformation of the ventricles and posterior fossa. 
The progressive scoliosis in two of these individuals is likely to be causally related to the 
mutation, because vertebral and thoracic defects were also observed in mouse mutants 
homozygous for the null mutation in Zic1.278 In family 5, a heterozygous missense variant 
p.Gly400Arg, present in the same C-terminal region of the ZIC1 protein, segregated 
through three generations in six affected individuals. The phenotype in this family was 
variable, with two individuals having documented bicoronal synostosis and another a 
DWM. Associated learning disabilities were less severe than in subjects with truncations. 
Interestingly, MRI scans showed that several individuals from this family not formally 
diagnosed with DWM nevertheless had more subtle abnormalities in the conformation 
of the posterior fossa (Figure 7.1J). Hence the cerebral features were reminiscent of, but 
milder than, the malformations described in the previous cases with contiguous ZIC1-
ZIC4 deletions. In contrast to many craniosynostosis syndromes, no diagnostic limb 
anomalies were apparent in any of the affected individuals.
In assessing the association of ZIC1 mutations with craniosynostosis, two features 
are particularly striking: the highly localized distribution of the mutations and the 
severity of the phenotype. All five mutations predict protein alterations within a 
15-residue stretch encoded by the final exon. The occurrence of distinct phenotypes 
and/or patterns of inheritance associated with truncations localized to the terminal 
exon is a well-recognized indication that escape from nonsense-mediated decay might 
be responsible.271 Indeed, we were able to demonstrate that the transcript carrying the 
nonsense mutation was stable in a fibroblast cell line from the individual (subject 1) with 
the most N-terminal truncation (Figure 7.2B). The qualitative difference in phenotype 
associated with heterozygous truncating mutations, compared to previously reported 
heterozygous deletions,254,270 supports a gain-of-function mechanism (see also below). 
In the four case subjects with truncating mutations, the coronal synostosis was always 
bilateral and associated with marked brachycephaly (Figures 7.1A–G), consistent with 
a severe, early effect on cranial suture formation; localized sutural ossification defects 
also occurred frequently. Craniosynostosis accompanied by DWM is rare, although an 
association with sagittal synostosis was reported previously.279
To investigate the mechanism by which these mutations could disturb coronal 
suture biogenesis, we first explored their functional effect in a previously established 
Xenopus assay. Injection of several constructs truncated at different positions in the 
C-terminal region led to disrupted en-2 expression in a majority of treated embryos, 
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provided that the zinc finger domain remained intact (Figure 7.3). Mostly the disrupted 
expression pattern involved combinations of upregulation, shifting, and expansion of 
en-2 expression (for examples see Figure 7.3B), although with the larger truncations 
retaining all Zn fingers, some embryos showed reduced en-2 expression. The zic1∆C 
construct has been used previously in Xenopus to obtain enhanced biological responses 
to zic1 in several assays in which sensitization of the ectoderm to Bmp inhibition led to 
activation of genes expressed in the neural crest and neural tube; this was interpreted 
as showing that the C-terminal region has negative regulatory activity.272 The biological 
basis of this activity remains unknown; based on the enhanced en-2 expression associated 
with both the very C-terminal truncation p.Ala437* and the two missense substitutions, 
this might involve protein interaction over several parts of the ZIC1 C-terminal region, 
which shows several patches that are conserved between multiple ZIC paralogs (Figure 
7.2C). Although the Xenopus assay supports the genetic evidence that the c.1198G>C, 
p.(Gly400Arg) substitution is causative of the phenotype in family 5, a cautionary note 
is provided by the finding that p.Thr414Ala also disrupted en-2 expression, because this 
variant occurs too frequently (at 1 in 1,167 alleles) to be penetrant for craniosynostosis 
in more than a small proportion of individuals who carry this variant.
In a second approach to understand the pathogenic mechanisms, we asked 
whether the pattern of Zic1 expression was consistent with a specific role in coronal 
suture biogenesis. We found a previously undescribed, transient zone of Zic1 expression 
in the supraorbital region at E11.5 (Figure 7.4) that is spatially and temporally overlapping 
with that of En1 (Figure 7.4) and is consistent with an early instructive role for Zic1 in 
the supraorbital regulatory centre; combining these observations with the finding of 
increased en-2 expression driven by mutant ZIC1 constructs in the Xenopus experiments, 
we propose that the coronal synostosis phenotype associated with the human 
mutations might be attributable to alteration of EN1 expression in the supraorbital 
regulatory centre, thus disrupting the patterning of the coronal suture at a very early 
stage in its development. The induction of engrailed expression by ZIC1 orthologs is well 
characterized in both Drosophila251,280 and Xenopus272 and is thought to act through the 
Wnt signalling pathway.261 A further component of this signalling network is likely to be 
Lmx1b, which encodes a LIM-homeodomain protein and is upregulated in early neural 
crest of Xenopus.281 In the mouse, Lmx1b is prominently expressed in the supraorbital 
region at E11.5, and homozygous mutants have severely abnormal cranial sutures.282 In 
humans, heterozygous mutations in LMX1B usually cause nail-patella syndrome [MIM: 
161200],283 but a specific missense mutation in the N-terminal arm of the homeodomain 
has been associated with craniosynostosis.128
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Putting the evidence together, we propose that the ZIC1 mutations we have 
described serendipitously uncover an important role for this transcription factor in early 
lineage commitment at the supraorbital regulatory center127 and that En1 is likely to 
represent a key target gene. This will stimulate further work to define more precisely the 
role of Zic1 in the coronal suture and to delineate the function of the conserved C-terminal 
domain. In ZIC2, constructs with holoprosencephaly-associated mutations C-terminal 
to the zinc fingers showed variable loss of transactivation activity,284 whereas in ZIC3, 
the single missense mutation beyond the zinc fingers reported to date (in a simplex 
case subject with congenital heart disease) was uniquely associated with increased 
transactivation activity.285 Collectively these data highlight the distinct properties of the 
C-terminal domain of ZIC proteins. The sequence conservation identified in this region 
(Figure 7.2C) suggests that a shared but currently unexplored mechanism exists for 
their regulatory function. Finally, although ZIC1 mutations are rare because the genetic 
target is localized, the complications for intellectual and skeletal development are more 
serious than is usually the case with coronal synostosis; therefore, genetic testing is 
recommended when the more common diagnostic possibilities (involving mutations in 
TWIST1, FGFR3, FGFR2, and TCF12)59,125 have been excluded.
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Case reports
Subject 1
This male was the first child born to a healthy unrelated couple, aged 38.9 years (father) 
and 28.5 years (mother) at the time of birth. The mother had four healthy children by a 
previous relationship. A brother born subsequently had metopic synostosis but this is 
presumed to be coincidental since he had normal development and was negative for 
the ZIC1 mutation.
During the pregnancy, renal dilatation had been noted at 22 weeks’ gestation; a 
foetal blood sample showed a normal karyotype. The proband was born at 37 weeks’ 
gestation by Caesarean section owing to persistent transverse lie, weighed 2.98 kg and 
was noted to have an abnormal head shape at birth. On assessment aged 20 weeks, his 
occipito-frontal circumference (OFC) was 38.5 (-3.5 SD). He was noted to have severe 
brachycephaly, a high forehead, downslanting palpebral fissures and an open posterior 
fontanelle. The remainder of the examination was normal except for a transverse palmar 
crease on the right hand. The computed tomography (CT) head scan showed bilateral 
coronal synostosis and no identifiable cerebral abnormality. He underwent a fronto-
orbital advancement and remodelling procedure at the age of 7 months. By the age of 8 
months he was noted to have developmental delay, with age-equivalent development 
at 4-5 month level. On formal assessment at 29 months using Bayley Scales of Infant 
Development (2nd Ed), his motor development was equivalent to 17 months and mental 
development to 12 months. Hearing and vision assessments were normal, although he 
previously required insertion of grommets. At 2.5 years his intracranial pressure (ICP) 
was measured because of concerns about slow head growth and delayed development, 
this was markedly increased (baseline 25-30 mm Hg, peaks up to 50 mm Hg) and he 
underwent a posterior release and remodelling procedure. By 3 years he was showing 
hyperactive behaviour, with sleep disturbance and head-banging. A repeat ICP 
measurement aged 4.6 years was again elevated with episodes of abnormal pressure 
in the 25-35 mm Hg range, and he underwent a posterior release and advancement 
procedure.
At the age of 5 years he was noted to have a stricture of his foreskin and was 
developing a scoliosis. By 8 years, the left sided thoraco-lumbar curve measured 50°, 
and he had extensive spina bifida occulta in his lower lumbar spine; he subsequently 
had spinal surgery at the age of 10 years. He started to develop intermittent outbursts 
of aggressive behaviour, but several measurements of ICP were normal. A magnetic 
resonance imaging (MRI) brain scan showed abnormal configuration of the ventricles 
and corpus callosum. His developmental progress was slow and he attended a school for 
children with special educational needs. Genetic testing for causes of learning disability 
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including repeat karyotype, telomere screen, FRAX and PW71B methylation (for Prader-
Willi/Angelman syndrome) were normal. Testing for craniosynostosis mutations in the 
research laboratory (FGFR2, FGFR3, TWIST1) was normal. On assessment at the age of 
13 years, he continued to have violent outbursts and poor sleeping routine. He had 
no language and only limited communication using signs, but his gross motor skills 
and comprehension were less severely delayed. He showed autistic features, being 
dependent on routines and focused on individual tasks.
Subject 2
This female was the only child of healthy unrelated parents aged 34.4 years (father) 
and 31.7 years (mother). She was born at term by forceps delivery following a normal 
pregnancy and weighed 3.23 kg. Although well at birth she fed poorly and was referred 
at the age of 4 months for assessment of an unusual head shape and dysmorphic 
appearance with “almond shaped eyes” and down-slanted palpebral fissures, when a 
skull radiograph showed craniosynostosis. A clinical geneticist noted a high forehead, 
large open anterior fontanelle, flat occiput, maxillary hypoplasia and normal extremities, 
and suggested a diagnosis of Crouzon syndrome. Her development was moderately 
delayed; she walked unsupported at 2 years and had a vocabulary of 30 words at 2.8 
years. She attended special schools for children with moderate to severe learning 
disability. She had surgery for divergent strabismus aged 3 years. CT head scan at 9 
years showed dilated lateral ventricles and agenesis of the corpus callosum. At the 
age of 13 years she was noted to have a kyphoscoliosis. Plain radiographs showed 
multiple abnormalities of the thoracic spine and ribs and spondylolisthesis at L5/S1. MRI 
scan aged 17 years confirmed the previous findings and demonstrated a retroverted 
odontoid peg impinging on the cranio-cervical junction. There was no deterioration on 
orthopaedic follow-up to the age of 21 years.
She was referred for craniofacial assessment at the age of 23 years. Her head 
circumference was 48.5 cm (-5 SD) and height 149 cm (-2.2 SD). She was noted to 
be markedly brachycephalic with a high, flat brow and low frontal hairline. The 
remainder of the examination was normal and did not reveal diagnostic features of any 
craniosynostosis syndrome. Genetic testing (FGFR1, FGFR2, FGFR3, TWIST1) was negative 
and the karyotype was normal. CT scanning was consistent with bicoronal synostosis 
and demonstrated dilatation of the trigone and temporal regions of the ventricles. No 
surgical intervention was undertaken in view of her stable state. Currently aged 36 
years, she lives in supervised residential accommodation, is able to communicate in 
short sentences and wash, dress and feed herself, but requires help with cooking.
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Subject 3
This boy was the first child born to healthy unrelated parents after a normal pregnancy 
and weighed 3.34 kg (-0.1 SD). He was noted to have brachycephaly shortly after birth 
and was referred for craniofacial assessment aged 6 weeks. At 19 weeks his OFC was 
39.0 cm (-2.8 SD) and cephalic index was 1.24. He had a low frontal hairline and normal 
extremities; on clinical genetic assessment his appearance was considered consistent 
with either Muenke or Saethre-Chotzen syndrome, but genetic testing of FGFR3 and 
TWIST1 was normal. The CT scan at the age of 5 months showed bicoronal synostosis, a 
patent metopic suture, a large wormian bone in the position of the anterior fontanelle, 
and an ossification defect in the sagittal suture. He developed progressive turricephaly 
and underwent a posterior distraction procedure aged 8 months followed by fronto-
orbital advancement and remodelling aged 2.4 years.
He had mild developmental delay with speech dysfluency, and occasional tantrums 
with changes in routine. Tests of vision and hearing were normal. At the age of 8 years 
he was attending a normal school but was receiving 1:1 educational support because 
of delayed learning. Array comparative genomic hybridisation was normal except for a 
140 kb deletion on chromosome 17 that was inherited from the mother and therefore 
presumed to be coincidental to the phenotype.
Subject 4
This boy was the fourth child of healthy unrelated parents aged 41 years (father) 
and 36 years (mother); an older sibling had trisomy 18. The proband was born at 38 
weeks’ gestation, weighing 4.27 kg. An altered skull shape was immediately apparent; 
on assessment by the plastic surgery department at the age of 2.5 months, this was 
clinically consistent with bilateral coronal synostosis and microcephaly (OFC 36 cm; -2.1 
SD), but without significant exorbitism, ptosis or malformations of the extremities. 3D 
CT scan showed bilateral coronal synostosis and a partial right lambdoid synostosis; the 
metopic and mid-part of the sagittal suture were widely patent. A clinical diagnosis of 
Muenke or Saethre-Chotzen syndrome was considered, but appropriate genetic testing 
was negative. Fronto-orbital and supraorbital rim remodelling, and osteotomy of the 
right lambdoid suture were performed at the age of 7 months.
On reassessment at the age of 1 year, delayed development was apparent. An 
MRI brain scan at 16 months showed a short corpus callosum, mildly enlarged lateral 
ventricles, a peaked tentorium cerebelli, enlarged foramen magnum with hypoplastic 
pons and cerebellum with prominent cerebellar folia and signal void near the cervical 
cord. The left transverse and sigmoid sinuses, together with the jugular foramen were 
enlarged, whereas on the right the transverse and sigmoid sinuses were underdeveloped. 
Ophthalmological assessment at the age of 18 months showed exotropia of the right 
14845-goos-layout.indd   128 13/11/2017   19:20
129
Gain-of-function mutations in ZIC1
eye, latent nystagmus, strabismus sursoadductorius with V motility and bilateral 
granular pigmented retinae. Metabolic testing was normal. Adenotonsillectomy was 
performed at the age of 2 years because of recurrent tonsillitis and otitis media.
Development continued to be delayed and was formally assessed at the age of 
34 months. Motor development was at 15 months equivalent, but no formal testing 
of mental development or speech was possible. His back was hyperpigmented and 
pedes plano valgi were present. At 4 years, speech and gait were noted to be ataxic and 
autistic spectrum disorder and attention deficit hyperactivity disorder were diagnosed. 
Optic nerve hypoplasia was noted, worse in the right eye in which vision was reduced 
to 30% of normal; the left eye was myopic (-2.25 dpt).
Subject 5:III.3 (proband)
This male was the second child born at 38 weeks’ gestation to unrelated parents. His 
grandfather (I.1), mother (II.2) and half-brother (III.1) had a similar head shape (see 
below). He weighed 2.94 kg and was well except for neonatal jaundice. At 30 months 
a brachycephalic head shape was noted with OFC of 46 cm (-2.5 SD), associated with 
patent posterior fontanelle (3.3 cm), an asymmetrical face, beaked nose, a high palate, 
and downslant and ptosis of the eyes. No hearing deficits or malformations of the upper 
or lower extremities were present. A clinical diagnosis of Saethre-Chotzen syndrome 
was suggested.
His development was generally delayed; he started walking at the age of 2.5 
years and had delayed speech. He was generally hypotonic with joint laxity. An 
electroencephalogram (EEG) showed an irregular and diffuse disordered background 
pattern with accentuated frontal dysfunction. He had a bilateral convergent strabismus.
He was referred for plastic surgical assessment at the age of 3.5 years. The 
craniofacial features were as noted previously. Vision was normal with glasses. Skull 
radiographs showed bicoronal synostosis with increased thumb printing of the frontal 
bones. CT head scanning demonstrated in addition a patent metopic suture, bilateral 
bony defect of the lambdoid suture, and normal ventricles and posterior fossa. No 
surgery was performed because of his age.
His most recent review was at the age of 19 years. He still complained of 
headaches. He had a mildly delayed development and lived under social supervision. 
His communication was normal. Mild flattening of the left supra-orbital region, mild 
asymmetry of the skull, and downslant and exorbitism of the eyes were present.
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Subject 5:III.1
The older half-brother of the proband was born at 40 weeks’ gestation with a weight 
of 4.00 kg and a length of 52 cm. He was well during infancy but was clumsy with 
mildly delayed developmental milestones (walked at 3 years, rode a bicycle at 6 years, 
swimming certificate at 12 years). He had a large anterior fontanelle that did not close 
until 4 years of age. Attention deficit disorder was diagnosed.
At the age of 8 years he was investigated for suspected hearing loss. He had 
persisting central hypotonia, was dysarthric, mildly dysphasic and dyspraxic, and was 
unable to heel-toe walk. Hyperpigmentation was noted over his back. He was found 
to have a 50 dB left-sided sensorineural hearing loss; auditory evoked potentials 
suggested a sensorineural cause. CT head scan showed cystic dilatation of the 4th 
ventricle communicating with the cisterna magna, and hypoplasia of the cerebellar 
vermis. The third and lateral ventricles and the foramina of Luschka and Magendi were 
normal. These features were consistent with a variant of Dandy-Walker malformation. 
Visual evoked potentials were normal and a radio-iodinated serum albumin brain scan 
suggested obstruction of drainage of the left lateral ventricle. Radiology of the spine 
showed hypolordosis of the cervical spine and spina bifida occulta with absent arches 
of the L4, L5 and S1 vertebrae.
During the latter part of childhood his symptoms persisted. At the age of 15 years 
LHRH deficiency was diagnosed because of pubertal delay and he was started on 
pulsatile LHRH therapy. On further assessment aged 16 years, his OFC was 53 cm (-1.96 
SD) and hyperpigmentation of his back was present. An MRI scan confirmed the earlier 
CT findings and showed atrophy of the cerebellum, the brachium pontis and temporo-
basal lobes with widened sulci.
Subject 5:II.2
Little detailed information is available on the mother of III-1 and III-3. She reported 
that as a child she had an enlarged late-closing fontanel, and had learning disability 
requiring her to repeat classes in both primary and secondary school. She suffered from 
vertigo and had a clumsy tandem gait. MRI scan showed atrophy of the rostral part of 
the cerebellum and pons, similar to, but less severe than, III-1.
The family was investigated for a suspected autosomal dominant cerebellar 
atrophy, but relevant genetic testing (SCA1, SCA2, SCA3 and SCA6) was negative in both 
5:II.2 and 5:III.1.
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Subject 5:III.6
The proband’s male cousin, the third child in the sibship (the two older siblings were 
healthy) was born at 37 weeks’ gestation after an uneventful pregnancy, weighing 
3.35 kg. He was referred for a plastic surgery opinion at 1 month of age because of 
concerns about his head size. He was microcephalic (OFC 38.5cm at 3.5 months; -1.9 SD) 
and noted to have brachycephaly, hypoplastic supraorbital ridges, hypertelorism, mild 
ptosis of the right eye, downslanting palpebral fissures, divergent strabismus, a high 
narrow palate, normal ears and symmetrical defects palpable over the occipito-parietal 
region. Additional features noted were axial hypotonia (but with increased muscle 
tone of the upper extremities), mild tapering of the fingers, clinodactyly of the 4th and 
5th toes and a sacral dimple. A clinical diagnosis of Saethre-Chotzen syndrome was 
suggested. 3D CT scanning at the age of 2 months showed bilateral coronal synostosis 
with bilateral large parietal foramina. Ultrasound of the brain was normal. A fronto-
orbital advancement was performed at the age of 11 months. The divergent strabismus 
persisted and posterior tenotomies were performed at the age of 3 years and 5 months.
At the age of 13 years an MRI brain scan was performed. The fourth ventricle 
and both superior cerebellar peduncles were mildly enlarged, with a prominent great 
cerebral vein and inferior sagittal sinus. The posterior fossa was small with a peaked 
tentorium cerebelli, short and steep straight sinus with mild hypoplasia of the dorsal 
part of the pons and inferior part of the cerebellar vermis. There was no Chiari or Dandy-
Walker malformation.
His schooling history is not documented. Formal psychological testing was 
performed at the age of 16 years. The WISCIII scores were full scale IQ 89, verbal IQ 
96, performance IQ 84. The Child Behaviour Checklist 6-18, Social Communication 
Questionnaire, and Children’s Communication Checklist-2 NL were normal. The OFC was 
55 cm (0 SD). He had small teeth and wore orthodontic braces.
Subject 5:II.4
This individual is the sister of II.2 and mother of III.6. As a child she had a strabismus 
correction, but no other surgery. She had mildly delayed development with attention 
deficit, aberrant fine motor skills and clumsiness, but attended a normal school. Her 
hearing and balance were normal. Currently aged 53 years, she complains of persistent 
severe headaches, forgetfulness and dental problems. On examination her height was 
1.62 m (-0.3 SD), she had brachymicrocephaly (OFC 51 cm, -2.9 SD), vertical orbital 
dystopia, ptosis of the left upper eyelid, midface hypoplasia, nasal deviation, and facial 
and occlusal asymmetry with narrow maxilla, crowding of the upper front teeth, absence 
of the lower right first molar and upper right canine, and prominent crura of both ears. 
The hands and feet were normal. MRI brain scan showed asymmetry of the skull base 
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and head shape, an enlarged foramen magnum, a peaked tentorium cerebelli, mildly 
hypoplastic inferior part of the cerebellar vermis and possibly a small defect of the 
hiatus tentorium cerebelli.
Subject 5:I.1
The deceased father of II.2 and II.4 (I.1) had a high forehead, facial asymmetry and 
hearing deficits, suggesting that the ZIC1 mutation present in his two daughters had 
been transmitted from him.
14845-goos-layout.indd   132 13/11/2017   19:20
14845-goos-layout.indd   133 13/11/2017   19:20
14845-goos-layout.indd   134 13/11/2017   19:20
C h a p t e r  8
Identification of causative variants in 
TXNL4A in Burn-McKeown syndrome 
and isolated choanal atresia
Jacqueline A.C. Goos, Sigrid M.A. Swagemakers,* Stephen R.F. Twigg,* Marieke F. van Dooren, A. 
Jeannette M. Hoogeboom, Christian Beetz, Sven Günther, Frank J. Magielsen, Charlotte W. Ockeloen, 
Maria A. Ramos-Arroyo, Rolph Pfundt, Helger G. Yntema, Peter J. van der Spek, Philip Stanier, Dagmar 
Wieczorek, Andrew O.M. Wilkie, Ans M.W. van den Ouweland, Irene M.J. Mathijssen, Jane A. Hurst
*Equal contributors
European Journal of Human Genetics July 2017
14845-goos-layout.indd   135 13/11/2017   19:20
136
Chapter 8
Abstract
Burn-McKeown syndrome (BMKS) is a rare syndrome characterized by choanal atresia, 
prominent ears, abnormalities of the outer third of the lower eyelid, structural cardiac 
abnormalities, conductive and sensorineural hearing loss, and cleft lip. Recently, 
causative compound heterozygous variants were identified in TXNL4A. We analysed an 
individual with clinical features of BMKS and her parents by whole genome sequencing 
and identified compound heterozygous variants in TXNL4A (a novel splice site variant 
(c.258-2A>G, (p.?)) and a 34 bp promoter deletion (hg19 chr18:g.77748581_77748614del 
(type 1Δ) in the proband). Subsequently, we tested a cohort of 19 individuals with (mild) 
features of BMKS and 17 individuals with isolated choanal atresia for causative variants 
in TXNL4A by dideoxy-sequence analysis. In one individual with BMKS unrelated to the 
first family, we identified the identical compound heterozygous variants. In an individual 
with isolated choanal atresia, we found homozygosity for the same type 1Δ promoter 
deletion, whilst in two cousins from a family with choanal atresia and other minor 
anomalies we found homozygosity for a different deletion within the promoter (hg19 
chr18:g.77748604_77748637del (type 2Δ)). Hence, we identified causative recessive 
variants in TXNL4A in two individuals with BMKS as well as in three individuals (from two 
families) with isolated choanal atresia.
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Introduction
Burn-McKeown syndrome (BMKS) was first described in five children by Burn et al.286 It 
is a rare disorder characterized by choanal atresia, prominent ears, hypertelorism with 
short palpebral fissures and abnormalities of the outer third of the lower eyelids. Other 
features that can be observed are structural cardiac abnormalities, conductive and 
sensorineural hearing loss, and unilateral cleft lip.286 There is clinical overlap with both 
Treacher Collins and CHARGE syndromes.
Burn et al.286 advised counselling a high recurrence risk in families with BMKS, but 
the inheritance pattern remained unclear until recently. As the syndrome was repeatedly 
described in siblings and mainly in males, an autosomal recessive286 or X-linked 
inheritance pattern was suggested.287 However, the identification of a chromosomal 
rearrangement, 46,XX,r(18)(p14q23), in an isolated female case with features of BMKS 
suggested terminal 18p or 18q as the locus for the disorder.286 This was borne out 
by the detection of causative compound heterozygous variants in TXNL4A (located 
on chromosome 18q23), identified more than 20 years after the initial description of 
BMKS.61
TXNL4A is a member of the U5 spliceosomal complex that is critical for pre-mRNA 
splicing.288 It has been suggested that reduced expression of TXNL4A influences the 
splicing of a specific subset of pre-mRNAs, resulting in the tissue-specific phenotypic 
spectrum of BMKS.61,289 In the present study, we describe new causative variants in 
TXNL4A and expand the associated phenotypic spectrum.
Subjects and methods
Subjects
Ethical approval from the board of the Medical Ethical Committee of the Erasmus MC, 
University Medical Centre Rotterdam, the Netherlands, was given for whole genome 
sequencing (MEC-2012-140) and for retrospective data collection (MEC-2013-547). UK 
samples were collected following approval from the Great Ormond Street Hospital for 
Children NHS Trust Ethics Committee (REC No. 08H0713/46). Informed consent was 
received from the individuals and parents.
Whole genome sequencing was performed on DNA of the members of family 1 
(see Figure 8.1).
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Figure 8.1. Pedigrees of families
1	
 
Symbol definitions:   not affected,         BMKS,                    lagophtalmos, 
 
                  choanal atresia,               prognathism,     maxillary hypoplasia.  
 
	 	
	  	  	  
1Δ = Promoter deletion type 1Δ (hg19 chr18:g.77748581_77748614del), 2Δ = Promoter deletion 
type 2Δ (hg19 chr18: g.77748604_77748637del), NA = Not available, Spl = splice site variant, 
−/− = no causative variant in TXNL4A.
To identify further mutation-positive individuals, dideoxy-sequence analysis of the 
promoter region, the exons and the exon/intron boundaries of TXNL4A was performed 
using DNA of 19 individuals who have clinical features that overlap with (mild) BMKS. In 
addition, 17 individuals with isolated choanal atresia were also tested for mutations in 
TXNL4A. In addition, 29 of the DNA samples were analysed for copy number variations 
in TXNL4A using a multiplex ligation-dependent probe amplification (MLPA) assay as 
described by Wieczorek et al.61
The variants identified were described according to HGVS nomenclature,148 using 
the reference sequences NM_006701.2, ENST00000269601 and ENSG00000141759, on 
GRCh37/hg19 and were submitted to the Leiden Open Variation Database (http://www.
lovd.nl/TXNL4A).
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Whole genome sequencing
Before publication of the paper of Wieczorek et al.,61 whole genome sequencing was 
performed on DNA of the proband of family 1 (III.2) and her parents (see Figure 8.1) 
by Complete Genomics, a BGI company (Mountain View, CA, USA) as described by 
Drmanac.104 Variants were annotated using NCBI build 36.3/hg18 and dbSNP build 130. 
Data were analysed using cga tools version 1.6.0.43 and TIBCO Spotfire 7.0.0 (TIBCO 
Software Inc., Boston, MA, USA). The annotations were converted to GRCh37/hg19 by 
using Human BLAT search on the UCSC website (Kent Informatics, Inc., Santa Cruz, CA, 
USA) as described previously.146
An autosomal dominant disease model was tested in family 1. The analysis was 
restricted to novel non-synonymous variants, variants disrupting a splice site (± 2 bp), 
and insertions or deletions in the coding sequence (± 50 bp). 
The remaining variants were analysed with Annovar,290 to get an indication of the 
pathogenicity and the ESP frequency as given in Exome Variant Server (EVS, NHLBI GO 
Exome Sequencing Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) 
[April 2014 accessed]). We focused on variants that were located in genes without loss-
of-function mutations in EVS.
Confirmation by dideoxy-sequence analysis
The variants identified by whole genome sequencing were validated by dideoxy-
sequence analysis (all primer sequences are provided in Supplementary Table 8.1). 
Amplification reactions were performed according to standard procedures. PCR products 
were purified using Agencourt AMPure (Agencourt, Beckman Coulter Inc., Brea, CA, USA). 
Direct sequencing of both strands was performed using Big Dye terminator version 3.1 
(Applied Biosystems, Foster City, CA, USA) as recommended by the manufacturer. Dye 
terminators were removed using Agencourt CleanSeQ (Agencourt) and loaded on an 
ABI 3130XL Genetic Analyzer (Applied Biosystems). The sequences were analysed using 
SeqPilot version 4.1.2 build 507 (JSI Medical Systems Gmbh, Kippenheim, Germany).
Confirmation of effect of the variants on RNA expression
To analyse the effect of the variants on RNA expression, cDNA was analysed by restriction 
enzyme digestion and deep sequencing. First, RNA was extracted according to the 
manufacturer’s protocol from venous blood collected into PAXgene Blood RNA tubes 
(Qiagen N.V., Venlo, The Netherlands) from individuals II.1, II.2 and III.2 (Figure 8.1, family 
1). cDNA was synthesized using the RevertAid First Strand cDNA kit (Thermo Scientific 
Inc., Waltham, MA, USA), with random hexamer primers according to the manufacturer’s 
instructions. Primers were designed for all exons and intron two to screen for truncations 
and intron retention (Supplementary Table 8.1). cDNA was amplified and products were 
electrophoresed on agarose gels and DNA was visualized by staining with ethidium 
bromide (EtBr).
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Digestion with PshAI and AhdI and electrophoresis of digests
To assess the effect of the paternal variant on RNA expression in family 1, cDNA 
amplification products were digested with PshAI or AhdI (New England Biolabs Inc., 
Ipswich, MA, USA) and analysed by agarose gel electrophoresis. The forward primer was 
mutated to allow digestion with AhdI (underlined and bold ‘a’ in Supplementary Table 
8.1).
Deep sequencing by Ion PGM Sequencing
To distinguish between the wild-type and mutant allele, two heterozygous SNPs in the 
3’-UTR of TXNL4A that were identified in the WGS data from the parents of the family 
1 proband were used. To quantify the effect of the maternal variant, deep sequencing 
covering the SNP was performed on cDNA of the proband. Primers are given in 
Supplementary Table 8.1. The cDNA amplification products were diluted 1/100 and 2 μl 
was used in a second round PCR, with a reverse primer including the Ion PGM P1 adapter, 
and a forward primer with the Ion PGM A adapter sequence and a barcode sequence 
(reaction conditions available on request). Amplification products (roughly equal 
amounts as judged by EtBr staining by agarose gel electrophoresis) were combined and 
then purified with AMPure beads (Beckman Coulter). Emulsion PCR and enrichment was 
performed with the Ion PGM Template OT2 200 Kit (Life Technologies) according to the 
manufacturer’s instructions. Sequencing of enriched templates was performed on the 
Ion Torrent PGM (Life Technologies) for 125 cycles using the Ion PGM Sequencing 200 
kit v2 and Ion 316 chips. Data were processed with Ion Torrent platform-specific pipeline 
software v4.2.1.
Results
Whole genome sequencing of family 1
The proband of family 1 and her parents were analysed by WGS. Variants remaining after 
the various filtering steps are available on request. By testing the expected autosomal 
dominant disease model, we identified a novel splice site variant upstream of the last 
exon in TXNL4A (c.258-2A>G, (p.?)), that was inherited from the father. According to 
both cga tools and ANNOVAR, the splice site variant was predicted to be deleterious. As 
this variant was present in the 3’ splice site consensus sequence, it was highly conserved 
with a PhyloP score of 1.824 × 10− 5. The variant was not present in ESP, 1000 Genomes 
(The 1000 Genomes Project Consortium, 2012, URL: http://www.1000genomes.
org/154), Ensembl,291 nor in our in-house Huvariome database.153 However, it did have 
an allele frequency of 7.31× 10− 6 in gnomAD.111 During the analysis, the phenotype was 
recognized as suspected BMKS. Therefore, recessive variants on chromosome 18 were 
implicated and the DNA sequence of TXNL4A was scrutinized manually. Based on the 
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publication of Wieczorek et al,61 the likely significance of a 34 bp deletion within the 
promoter became apparent (hg19 chr18:g.77748581_77748614del, referred to as type 
1Δ and inherited from the mother).61 The presence of both variants was confirmed by 
dideoxy sequencing (Figure 8.2).
Figure 8.2. Electropherograms of dideoxy-sequence analyses. Red line indicates the start 
of the deletion. A: control DNA. B: splice site variant in DNA of III.2 of family 1. C: region of 
type 1Δ deletion in control DNA. D: heterozygous type 1Δ deletion in DNA of III.2 of family 1. 
E: homozygous type 1Δ deletion as seen in DNA of III.1 of family 3. F: region of type 2Δ deletion in 
control DNA. G: heterozygous type 2Δ deletion as seen in DNA of IV.6 of family 4. H: homozygous 
type 2Δ deletion as seen in DNA of V.4 of family 4.
cDNA analysis of TXNL4A 
RT-PCR analysis of the proband of family 1 and her parents, followed by agarose gel 
electrophoresis, did not show any aberrantly spliced products in any of the samples, 
despite the presence of the predicted splice site variant in both the proband and her 
father. WGS data indicated that both parents each carried a different sequence change 
within the 3’ UTR of TXNL4A that was not inherited by their daughter (thus located on 
the reference alleles): the father was heterozygous for hg19 chr18:g.77733297dupC 
(rs77355432, dbSNP build 146) and the mother for hg19 chr18:g.77733273C4T 
(rs4798931). Primers were designed to amplify both SNPs in one amplicon. 
The effect of the 3’ acceptor variant c.258-2A>G on splicing, was assessed using the 
restriction enzymes AhdI and PshAI. AhdI was specific for the 3’ UTR dupC (reference 
allele, not passed to the proband), while PshAI was specific for the mutant allele in cDNA 
from the father (passed to the proband). The primer was designed to amplify the alleles 
equally, had they both been present in the cDNA. Using AhdI, the cDNA of the father 
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was digested almost to completion (Figure 8.3), and using PshAI the cDNA remained 
undigested (data not shown), indicating that there was no or extremely reduced mature 
transcript from the mutant allele.
Deep sequencing of maternal cDNA demonstrated reduced expression from the 
allele with the type 1Δ: in a total of 36,924 reads, 8,636 reads (23%) were of the reference 
C (the allele with the promoter variant), and 28,283 reads (77%) contained the variant T 
(wildtype promoter allele).
Figure 8.3. Restriction enzyme digest analysis of rs77355432 SNP in cDNA from family 1. 
Expected fragment sizes reference allele 249 bp (WT), alternative allele 215+34 bp (dupC). Lane 1, 
uncut DNA. Lane 2, cDNA from the proband is not digested with AhdI. Lane 3, cDNA of the father 
is cut almost to completion with AhdI. Lane 4, cDNA of the mother is uncut with AhdI. Lane 5, 
negative control.
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Expansion of the mutation spectrum
Dideoxy sequencing of TXNL4A was performed on DNA obtained from 19 index cases 
with (mild) features of BMKS. The proband of family 2 (Figure 8.1, III.1 of family 2) was 
found to carry the identical variants to those of the family 1 proband. Analysis of 
parental samples showed that they were present in compound heterozygous state with 
the type 1Δ deletion inherited from the father and the splice site variant inherited from 
the mother. In addition, 17 index cases with choanal atresia were tested for mutations 
in TXNL4A. In two probands, homozygosity for a promoter deletion was identified. The 
proband of family 3 (Figure 8.1, III.1 of family 3) had a uniparental disomy of chromosome 
18p11.32q23, leading to homozygosity for the type 1Δ deletion. The family 4 proband 
(Figure 8.1, V.4 of family 4) was homozygous for a slightly different promoter deletion: 
hg19 chr18:g.77748604_77748637del corresponding to type 2Δ in Wieczorek et al.61 The 
same genotype was also present in his first cousin (Figure 8.1, V.6 of family 4). 
MLPA analysis was performed on the 29 samples with sufficient DNA available. This 
included samples of both families 3 and 4 (Table 8.2). Large rearrangements were not 
identified in any of these samples.
Subjects
Nineteen individuals with clinical features overlapping with BMKS syndrome and 17 
individuals with isolated choanal atresia were tested for mutations in TXNL4A. Causative 
variants were identified in five individuals. An overview of the clinical phenotype of 
these individuals is given in Table 8.1. The proband of family 4 and his first cousin (Figure 
8.1, V.4 and V.6 of family 4) were previously described as patients 1 and 3 in the paper of 
Ramos-Arroyo et al.292 All individuals had choanal atresia and normal development. In 
three out of five, their pregnancy was complicated by polyhydramnios. The same three 
had a prominent nasal bridge. Maxillary hypoplasia was also seen in the same three 
individuals, and micrognathia was seen in two out of them. Two out of five individuals 
had defects of the lower eyelids. The proband of family 4 and his first cousin had 
oligodontia, however, due to the high prevalence of this condition,293 we cannot rule 
out that this is a separate condition that is segregating within this family.292
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Discussion
In two out of 20 unrelated individuals with clinical features of BMKS, we identified 
compound heterozygosity in TXNL4A for a novel splice site variant, c.258-2A>G, (p.?) 
and the type 1Δ promoter variant, hg19 chr18:g.77748581_77748614del. Our findings 
support the idea that causative TXNL4A variants do not completely ablate function in 
BMKS.61
In nine out of 11 affected families, Wieczorek et al.61 found a rare loss-of-function 
variant (nonsense, frameshift or microdeletion) on one allele in conjunction with a 
promoter deletion on the other allele. In our deep sequencing analysis of RNA isolated 
from blood, expression of the type 1Δ mutant allele was reduced by ~ 69%. This is in 
keeping with a luciferase reporter gene assay, where the promoter activity of constructs 
containing type 1Δ deletion was reduced by 59% compared to a wild-type construct.61 
The presence of the splice-site variant on the other TXNL4A allele of the family 1 
proband most likely leads to loss-of-function, since analysis of paternal cDNA based 
on the closely adjacent SNP rs77355432, indicated no evidence of transcription of this 
allele (Figure 8.3). Wieczorek et al.61 have shown that deletion of exon three combined 
with type 1Δ causes BMKS. Hence, we can conclude that the variants identified in the 
probands of families 1 and 2 are the underlying causes of the clinical phenotype.
In the paper of Wieczorek et al.61 the allele frequency of the promoter deletions 
in German control samples was estimated at 0.76%. A single homozygous type 1Δ 
deletion was identified in 3,343 population-based German and South Asian samples. 
Unfortunately, data about the craniofacial phenotype in that individual were not 
available. In this study, we sequenced a cohort of 17 individuals with choanal atresia 
and also identified a homozygous type 1Δ deletion (family 3). Although the predicted 
frequency of homozygous type 1Δ deletions was estimated at 1:17,300, which seemed 
to exclude this genotype as a cause for BMKS, Wieczorek et al.61 stated that this genotype 
might lead to a mild phenotype. It seems likely that the isolated bilateral choanal atresia 
identified in the proband of family 3 might be part of this mild phenotype, especially 
since choanal atresia is one of the major anomalies of BMKS. As isolated choanal atresia 
is a feature of the Tbx22 knock-out mouse,294 the individuals with isolated choanal 
atresia were screened for mutations in TBX22, but causative variants were not found.
In family 4, homozygosity for the pathogenic promoter variant type 2Δ was found 
to segregate in the affected individuals. Wieczorek et al.61 also found a homozygous 
type 2Δ case in an individual with true BMKS and showed that promoter activity of a 
construct containing type 2Δ was reduced by 72% compared to wild-type, indicating 
a stronger reduction of TXNL4A expression than type 1Δ. However, individuals with the 
type 2Δ (family 4) seem to be less severely affected than the compound heterozygotes; 
only choanal atresia, hypodontia and some minor anomalies were seen (Table 8.2). 
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Further screening of family 4 identified eight members who were heterozygous for type 
2Δ, and interestingly minor anomalies were present in two of them (Figure 8.1 and Table 
8.2). Our data support the proposed dosage-specific effect.61,289
Wieczorek et al.61 identified causative variants in nine out of 11 families, compared 
to two out of 18 in this study. This may be attributed to the fact that in this work 
individuals were included with only mild features of BMKS and may overlap with 
other conditions such as bilateral craniofacial microsomia, CHARGE phenotype, 
and asymmetrical Treacher-Collins like phenotype. Recently, it has been shown that 
ribosomopathies, such as Treacher Collins syndrome, and spliceosomopathies can have 
similar craniofacial phenotypes.289 In contrast to CHARGE and Treacher Collins syndrome, 
individuals with BMKS tend to have a normal intellectual development, however, there 
is otherwise significant clinical overlap. Therefore, we suggest it will be important to test 
for mutations in TXNL4A if the clinical phenotype is indicative of BMKS, but also if the 
clinical phenotype is indicative of these other conditions should their appropriate gene 
tests report negative.
Conclusion
We describe the finding of the splice site variant c.258-2A>G, combined with promoter 
deletion type 1Δ, in TXNL4A as the genetic cause of BMKS in two unrelated individuals. 
Homozygosity for the type 1Δ deletion was identified in a third individual with isolated 
choanal atresia. Homozygosity for the type 2Δ deletion was identified in a family 
with choanal atresia and other minor anomalies. These results confirm that variants 
affecting function of TXNL4A are the cause of BMKS and possibly a cause of isolated 
choanal atresia, underlining the tissue-specific nature of craniofacial disorders caused 
by spliceosomal defects.289
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Abstract
Craniosynostosis, the premature fusion of one or more cranial sutures, occurs in ~1 in 
2,250 births, either in isolation or as part of a syndrome. Mutations in at least 57 genes 
have been associated with craniosynostosis, but only a minority of these are included in 
routine laboratory genetic testing.
We used exome or whole genome sequencing to seek a genetic cause in a cohort 
of 40 subjects with craniosynostosis, selected by clinical or molecular geneticists as 
being high-priority cases, and in whom prior clinically-driven genetic testing had been 
negative.
We identified likely associated mutations in 15 patients (37.5%), involving 14 different 
genes. All genes were mutated in single families, except for IL11RA (2 families). We 
classified the other positive diagnoses as follows: commonly mutated craniosynostosis 
genes with atypical presentation (EFNB1, TWIST1); other core craniosynostosis genes 
(CDC45, MSX2, ZIC1); genes for which mutations are only rarely associated with 
craniosynostosis (FBN1, HUWE1, KRAS, STAT3); and known disease genes for which a 
causal relationship with craniosynostosis is currently unknown (AHDC1, NTRK2). In 
two further families, likely novel disease genes are currently undergoing functional 
validation. In 5 of the 15 positive cases, the (previously unanticipated) molecular 
diagnosis had immediate, actionable consequences for either genetic or medical 
management (mutations in EFNB1, FBN1, KRAS, NTRK2, STAT3).
This substantial genetic heterogeneity, and the multiple actionable mutations 
identified, emphasises the benefits of exome/whole genome sequencing to identify 
causal mutations in craniosynostosis cases for which routine clinical testing has yielded 
negative results.
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Introduction
Accurate molecular classification is critical for the clinical management, counselling 
and prognosis of individuals with suspected monogenic diseases, particularly where 
early diagnosis and intervention would substantially influence decision-making by the 
clinician or family. Traditional phenotypically guided genetic testing may fail to identify 
rarer causes of disease, as many conditions have a highly variable clinical presentation. 
The use of next-generation sequencing technologies to interrogate the exome 
sequence or whole genome sequence may circumvent some of these difficulties since 
these approaches are agnostic to the underlying genetic cause.143,145,258
Craniosynostosis, a condition that affects ~1 in 2,250 births,2,3 is defined as the 
premature fusion of one or more of the normally patent cranial sutures, a consequence 
of the disruption in the coordinated patterning, proliferation and differentiation of these 
tissues.295 It has a highly heterogeneous and complex aetiology with contributions from 
monogenic, chromosomal, polygenic and environmental factors all playing a role.125,127 
Craniosynostosis most commonly occurs in isolation, but a minority of cases are 
associated with additional clinical features as part of a syndrome, probably reflecting 
the co-option of pleiotropic signalling pathways to pattern and maintain the suture; 
association with over 100 human syndromes has been reported.129 An underlying genetic 
cause can be identified in ~24% of cases, with mutations in just six genes (in decreasing 
order of frequency: FGFR2, FGFR3, TWIST1, TCF12, ERF and EFNB1) together accounting 
for over three-quarters of monogenic diagnoses.59,63,128,131,133,134,136,138-140 At least 52 other 
genes have been identified as recurrently mutated in craniosynostosis,127,296 but these 
rarer targets do not tend to be included in molecular testing panels unless indicated 
by specific clinical features. Craniosynostosis may also present as a low-frequency 
association with intellectual disability syndromes, possibly related to disturbed 
maintenance of suture patency.127
To evaluate the utility of exome sequencing and whole genome sequencing in this 
context, we used these technologies to search for a molecular diagnosis in 40 patients 
with craniosynostosis who had previously been evaluated using existing routine 
molecular testing, without a diagnosis being made. Cases were identified as being of 
high priority for further investigation, either by craniofacial clinical geneticists or by 
laboratory scientists specialising in craniofacial molecular diagnostics. From this cohort, 
we identified an underlying molecular lesion in 15 (37.5%) families. We document 
several cases where the mutation identified either did not obviously fit with the original 
clinical diagnosis, or where identification of the causal mutation would have proved 
difficult using traditional methods of molecular testing. We highlight five families for 
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which diagnosis has immediately impacted on clinical management or counselling. 
This work illustrates the molecular diversity of causes of craniosynostosis and the added 
value that can be gained by a comprehensive diagnostic approach in difficult cases.
Subjects and methods
Ethics statement and prior clinical investigation
Written, informed consent for genetic research and publication of clinical photographs 
was obtained by the referring clinicians and their research teams. DNA was extracted 
from whole blood. Genetic testing by a clinically accredited laboratory was guided 
by the judgement of the referring clinician and diagnostic laboratory but usually 
included dideoxy sequencing of TWIST1, TCF12 and ERF (entire gene), FGFR2 and FGFR3 
(regions enriched for craniosynostosis-associated mutations) and multiplex-ligation 
dependent probe amplification of TWIST1 to exclude heterozygous deletions.59,125,140 
Since chromosomal abnormalities account for 13-15% of genetic diagnoses in 
craniosynostosis,59,128 a karyotype or array comparative genomic hybridisation was 
undertaken in the majority of cases. 
Cohort description
Subjects with craniosynostosis, who had previously been investigated by molecular 
genetic testing with normal findings, were identified either by four clinical geneticists 
with specialist expertise in craniosynostosis (n = 36) or by clinical laboratory scientists 
working in a specialist genetic diagnostic service (n = 20), for further investigation. 
Clinical geneticists were asked to prioritise cases thought most likely to have a genetic 
diagnosis (based on presence of syndromic features, multiple sutures affected, 
consanguinity or positive family history, and lack of any obvious environmental 
predisposition), particularly where there were active issues with genetic counselling. 
Twelve of the cases initially identified by clinical geneticists were excluded, either 
because further targeted genetic testing identified a monogenic cause (one case each 
with mutations in ERF,140 FGFR2,133 and FLNA,297 and two with IL11RA mutations),60 where 
enrolment into the Deciphering Developmental Disorders study145 was considered 
more appropriate (n = 5), or where samples were not available for analysis (n = 2). 
The remaining cases (n = 24), together with parental samples (where available) were 
enrolled into the craniofacial research study following informed consent. Sequencing 
comprised 12 singletons, one parent-child duo, ten parent-child trios and one trio 
comprising three affected individuals. Similar criteria were used by clinical laboratory 
scientists to prioritise 20 cases for exome sequencing, however clinical information 
tended to be more limited and availability of sufficient stored DNA sample was often 
a decisive factor for case inclusion. For the laboratory samples, consent for research 
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investigation was sought secondarily to enable the entire exome to be interrogated; 
two cases were excluded because consent was not obtained. In 16 of the remaining 18 
laboratory diagnostic cases, exome sequencing was performed on the proband only; 
in one instance the exome of an affected sibling was already available and in another 
the family trio subsequently had whole genome sequencing. Two duplicate families 
(29, 34) identified by both clinicians and laboratory scientists are listed under the latter 
category in Table 9.1, which summarises the patterns of cranial suture involvement and 
syndromic features of the final total of 40 patients/families analysed, with further details 
in Supplementary Table 9.1. In general, cases referred by clinical geneticists exhibited 
higher proportions of multisuture involvement and syndromic features (Table 9.1). The 
significance of differences between two groups was calculated using Fisher’s exact test.
Table 9.1. Cranial suture involvement in patients recruited for exome sequence/whole genome 
sequence. 
Non-syndromic Syndromic Combined
Total Mutation positive Total Mutation positive Total Mutation positive
Clinical genetic cases
 Metopic 0 0 2 2 2 2
 Sagittal 0 0 0 0 0 0
 Unicoronal 0 0 1 0 1 0
 Bicoronal 2 0 2 2 4 2
 Multisuture 3 1 12 5* 15 6
 Total 5 1 17 9 22 10
Molecular genetic cases
 Metopic 0 0 0 0 0 0
 Sagittal 0 0 2 0 2 0
 Unicoronal 5 1 1 1 6 2
 Bicoronal 2 0 2 1* 4 1
 Multisuture 1 0 5 2 6 2
 Total 8 1 10 4 18 5
*Includes likely novel disease gene, still undergoing validation.
Exome and whole genome sequencing
Exome capture of DNA from patients was carried out using the TruSeq v2 (Illumina), 
SureSelect Human All Exon Kit v4/v5 (Agilent) or SeqCap EZ Human Exome Library v2.0 
(NimbleGen) following the manufacturer’s instructions. We generated a library for each 
sample using DNA extracted from whole blood; usually we employed 3 μg DNA, except 
for SureSelect v5 processed samples from families 8, 16 and 17 only, for which we used 
200 ng DNA. Exome sequencing was performed on an Illumina HiSeq 2000 or 4000, with 
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75 bp or 100 bp paired-end reads. Whole genome sequencing was performed on 5 μg 
DNA extracted from blood by Complete Genomics (a BGI Company) and analysed as 
previously described.104
Bioinformatic analysis
Exome sequencing reads were mapped to the GRCh38 reference genome with Bowtie 
2298 and removal of artefacts (unmapped sequences, duplicate PCR products and likely 
pseudogene sequences) using custom Perl scripts.140 Variants were called using SAMtools 
v1.1299 and Platypus v0.5.2.259 Sequence reads from whole genome sequencing were 
mapped to the GRCh37 reference genome and analysed as previously described.104 
The pathogenicity of each variant was given a custom deleterious score based on a 
6-point scale,300 calculated using output from ANNOVAR.290 Variants predicted to affect 
splicing were assigned a deleterious score based on MaxEntScan score differences,301 
and the relationship of variants present in known disease-causing genes analysed for 
pathogenicity using ClinVar.302 Variants with minor allele frequency (MAF) >1% in dbSNP 
or ExAC were removed, and remaining variants examined manually by visualisation in 
GBrowse (hg37/hg38).303
In families comprising parent-child trios with a sporadic affected individual, we 
evaluated variants based on all likely modes of inheritance; de novo mutation, recessive 
(homozygous and compound heterozygous), and X-linked hemizygous variants (in 
males). For cases in which the parents were known to be related, the proband was 
usually sequenced as a singleton and the data interrogated for homozygous changes. 
For all samples, data were analysed for variants in 57 genes recurrently mutated in 
craniosynostosis127 and 1,313 genes curated as being mutated in developmental 
disorders.145
Variant validation
Confirmation of variants was carried out by dideoxy sequencing or restriction digest 
of genomic PCR amplification products. Primer sequences and conditions are detailed 
in Supplementary Table 9.2. Amplification products were sequenced using the BigDye 
Terminator v3.1 cycle sequencer system (Applied Biosystems) and visualised using 
BioEdit Sequence Alignment Editor (Ibis Biosciences) and Mutation Surveyor Software 
(SoftGenetics).
Where a previously undescribed de novo variant was identified in a singleton sample 
(i.e. HUWE1), correct sample relationships of the trio were checked by demonstrating 
consistent inheritance of nine microsatellite loci (D1S2826, D3S1311, D5S2027, D6S1610, 
D9S158, D10S548, D13S1265, D14S280 and D18S474), labelled with 6-FAM fluorescent 
tags.
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Results
Overview of molecular findings
We used either exome sequencing (n = 37) or whole genome sequencing (n = 3) to seek 
a causative mutation in the two patient cohorts. In the cases from clinical geneticists (n 
= 22), interpretation was often assisted by sequencing samples from unaffected parents 
or affected first-degree relatives; 23 additional samples were sequenced in this group 
(Supplementary Table 9.1). For most cases from the diagnostic laboratory, samples from 
relatives were either unavailable or not consented for analysis of exome sequencing/
whole genome sequencing (as described above) and, with two exceptions (total of 
three additional samples sequenced), these cases were analysed as singletons.
Mutations considered to be clinically significant (for the diagnosis of 
craniosynostosis and/or another genetic disorder) were identified in 15 of the 40 
patients (37.5%), including two cases associated with putative novel disease genes 
that are still undergoing validation (Table 9.2). Significantly more positive diagnoses 
were found in syndromic (13/27) than non-syndromic (2/13) patients (one-tailed p = 
0.046). The number of mutations identified in patients recruited via clinical geneticists 
(including the two duplicate ascertainments) was higher (11/24; 46%) compared with 
those recruited via the diagnostic laboratory (5/18; 28%), likely a consequence of more 
rigorous clinical selection and inclusion of sequencing data from a greater number of 
additional family members in these cases; however the difference was not significant 
(one-tailed p = 0.19). A positive diagnosis was obtained in a higher proportion of 
families in which multiple individuals were sequenced (6/14; 43%) than when singletons 
were sequenced (9/26; 35%), but this difference was also not significant. When the case 
solution rate was analysed in terms of total samples sequenced, sequencing of multiple 
individuals in a family appeared less cost-effective (six solved using a total of 40 exome 
sequencing/whole genome sequencing; an efficiency of 0.43 per exome/genome 
sequenced compared with singleton sequencing).
Table 9.2 summarises the 13 cases or families with mutation in a validated disease 
gene. Seven of the mutations identified (in AHDC1, EFNB1, FBN1, IL11RA, KRAS, MSX2, 
STAT3) were previously reported; in two instances (CDC45 and HUWE1), the patients 
contributed to the first reported disease gene identification;258,304 and in four cases, the 
mutations are newly identified and help to extend the genotype-phenotype spectrum 
(mutations in IL11RA, NTRK2, TWIST1, ZIC1). The associated phenotypes are summarised 
in Table 9.2 and complete details are provided in Supplementary Table 9.1. Aside from 
the importance of a molecular diagnosis to end the diagnostic odyssey and to enable 
precise genetic counselling (with appropriate estimation of recurrence risk and testing 
of at-risk family members), in five families the diagnosis had unexpected, actionable 
consequences for immediate clinical management. Details of these latter cases are
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provided as brief case reports to illustrate the range of diagnostic and management 
issues encountered; more complete descriptions are provided as Case Reports in the 
Supporting Information.
Case reports
Family 11: FBN1 mutation
This boy (II-3 in Figure 9.1A) was initially diagnosed with Shprintzen-Goldberg 
syndrome (based on the combination of sagittal synostosis, blue sclerae, micrognathia, 
ligamentous laxity, bilateral recurrent inguinal hernia, tall stature and mildly abnormal 
aortic contour on echocardiography. However sequencing of SKI, in addition to TGFBR1 
and TGFBR2, did not reveal any mutations.311
Exome sequencing was performed on the proband only. Concomitantly, the referring 
clinician reported that the patient, now aged 8 years, had presented with subluxed 
lenses; together with the aortic findings, this suggested possible Marfan syndrome 
(MFS). Scrutiny of the exome sequencing data revealed two rare heterozygous variants 
in the FBN1 (Fibrillin 1) gene, c.2615A>G, p.(Lys872Arg) and c.8226+5G>A. Dideoxy 
sequencing of parental samples showed that whereas the p.Lys872Arg substitution 
had been inherited from the unaffected father (not shown), the c.8226+5G>A variant 
had arisen de novo (Figure 9.1A). The c.8226+5G>A variant, which was re-confirmed in 
a diagnostic laboratory, has been identified previously in a patient with a progeroid 
variant of MFS;307 a different mutation of the same splice site (c.8226+1G>A) was shown 
to cause skipping of the upstream exon, introducing a frameshift and premature stop 
codon.312 
Confirmation of the molecular diagnosis of MFS has triggered a program of lifelong 
monitoring owing to the association with progressive aortic dilatation; aged 10 years, 
mild aortic root dilatation was observed (Z score = 3.02). Of note, craniosynostosis is an 
extremely rare, but previously recognised association of MFS.313,314
Family 21: KRAS mutation
This girl presented neonatally with a cloverleaf skull appearance. 3D-CT revealed 
synostosis of multiple cranial sutures. There were no additional syndromic features and 
cardiac examination was normal. Raised intracranial pressure (ICP) was documented, 
requiring a posterior vault expansion with springs, performed at the age of 3 months, 
and insertion of a right parieto-occipital ventriculo peritoneal shunt.
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root dilatation was observed (Z score=3.02). Of note, craniosy-
nostosis is an extremely rare but previously recognised associ-
ation of MFS.42 43
Family 21: KRAS mutation
This girl presented neonatally with a cloverleaf skull appearance.
3D-CT revealed synostosis of multiple cranial sutures. There
were no additional syndromic features and cardiac examination
was normal. Raised intracranial pressure (ICP) was documented,
requiring a posterior vault expansion with springs, performed at
the age of 3 months, and insertion of a right parietooccipital
ventriculoperitoneal shunt.
WGS of the parent–child trio identiﬁed a heterozygous de
novo mutation (c.40G>A encoding p.V14I) in KRAS, which has
been reported previously in patients with Noonan syndrome.36
In the light of the exome results, an echocardiogram was per-
formed, which was normal at almost 3 years of age, but she will
continue cardiac surveillance. A coagulation screen has been
normal but recommendations have been made to repeat it prior
to any future surgery. Craniosynostosis is a rare but previously
recognised complication of Noonan syndrome, being particu-
larly associated with KRAS mutations.44
Family 25: EFNB1 mutation
The female proband (II-1 in ﬁgure 1B), the ﬁrst-born child to
healthy parents with no relevant family history, was noted to
have facial asymmetry at birth. Physical examination showed
hypertelorism and ridging over the right coronal suture. A
3D-CT scan conﬁrmed right coronal synostosis. She underwent
a fronto-orbital advancement and remodelling (FOAR) proced-
ure aged 15 months.
ES identiﬁed a heterozygous mutation (c.325C>T; p.Arg109Cys)
in the X-linked EFNB1 (ephrin-B1) gene, previously reported in a
patient with craniofrontonasal syndrome (CFNS).38 Dideoxy
sequencing of the parents showed that the clinically unaffected
father (I-1) was hemizygous for the same variant (ﬁgure 1B). CFNS
presents a paradoxical pattern of severity for an X-linked disorder,
with heterozygous females more severely affected than hemizygous
males, who can be non-penetrant.45 The result predicts that 100%
of female children of the father would be expected to exhibit CFNS
and/or craniosynostosis, and the couple have elected to enrol in a
programme of preimplantation genetic diagnosis (PIGD), selecting
only male embryos for uterine transfer.
Family 29: STAT3 mutation
This boy (II-1 in ﬁgure 1C) presented to the craniofacial unit at
2 years of age with mild mid-facial hypoplasia, a short nose
with a convex ridge, exorbitism and mild global development
delay; 3D-CT scan demonstrated fusion of all of the cranial
sutures with convexity of the closed anterior fontanelle, promin-
ent ventricles and crowded basal cisterns. At the age of 2 years
2 months, ophthalmological assessment showed bilateral papil-
loedema and invasive monitoring demonstrated signiﬁcantly
raised ICP. He underwent a posterior vault expansion with inser-
tion of springs at the age of 28 months.
ES of the proband was performed. This identiﬁed a heterozy-
gous c.1915C>T (p.Pro639Ser) mutation in the SH2 domain
Figure 1 Family pedigrees, clinical photographs/3D-CT scans and sequencing traces of families with mutations identiﬁed in FBN1 (A), EFNB1
(B) and STAT3 (C). Each panel shows the location of the mutation (red line) within the gene structure (exons in blue), family pedigree (affected
individuals are in black, black arrow depicts the proband and individuals selected for exome sequence/whole genome sequence are indicated with a
red asterisk), sequence traces of indicated individuals (red arrow indicates position of mutation) and clinical photographs (B) and 3D-CT scans (C) of
affected individuals. Note facial asymmetry associated with right unicoronal synostosis in patient with EFNB1 mutation (B); there is moderate
hypertelorism, but the grooving of the nasal tip usually observed in craniofrontonasal syndrome is absent. In the patient with the STAT3 mutation
(C), images with soft tissue windows (left and centre) show exorbitism, mid-face hypoplasia and vertex bulge; image with bone windows (right)
shows fusion of all sutures of the skull vault.
Developmental defects
264 Miller KA, et al. J Med Genet 2017;54:260–268. doi:10.1136/jmedgenet-2016-104215
Figure 9.1. Family pedigrees, clinical photograp s/3D-CT scans a d sequencing traces of 
families with mutations identifie  in FBN1 (A), EFNB1 (B) and STAT3 (C). Each panel shows 
the location of the mutation (red line) within the gene structure (exons in blue), family pedigree 
(affected individuals are in black, black arrow depicts the proband and individuals s lected for 
exome sequence/whole genome sequence are indicated with a red asterisk), sequence traces of 
indicated individuals (red arrow indicates position of mutation) and clinical photographs (B) and 
3D-CT scans (C) of affect d individuals. Note facial asymme ry associated with right unicoronal 
synostosis in patient with EFNB1 mutation (B); there is moderate hypertelorism, but the grooving 
of the nasal tip usually observed in craniofrontonasal syndrome is absent. In the patient with the 
STAT3 mutatio  (C), images with soft tissue windows (left and centre) show exorbitism, midface 
hypoplasia and vertex bulge; image with bone windows (right) shows fusion of all sutures of the 
skull vault.
Whole genome sequencing of the parent-child trio identified a heterozygous de novo 
mutation (c.40G>A encoding p.Val14Ile) in KRAS, which has be  reported previously in 
patients with Noonan syndrome.308 In th  light of the exome results, an echocardiogram 
was performed, which was normal at almost 3 years of age, but she will con inue cardiac 
surveillance. A coagulation screen has been normal but recommendations have been 
ma e to repeat it prior to any future surgery. Craniosynostosis is a rare but previously 
recognised complication of Noonan syndrom , b ing p rticularly ssociated with KRAS 
mutations.315
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Family 25: EFNB1 mutation
The female proband (II-1 in Figure 9.1B), the first-born child to healthy parents with 
no relevant family history, was noted to have facial asymmetry at birth. Physical 
examination showed hypertelorism and ridging over the right coronal suture. A 3D-CT 
scan confirmed right coronal synostosis. She underwent a fronto-orbital advancement 
and remodelling (FOAR) procedure aged 15 months.
Exome sequencing identified a heterozygous mutation (c.325C>T, p.(Arg109Cys)) 
in the X-linked EFNB1 (ephrin-B1) gene, previously reported in a patient with 
craniofrontonasal syndrome (CFNS).205 Dideoxy sequencing of the parents showed 
that the clinically unaffected father (I-1) was hemizygous for the same variant (Figure 
9.1B). CFNS presents a paradoxical pattern of severity for an X-linked disorder, with 
heterozygous females more severely affected than hemizygous males, who can be 
non-penetrant.316 The result predicts that 100% of female children of the father would 
be expected to exhibit CFNS and/or craniosynostosis, and the couple have elected to 
enrol in a programme of pre-implantation genetic diagnosis (PIGD), selecting only male 
embryos for uterine transfer.
Family 29: STAT3 mutation
This boy (II-1 in Figure 9.1C), presented to the craniofacial unit at 2 years of age with 
mild midfacial hypoplasia, a short nose with a convex ridge, exorbitism and mild global 
development delay; 3D-CT scan demonstrated fusion of all of the cranial sutures 
with convexity of the closed anterior fontanelle, prominent ventricles and crowded 
basal cisterns. At the age of 2 years 2 months, ophthalmological assessment showed 
bilateral papilledema and invasive monitoring demonstrated significantly raised ICP. He 
underwent a posterior vault expansion with insertion of springs at the age of 28 months. 
Exome sequencing of the proband was performed. This identified a heterozygous 
c.1915C>T, p.(Pro639Ser) mutation in the SH2 domain encoded by STAT3 (signal 
transducer and activator of transcription 3), which was previously reported in a case of 
hyper-IgE/Jobs syndrome (HIES).311 Dideoxy sequencing of the parents showed that the 
mutation had arisen de novo (Figure 9.1C).
Upon feedback of this finding it transpired that the proband had more recently 
presented at the age of 3 years 3 months with an upper respiratory tract infection, 
progressing to severe necrotising pneumonia with a pulmonary abscess and 
pneumatocele. He developed a pneumothorax and bronchopleural fistula; following 
two unsuccessful attempts at surgical resection, he required a right lower lobe 
segmentectomy. A large secundum atrial septal defect required patch closure at 5 years 
of age. Further immunological assessment demonstrated a markedly elevated total 
IgE of 3091 kU/L (normal range 0-52). He commenced prophylactic azithromycin and 
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itraconazole and is awaiting a suitably matched donor for stem cell transplantation. 
Bone mineral density assessment was normal but he takes multivitamin supplements 
including vitamin D and is under enhanced dental and skeletal surveillance.
Family 37: NTRK2 mutation
The female proband presented with an asymmetric face at 12 months of age and left 
coronal synostosis was diagnosed on 3D-CT scan; there were no syndromic features. 
She underwent a FOAR procedure aged 17 months. On clinical follow-up at the age of 2 
years 8 months she was noted to have episodes of temper tantrums and was exhibiting 
speech and language delay. By the age of 6 years she required a school statement 
indicating moderate learning difficulties. Exome sequencing identified a heterozygous 
nonsense mutation (c.1330G>T, p.(Gly444*)) in NTRK2, encoding neurotrophic tyrosine 
receptor kinase, type 2, with a predicted loss of the entire intracellular tyrosine kinase 
domain. The proband’s mother did not carry the mutation and the father was not 
available for analysis. Dominant mutations of NTRK2 have been described in association 
with hyperphagic obesity associated with developmental delay (OBHD), and functional 
studies have pointed to haploinsufficiency as the likely pathogenic mechanism of a 
previously identified p.Tyr722Cys substitution.317,318
The discovery of the NTRK2 mutation prompted a further endocrinology assessment 
at the age of 7 years 6 months. Her height was 135.2 cm (+2.04 SD), weight 46.2 kg 
(+3.19 SD), and body mass index 25.3 kg/m2 (+3.1 SD), consistent with a diagnosis of 
OBHD. She was noted to have a long-standing history of hyperphagia. The oral glucose 
tolerance test was normal; streak ovaries and uterus were evident on ultrasound scan. 
Management implications have included referral to a clinical psychologist and dietician 
to address her eating behaviours, and regular monitoring for secondary complications 
including cardiovascular disease and diabetes.
Discussion
We present, to our knowledge, the first investigation of the added value provided by 
exome sequencing or whole genome sequencing in molecular genetic diagnosis of 
craniosynostosis, applied to two cohorts of patients (total of 40) identified as high-
priority cases by clinical or laboratory geneticists following negative results from routine 
molecular genetic testing. We identified 13 mutations in 12 confirmed disease genes 
that we considered to be pathogenic. Seven of the particular DNA sequence changes 
found were previously reported, whereas an additional six are currently unique to the 
patients described here. The newly identified variants were considered pathogenic 
using evidence from population MAF data, predictive computational data and studies 
of aberrant function (either performed ourselves or published in the literature), 
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according to guidelines from the Association for Clinical Genetic Science.319 In addition, 
we identified at least two likely novel disease-associated genes; further studies to 
corroborate these findings are ongoing, so details are not presented here. Including 
these latter cases, our overall success rate in identifying pathogenic mutations was 
15/40 (37.5%), which is towards the upper end of the range usually quoted in exome 
sequencing/whole genome sequencing analysis of other diseases with a major genetic 
component.143,145,258 We used a mixed strategy of sequencing both singletons and 
multiple family members; the latter strategy was associated with a higher success rate 
per family, but the former with a 2.3-fold higher success rate per sample sequenced. 
Although trio sequencing is the favoured design in many other exome sequencing/
whole genome sequencing studies because complete bioinformatic analysis of the data 
is more straightforward,143,145,258 singleton sequencing appears more cost-effective in a 
diagnostic setting.
Craniosynostosis comprises a very diverse group of disorders and its causes are 
correspondingly heterogeneous, with intrauterine foetal head constraint, reduced 
transduction of stretch forces from the growing brain owing to poor intrinsic growth, 
and polygenic background all likely to play substantial roles, in addition to monogenic 
causes.127 Since a major motivation of this work was to use next generation sequencing 
to identify novel disease genes in craniosynostosis, we selected cases suspected to have 
a genetic cause, based on positive family history, presence of additional syndromic 
features or multiple suture fusions, and for which clinically guided genetic testing had 
been normal. Although this strategy was successful, with at least four newly recognised 
disease genes for craniosynostosis being identified as part of this study (CDC45304 and 
HUWE1,258 and two awaiting further corroboration), the major finding presented here 
is that next generation sequencing is very valuable for diagnosis of a long “tail” of rare 
genetic associations with craniosynostosis. All of these positive diagnoses have made 
a critical difference to genetic counselling, with some having broader management 
implications.
To understand why a genetic diagnosis in craniosynostosis may elude standard 
molecular diagnostic testing, we categorised each additional diagnosis in terms of 
the molecular genetic framework recently presented by Twigg and Wilkie.127 These 
authors identified 57 genes as recurrently mutated in craniosynostosis, of which they 
categorised 20 as “core genes” (craniosynostosis present in >50% of patients with 
specific categories of mutation in that gene), whilst mutations in the remaining 37 
genes were associated with craniosynostosis in only a minority of cases. The core genes 
could be further subdivided into six with mutations each accounting for over 0.5% of all 
craniosynostosis, and 14 more rarely mutated genes. Figure 9.2 summarises how the 13 
identified mutations are classified according to this framework. While, not surprisingly, 
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the number of mutations identified, as a proportion of total genes in the category, rose 
progressively as the pathogenic hierarchy was ascended, there were multiple genes in 
each category. This includes two genes (NTRK2, AHDC1), for which we are unaware of 
any previous association with craniosynostosis; it is unclear whether the co-occurrence 
of the mutation and sentinel phenotype is causally linked (potentially through the 
adverse effect of the mutation on brain development),127 or simply coincidental.
In the cases found to have mutations in the “core” genes, the question arises why 
these were not identified by testing within the routine diagnostic service. In the patients 
with EFNB1 and TWIST1 mutations, the diagnosis was missed because analysis of the 
relevant gene had not been requested by the clinician; either because of an unusually mild 
presentation (EFNB1, Figure 9.1B), or a severe, atypical presentation (TWIST1). Of the other 
core genes, homozygous mutations in IL11RA, first described in 2011,60 are increasingly 
recognised, especially in consanguineous families from the Indian subcontinent, and 
clinical diagnostic testing has now been introduced in the UK (http://ukgtn.nhs.uk/
uploads/tx_ukgtn/CRSDA_IL11RA_GD_Sept_14.pdf). Although a specific heterozygous 
mutation of MSX2 encoding Pro148His was the first molecular lesion to be described in 
craniosynostosis in 1993,130 only two further families (both segregating p.Pro148Leu) 
have subsequently been reported worldwide,305,306 and the family described here (also 
with p.Pro148Leu) is the first known in the UK. Finally, the CDC45 patient contributed 
to the recent identification of mutations in this gene,304 and the patient with the ZIC1 
mutation extends the currently described genotype phenotype correlation,65 being 
the first with a mutation in exon 2 and also the first with involvement of the sagittal 
suture instead of the originally described presentation with bilateral coronal synostosis. 
As in any branch of genetic medicine, achieving a precise molecular diagnosis has 
immediate implications for genetic counselling, both in terms of recurrence risk and 
for targeted preventive measures. The common craniosynostosis syndromes all show 
dominant patterns of inheritance, so that when parents are clinically unaffected, empiric 
recurrence risks are low (around 5%).125,126 Our cohort illustrates two scenarios where 
providing the standard genetic advice would substantially underestimate recurrence 
risks. In family 25 (EFNB1 mutation), the clinically unaffected father was shown to be 
hemizygous for the mutation originally identified in his daughter, indicating that 
the risk of CFNS in future female children is 100%. In family 3 (CDC45 mutation), the 
autosomal recessive inheritance of this disorder raises the recurrence risk for children 
of the unaffected parents to 25%. Both findings have affected reproductive decision-
making; one family is seeking PIGD, whereas in the other, the option not to have further 
children is being considered.
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severe, atypical presentation (TWIST1). Of the other core genes,
homozygous mutations in IL11RA, ﬁrst described in 2011,22 are
increasingly recognised, especially in consanguineous families
from the Indian subcontinent, and clinical diagnostic testing has
now been introduced in the UK (http://ukgtn.nhs.uk/uploads/tx_
ukgtn/CRSDA_IL11RA_GD_Sept_14.pdf). Although a speciﬁc
heterozygous mutation ofMSX2 encoding Pro148His was the ﬁrst
molecular lesion to be described in craniosynostosis in 1993,49
only two further families (both segregating p.Pro148Leu) have
subsequently been reported worldwide,33 34 and the family
described here (also with p.Pro148Leu) is the ﬁrst known in the
UK. Finally, the CDC45 patient contributed to the recent identiﬁ-
cation of mutations in this gene,32 and the patient with the ZIC1
mutation extends the currently described genotype–phenotype
correlation,50 being the ﬁrst with a mutation in exon 2 and also
the ﬁrst with involvement of the sagittal suture instead of the ori-
ginally described presentation with bilateral coronal synostosis.
As in any branch of genetic medicine, achieving a precise
molecular diagnosis has immediate implications for genetic coun-
selling, both in terms of recurrence risk and for targeted prevent-
ive measures. The common craniosynostosis syndromes all show
dominant patterns of inheritance, so that when parents are clinic-
ally unaffected, empiric recurrence risks are low (around
5%).7 51 Our cohort illustrates two scenarios where providing
the standard genetic advice would substantially underestimate
recurrence risks. In family 25 (EFNB1 mutation), the clinically
unaffected father was shown to be hemizygous for the mutation
originally identiﬁed in his daughter, indicating that the risk of
CFNS in future female children is 100%. In family 3 (CDC45
mutation), the autosomal-recessive inheritance of this disorder
raises the recurrence risk for children of the unaffected parents to
25%. Both ﬁndings have affected reproductive decision-making;
one family is seeking PIGD, whereas in the other, the option not
to have further children is being considered.
In addition to the genetic implications, in several cases (muta-
tions in the FBN1, KRAS, NTRK2 and STAT3 genes), the
molecular diagnosis has had immediate implications for clinical
management, as described in the case reports, so genetic diagno-
sis was additionally important. Mutations in each of these genes
are only infrequently associated with craniosynostosis; indeed,
the presence of the craniosynostosis may have delayed correct
diagnosis by laying a confusing trail. As a result of the molecular
diagnosis, appropriate, potentially life-saving monitoring has
been instigated. The high apparent rate of rare actionable muta-
tions identiﬁed in complex craniosynostosis without an obvious
diagnosis may reﬂect developmental pleiotropy of signalling in
the cranial sutures, with multiple pathways, co-opted from more
ancient uses in embryogenesis, implicated at different stages of
suture development.8
In summary, our ﬁndings illustrate the considerable added
value provided by ES/WGS to the precise diagnosis of patients
with craniosynostosis suspected to have a genetic cause, but
where routine testing has failed to elucidate this. As technologies
improve, a strategic question in molecular diagnostics is whether
it is preferable to extend panel tests to more genes or whether to
opt directly for ES/WGS. Aside from the most common
disease-associated mutations, for which targeted testing currently
remains cost-effective, we propose, based on the distribution of
mutations identiﬁed (ﬁgure 2), together with the substantial
burden of actionable ﬁndings (case reports), a low threshold for
implementing ES/WGS. An additional beneﬁt of this strategy is
that it may identify new disease loci,2 32 enabling improved diag-
nostic and management strategies in the future.
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Figure 2 Identiﬁed mutations and their association within the
classiﬁcation of craniosynostosis-associated genes proposed by Twigg
and Wilkie.8
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Figure 9.2. Identifie  t tions and their association within t e classification of craniosynostosis-
associated genes proposed by Twigg and Wilkie.127
In addition to the genetic implications, in several cases (mutations in the FBN1, 
KRAS, NTRK2 nd STAT3 genes), the molecular diagn sis has had immediate implications 
for clinical management, as described in the cas  reports, so gen tic diagnosis was 
additionally important. Mutations in each of these genes are only infr quently associated 
with craniosynostosis; i deed, the presence of the craniosynostosis may have delayed 
correct diagnosis by laying a confusing trail. As a result of the molecular diagnosis, 
appropriate, potentially life-saving monitoring has been instigated. The high apparent 
rate of rare actionable mutations identified in complex craniosynostosis without an 
obvious diagnosis may reflect developmental pleiotropy of signalling in the cranial 
sutures, with multiple pathways, co-opted from more ancient uses in embryogenesis, 
implicated at different stages of suture development.127
In summary, our findings illustrate the considerable added value provided by 
exome sequencing/whole genome sequencing to the precise diagnosis of patients 
with craniosynostosis suspected to have a genetic cause, but where routine testing 
has failed to elucidate this. As technologies improve, a strategic question in molecular 
diagnostics is whether it is preferable to extend panel tests to more genes, or whether 
to opt directly for exome sequencing/whole genome sequencing. Aside from the 
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most common disease-associated mutations, for which targeted testing currently 
remains cost-effective, we propose, based on the distribution of mutations identified 
(Figure 9.2), together with the substantial burden of actionable findings (case reports), 
a low threshold for implementing exome sequencing/whole genome sequencing. An 
additional benefit of this strategy is that it may identify new disease loci,258,304 enabling 
improved diagnostic and management strategies in the future.
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Case Reports
Family 11: FBN1 mutation
This boy (II‐3 in Figure 9.1A) is the third child of healthy parents from the Middle East, 
with no prior family history of craniosynostosis. He was born at 37 weeks’ gestation (birth 
weight 2,830 g (‐0.25 SD); length 52 cm (+1.76 SD); OFC 33.4 cm (‐0.03 SD)) and needed 
neonatal care for treatment of amniotic fluid aspiration. A clinical genetics opinion was 
requested because of dysmorphic features, a large fontanelle, and stridor caused by left 
vocal cord palsy. A skeletal survey and ophthalmology assessment were normal, and no 
unifying diagnosis was made.
On further evaluation at the age of 10 months, he was noted to have a long narrow 
face, scaphocephaly, large (3 cm x 4 cm) anterior fontanelle, blue sclerae, vertical dimple 
on the chin and hypermobility of his small joints. His length was 75 cm (75th centile), 
and developmental milestones were normal. A skeletal survey was repeated, and 
craniofacial investigation confirmed sagittal synostosis. A total calvarial remodelling 
procedure was performed at the age of 3 years 10 months. A diagnosis of Shprintzen‐
Goldberg syndrome (SGS)[MIM: 182212] was proposed, based on the combination of 
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sagittal synostosis, exorbitism, downslanting palpebral fissures, blue sclerae, prominent 
nasal bridge, midface hypoplasia, micrognathia, syndactyly of the fingers, ligamentous 
laxity, recurrent inguinal hernia and tall stature. Targeted sequencing of the SKI gene,311 
in addition to TGFBR1 and TGFBR2, did not reveal any mutations. Echocardiography, 
when initially performed at 2 years 9 months, was normal; on repeat examination at 
the age of 4 years, requested because of the phenotypic overlap with Marfan syndrome 
(MFS)[MIM: 154700], the cardiologist considered that the shape of the aorta was mildly 
abnormal (although the dimensions were within normal limits), and he continued to be 
followed up. 
We performed whole exome sequencing of the proband as a singleton; 
concomitantly, the referring clinician reported that the patient, by now aged 8 years, had 
recently presented with subluxed lenses, a mild scoliosis and a mildly dilated aorta. His 
modified Ghent score was 7/20, suggesting a possible diagnosis of Marfan syndrome. 
Scrutiny of the whole exome sequencing data revealed two rare heterozygous variants 
in the FBN1 (Fibrillin 1) gene, c.2615A>G encoding p.Lys872Arg and the splice site 
variant c.8226+5G>A; Figure 9.1A). Dideoxy‐sequencing of parental samples showed 
that whereas the p.Lys872Arg variant had been inherited from the unaffected father (not 
shown), the c.8226+5G>A had arisen de novo (Figure 9.1A). The c.8226+5G>A variant, 
which was re‐confirmed in a diagnostic laboratory, has been identified previously in a 
patient with a progeroid variant of MFS;307 a different mutation of the same splice site 
(c.8226+1G>A) caused skipping of the associated exon, introducing a frameshift and 
premature stop codon.312
Confirmation of the molecular diagnosis of MFS has triggered a program of lifelong 
monitoring owing to the association with progressive aortic dilatation; aged 10 years, he 
has mild aortic root dilatation (Z score = 3.02). Of note, craniosynostosis is an extremely 
rare, but previously recognized association of MFS.313,314
Family 21: KRAS mutation
This girl, born to healthy unrelated parents, presented neonatally with a cloverleaf skull 
appearance. Computed tomography (CT) scanning revealed synostosis of both coronal 
sutures, the posterior part of the sagittal, both lambdoids and partial sphenoidal 
synostosis. There were no additional syndromic features and cardiac examination 
was normal. Due to CT and ophthalmological evidence of raised intracranial pressure 
(ICP), a posterior vault expansion with springs was performed at 3 months of age; the 
springs were removed 3 weeks later owing to infection. Due to persisting raised ICP, a 
right parieto‐occipital ventriculo‐peritoneal shunt was inserted aged 7 months which 
has required a number of revisions. She was suspected to have Crouzon syndrome but 
targeted sequencing of FGFR2, FGFR3, TWIST1, TCF12 and ERF was normal, as was TWIST1 
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multiplex ligation‐dependent probe amplification (MLPA) and array‐CGH chromosome 
testing. Whole genome sequencing of the parent‐child trio identified a heterozygous de 
novo mutation (c.40G>A encoding p.Val14Ile) in KRAS. This mutation has been reported 
previously in patients with Noonan syndrome.308 Although KRAS mutations only account 
for ~7% of the Noonan syndrome spectrum,320 craniosynostosis has been reported in 6 
patients with KRAS mutations to date.308,315,320,321
Prior to the exome result a diagnosis of Noonan syndrome had not been suspected 
as the patient did not have typical antenatal findings, facial features or significant cardiac 
or feeding abnormalities, and cloverleaf skull has not been reported previously in 
Noonan syndrome or related disorders. In light of the exome results the proband had an 
echocardiogram at almost 3 years of age; this was normal but she will continue cardiac 
surveillance. A coagulation screen has been normal but recommendations have been 
made to repeat it prior to any future surgery. Her development has been moderately 
delayed and her parents and community paediatricians have been given information 
about the spectrum of neurodevelopmental and behavioural phenotypes occurring in 
Noonan syndrome. In addition the finding of a de novo mutation accounting for her 
phenotype has facilitated accurate genetic counselling. A more complete account of 
this family will be published elsewhere.
Family 25: EFNB1 mutation
The female proband (II‐1 in Figure 9.1B), the first born child to healthy parents, with 
no relevant family history, was noted to have facial asymmetry at birth. Clinical 
assessment showed hypertelorism, orbital dystopia and ridging over the right coronal 
suture, but there were no additional dysmorphic features; in particular examination for 
signs of craniofrontonasal syndrome (CFNS [MIM: 304110] associated with grooving of 
the nasal tip, longitudinal splits of the finger‐ or toenails and cutaneous syndactyly) 
was negative (Figure 9.1B). A 3D‐CT scan confirmed right coronal synostosis. She 
underwent a fronto‐orbital advancement and remodelling (FOAR) procedure aged 
15 months. On preoperative developmental assessment (Bayley Scales of Infant and 
Toddler Development, 3rd edition), composite scores ranged from 86 (language) to 100 
(cognitive). Targeted sequencing of FGFR2, FGFR3, TWIST1 and TCF12 was normal.
Exome sequencing identified a heterozygous mutation (c.325C>T, p.(Arg109Cys)) 
in the X‐linked EFNB1 (ephrin‐B1) gene, previously reported in a patient with CFNS.205 
Dideoxy‐sequencing of the parents showed that the clinically unaffected father (I‐1) 
was hemizygous for the same variant (Figure 9.1B). CFNS presents a paradoxical pattern 
of severity for an X‐linked disorder, with heterozygous females more severely affected 
than hemizygous males, who can be non‐penetrant.316 This phenomenon is accounted 
for by cellular interference.192 This result predicts that 100% of female children of the 
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father would be expected to exhibit CFNS and/or craniosynostosis, and the couple have 
elected to enrol in a programme of pre‐implantation genetic diagnosis (PIGD), selecting 
only male embryos for uterine transfer.
Family 29: STAT3 mutation
This boy (II‐3 in Figure 9.1C), the only child of unrelated parents of Sri Lankan ethnicity, 
presented to the craniofacial unit at 2 years of age. His parents had been concerned 
about his head shape at 6 months but he was not investigated until the age of 1 year 
6 months. He had a history of recurrent ear infections and minor eczema behind his 
ears for which only emollients had been required. There was no relevant family history, 
except that his mother was recorded as having a large uterine fibroid. On examination 
he had mild midfacial hypoplasia, a short nose with a convex ridge, exorbitism and mild 
global development delay; 3D‐CT scan demonstrated fusion of all of the cranial sutures 
with convexity of the closed anterior fontanelle, prominent ventricles and crowded 
basal cisterns. At the age of 2 years 2 months, ophthalmological assessment, which 
had previously been normal, showed progression to bilateral papilledema and ICP bolt 
insertion with 48 hour monitoring confirmed significantly raised ICP. A sleep study did 
not show any obstructive sleep apnoea. A clinical diagnosis of Crouzon syndrome [MIM: 
123500] was suspected but targeted sequencing of FGFR2, FGFR3, TWIST1, TCF12 and 
ERF was normal. He underwent a posterior vault expansion with insertion of springs 
at the age of 28 months, with spring removal 8 months later. Formal dental review at 5 
years of age found established primary dentition with a class III incisor relationship due 
to midfacial hypoplasia.
Exome sequencing of the proband identified a heterozygous c.1915C>T, 
p.(Pro639Ser) mutation in the SH2 domain encoded by STAT3 (signal transducer and 
activator of transcription 3), which was previously reported in a case of Hyper‐IgE/Jobs 
syndrome (HIES) [MIM: 147060].310 Dideoxy sequencing of the parents showed that the 
mutation had arisen de novo (Figure 9.1C). Non-immunological manifestations of HIES 
can include distinctive facial features, hyperextensibility of the joints, bone fractures 
and in rare cases, craniosynostosis.60,322,323
Upon report of this finding to the referring clinician it transpired that the proband 
had presented to his local hospital at the age of 3 years 3 months with an upper 
respiratory infection, progressing to severe necrotising pneumonia associated with a 
pulmonary abscess and pneumatocele. Methicillin‐resistant Staphylococcus aureus was 
initially isolated and subsequently he grew a Stenotrophomonas maltophilia. Despite 
intravenous antibiotics he developed a pneumothorax and bronchopleural fistula. Due 
to persistence of the fistula after two surgical resections, he was admitted to a specialist 
cardiothoracic unit at 3 years 7 months of age where he required a further thoracotomy 
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with right lower lobe segmentectomy, resection of the sixth rib and an intercostal 
muscle pedicle to reinforce the repaired area. He was found to have a large secundum 
atrial septal defect for which he had a patch closure at 5 years of age. 
In view of the identification of the STAT3 mutation a detailed immunology 
assessment was undertaken. Of note, he had suffered a perforating otitis media with 
purulent discharge from which Staphylococcus aureus was isolated, and a single skin 
abscess on his neck at 3 years of age. As a baby he had had some cradle cap but no 
wider rash. There had been no significant gastrointestinal symptoms, sinusitis, tonsillitis 
or fractures. He had a molluscum contagiosum skin infection which was mild. His total 
IgE was 3091 kU/L (normal range 0‐52). Other salient findings were a good response to 
tetanus vaccination but a very poor response to pneumococcal conjugate vaccination, 
and relatively normal lymphocyte subsets but with raised levels of γδ T cells indicating 
immune dysregulation. He was found to have EBV (IgE‐VCA and IgM positive) and CMV 
(IgM negative, IgG positive) viremias, of which the former has become chronic. Varicella 
zoster serology was negative and eosinophil counts have been consistently normal. He 
commenced prophylactic azithromycin and itraconazole and is currently awaiting a 
suitably matched donor for stem cell transplantation. Bone mineral density assessment 
was normal but he takes multivitamin supplements including vitamin D.
HIES is a multisystem immunodeficiency syndrome associated with a clinical triad 
of recurrent staphylococcal skin boils, cyst‐forming pneumonias and extremely elevated 
IgE, usually manifesting in the first years of life. Typically it presents with a pustular rash 
in the new-born period which evolves into an eczematous dermatitis. Other features 
include mucocutaneous candidiasis, osteopenia with recurrent fractures, scoliosis, 
craniosynostosis which is said rarely to require surgery,324-326 and failure to exfoliate 
the primary dentition. Vascular abnormalities include tortuosity of medium sized 
arteries and aneurysms. Gastro‐intestinal features include gastro-oesophageal reflux 
disease, oesophageal dysmotility, and colonic diverticulae and perforations. There is 
also a predisposition to lymphoma. Management is directed at prevention and early 
aggressive treatment of pneumonia, abscesses and other infections using antibiotics, 
antifungal agents and skin antiseptics, treatment of eczema and optimisation of calcium 
and vitamin D intake. Surveillance for chest infections, scoliosis and retained primary 
dentition is indicated. A small number of patients have had stem cell transplantation 
with marked reduction in infections and significantly improved quality of life. 
Current recommendations in children with HIES  associated with serious respiratory 
complications are to proceed to stem cell transplant once the child is clinically stabilised 
if there is a well matched donor available. 
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The proband had an atypical neonatal course and presented with a Crouzon‐
like facial appearance and pansynostosis prior to developing the more characteristic 
clinical features that might have pointed to a diagnosis of HIES. Demonstration of a 
de novo STAT3 mutation accelerated referral for specialist immunological assessment 
and management allowing relatively early optimisation of treatment. As a result of the 
diagnosis closer dental and skeletal surveillance has been arranged. The findings have 
facilitated genetic counselling confirming that the parents have just a low germ‐line 
mosaic recurrence risk for future pregnancies with prenatal testing available should 
they wish.
Family 37: NTRK2 mutation
The female proband was the first born child to unrelated parents, with no relevant 
family history. Her birth weight was 3.2 kg (‐0.57 SD) and she had a normal neonatal 
course. She presented with an asymmetric face at 12 months of age and left coronal 
synostosis was diagnosed on 3D‐CT scan; there were no syndromic features and the 
head circumference at the age of 15 months was 47.0 cm (‐0.28 SD). She underwent a 
FOAR procedure aged 17 months and has also required a strabismus correction. Formal 
testing at 17 months indicated low average attainment (composite scores on sub‐tests 
85‐88, percentile rank 16‐21).327 Targeted sequencing of FGFR2, FGFR3, TWIST1 and 
TCF12, MLPA of TWIST1, karyotype and array CGH were all normal.
By the age of 2 years 8 months she was noted to have episodes of temper tantrums 
and was exhibiting speech and language delay. On formal assessment at the age of 3 
years 8 months, her standard scores for understanding and speaking language were 
82 and 97, respectively.328 Concerns about aggressive outbursts, ritualised behaviours, 
and language delay persisted at the age of 6 years and she required a school statement 
indicating moderate learning difficulties. In addition she was tall for her age with 
disproportionate weight gain, at the age of 6 years 8 months her height was 127.2 
cm (+1.56 SD) and weight was 38.6 kg (+3.08 SD). Exome sequencing identified 
a heterozygous nonsense mutation (c.1330G>T, p.(Gly444*) in NTRK2, encoding 
neurotrophic tyrosine receptor kinase, type 2, with a predicted loss of the intracellular 
tyrosine kinase domain. The proband’s mother did not carry the mutation and the father 
was not available for analysis. Dominant mutations of NTRK2 have previously been 
described in association with hyperphagic obesity associated  with developmental 
delay (OBHD) [MIM: 613886].317
The discovery of the NTRK2 mutation prompted a further endocrinology assessment 
at the age of 7 years 6 months. Her height was 135.2 cm (+2.04 SD), weight 46.2 kg (+3.19 
SD), and body mass index 25.3 kg/m2 (+3.1 SD). She was noted to have a long‐standing 
history of hyperphagia. The oral glucose tolerance test was normal; streak ovaries and 
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uterus were evident on ultrasound scan. Management implications have included 
referral to a clinical psychologist and dietician to address her eating behaviours, and 
regular monitoring for secondary complications including cardiovascular disease and 
diabetes.322 
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The merits of this thesis
The aim of this thesis was to obtain more insight into the genetic alterations that cause 
congenital craniofacial malformations, to improve genetic counselling and to gain 
further knowledge about the development of the head and face. Novel mutations have 
been identified in genes known to be associated with craniofacial malformations. Also, 
new craniofacial genes have been identified. Finally diagnostics have been improved by 
new genetic techniques, facilitating genetic counselling. 
New mutations have been identified in FGFR2. Expanding the analysis of FGFR2 
to all coding exons and exon/intron junctions has demonstrated once again that 
pathogenic mutations predominantly occur in the well-conserved functional regions 
of FGFR2.329 Also, we have shown that apparently synonymous substitutions in FGFR2 
can affect splicing and result in Crouzon syndrome.58 Therefore, we recommend that 
synonymous substitutions and variants outside the canonical AG/GT splice acceptor/
donor sequences are carefully evaluated as to whether they may have an effect on RNA 
splicing and therefore are pathogenic.58 
Using next generation sequencing, we have identified novel genetic causes of 
craniofacial malformations. One of these genes is TCF12.59 Presumably, the TCF12/TWIST1 
heterodimer protein complex plays an important role in coronal suture development 
by specifying the neural crest and cephalic mesoderm boundary,231,232 and/or inhibiting 
osteogenic differentiation via actions on RUNX2,233 bone morphogenetic protein234 
and/or fibroblast growth factor receptor signalling.228 Therefore, if a patient has isolated 
coronal suture synostosis and gene-specific testing of FGFR3 and TWIST1 is negative, 
TCF12 should be checked. 
We identified deletions in TCF12 in 4 of 108 (3.7%) individuals with coronal suture 
synostosis and previously negative genetic testing.146 Hence, screening for larger 
rearrangements in TCF12 seems essential if TCF12-related craniosynostosis is suspected. 
We also identified mutations in ZIC1 in patients with coronal suture synostosis.65 
Learning disabilities are frequently seen in these patients. The function of ZIC1 has been 
studied in the Xenopus by injecting several truncated constructs, leading to disrupted 
en-2 expression. Using in situ hybridisation, a transient zone of Zic1 expression was 
identified in the supraorbital region that overlaps that of En1. From this region, cells 
migrate and populate the coronal suture,24,30,37 indicating an early instructive role for 
Zic1 in the supraorbital regulatory centre. Combining these results, it seems likely that 
the coronal synostosis phenotype is attributable to alteration of EN1 expression in the 
supraorbital regulatory centre. Hence, if coronal suture synostosis in combination with 
learning disabilities is seen, ZIC1 should be tested.
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Additionally, compound heterozygous point mutations were identified in TXNL4A 
in patients with Burn-McKeown syndrome (BMKS).330 Reduced expression of TXNL4A is 
assumed to cause reduced tri-snRNP assembly, hypothetically influencing splicing of a 
specific subset of pre-mRNAs.61 Furthermore, homozygous 34 bp deletions in TXNL4A 
were identified in patients with (isolated) choanal atresia. Choanal atresia is a key feature 
of BMKS. This demonstrates the importance of screening for mutations in TXNL4A in 
patients with (mild) clinical features of BMKS.
The last part of this thesis has focused on the use of next generation sequencing 
as a diagnostic tool in patient cohorts. First, we tested 40 patients with whole exome or 
whole genome sequencing. In 15 out of 40 patients (37.5%) a mutation was identified; 
13 mutations in confirmed disease genes and at least two in novel disease-associated 
genes. 
Many of the pathogenic mutations identified were in genes rarely associated with 
craniosynostosis. In some of these cases, achieving a precise molecular diagnosis has 
had immediate implications for genetic counselling and for clinical management.  
Since phenotypes are getting less specific and single-gene tests are therefore 
getting less efficient, it seems worthwhile to apply next generation sequencing more 
frequently. An additional benefit of this strategy is the potential identification of new 
disease loci. 
Barriers of this thesis
Whole genome sequencing by Complete Genomics
We have used Complete Genomics’ whole genome sequencing to search for pathogenic 
mutations in the genomes of patients with craniosynostosis. The strengths and 
weaknesses of this technique can be assessed by looking at both practical and technical 
parameters.
Practical parameters include the required amount of DNA, the sequencing costs 
and the running time.331 When the samples were shipped, between 2012 and 2015, 
Complete Genomics required a large amount of DNA (at least 5 µg of DNA was required 
and more than 10 µg was strongly recommended). At the time of writing this thesis, 
Complete Genomics was a service provider and DNA was sent to the US to be sequenced 
in an external core facility. Therefore, the costs per genome were relatively high. 
However, there were no acquisition costs associated with the sequencing machine, all 
other materials and equipment. The turnaround time from shipping to receiving a full 
annotated genome was 3  months. 
Technological parameters include coverage of the genome, distribution of reads 
across different genomic regions, and SNV calling sensitivity and specificity. Several 
studies have compared these parameters between different sequencing technologies. 
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In one study Complete Genomics shows a high coverage distribution (<2% of bases 
not covered).331 However, another study found that Illumina covers more bases.332 The 
coverage at genomic positions corresponding to SNPs on the SNP array is on average 
40x and therefore lower than the overall average.331 Because Complete Genomics 
requires a higher average coverage in order to cover a similar fraction of the genome, we 
used Complete Genomics 80x sequencing in our samples (hypothetically 40x paternal 
and 40x maternal allele). Also, a considerable degree of sample-to-sample variation in 
coverage distribution is observed, which is not seen by other platforms.331 Complete 
Genomics performs well in GC rich regions (the least GC bias, leading to good coverage 
of CpG islands), but in GC poor regions Complete Genomics performs worst, and simple 
repeat regions are covered worst in comparison to other platforms.331 Comparing 
Complete Genomics with Illumina, it seems that Complete Genomics is slightly less 
sensitive, but does have fewer false positive calls.332 Nonetheless, both methods missed 
variants that were clearly called by the other technology,332 and each platform detected 
a large quantity of indels missed by the other.332   
In summary, every sequencing platform has its strengths and weaknesses and each 
platform is likely to miss some true functional rare variants.333 Therefore, several studies 
have suggested to sequence genomes with two platforms if budget permits 331-333 until 
these weaknesses are solved. 
Incidental findings
While analysing the whole genome or exome, there is an inevitable risk of discovering 
so-called “incidental findings”. Incidental findings are secondary genetic findings that 
are unrelated to the indication for obtaining the genetic test, but they may cause 
another disease. For example, the identification of a variant in a breast cancer gene 
like BRCA1, while trying to identify the genetic cause of a craniofacial malformation. All 
incidental findings combined are called the “incidentalome.”334 
The question arises what to do with these incidental findings. Should they be 
communicated to a patient or shouldn’t they? Compromising between the ethical 
principles of “duty to warn” versus “do no harm”. Especially since the findings can be 
irrelevant in childhood, such as findings concerning adult-onset diseases or information 
about carrier status. Also, one might state that the child’s autonomy should be 
respected and a child shouldn’t be burdened by these findings. Especially since only 
a few incidental findings are actionable, one recent study showed that 23 out of 1,000 
exomes (~2%) carried actionable pathogenic SNPs.335
For years, guidelines didn’t exist on how to communicate incidental findings. 
Returning of incidental findings differed per country, city and even per department. In 
our study design,  incidental findings were not communicated.  
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Fortunately, the ACMG has released recommendations for returning incidental 
findings,336 and currently patients who participate in whole exome sequencing can give 
their preference on the reporting of their incidental findings. 
Genetic discrimination
One of the drawbacks of participating in genetic research is concern about genetic 
discrimination, i.e. being treated differently based on genetic background, especially in 
cases of social necessities like healthcare, insurance, housing and employment.337   
In Europe, genetic discrimination is prohibited by the Convention on Biomedicine 
(1997), the Charter of Fundamental Rights of the European Union (2000), and the 
national legislation of many individual countries.337 In the Netherlands the Act on 
Medical Examinations was approved in 1998.338 This act protects individuals who want 
to obtain a civil employment contract, a pension, life insurance or disability insurance, 
by stating that below predefined sums no questions may be asked about untreatable 
hereditary diseases or about the results of genetic tests for such diseases in the applicant 
and his/her relatives.339 Insurance companies are legally obliged to disregard available 
genetic test results for insurance below predefined sums, except in cases of manifest 
disease.339 Applicants in turn are legally obliged to report any manifest disease.339
Despite this legislation, individual cases of genetic discrimination have been 
described. A systematic review on genetic discrimination in the life insurance sector 
shows that between 1991 and 2012 33 studies were performed concerning genetic 
discrimination.337 Six of these studies took place in Europe, two of which were in 
the Netherlands.337 These two studies addressed genetic screening on familial 
hypercholesterolemia340 and hypertrophic cardiomyopathy respectively.339 The 
latter suggested that the insurance companies’ risk assessment of hypertrophic 
cardiomyopathy mutation carriers is most often correct (95%). However, 5% of mutation 
carriers do encounter potentially unjustified problems at obtaining insurance.339 
Overall one might conclude that genetic discrimination exists. However, research 
on genetic discrimination in the context of omics studies remains absent in literature.337 
But it might be stated that the application of the Act on Medical Examination should 
be monitored, and the public should be informed and educated about the existing 
legislation when participating in genetic testing.337,339
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Recent developments in craniofacial genetics
Craniosynostosis
According to Twigg et al. in 2015,127 57 human genes have been described for which there 
is evidence that mutations are causally related to craniosynostosis (based on at least 
two affected individuals with congruent phenotypes). These genes were divided into 
two broad groups: 1. occurrence of craniosynostosis in >50% of independent mutations 
(“core genes”, 20 in total); 2. occurrence of craniosynostosis in only a minority of cases 
with the mutation.127 The latter group includes many genes that represent perturbations 
in osteogenesis rather than in the biology of cranial suture development per se (such 
as filaminopathy, hypophosphatasia, mucopolysaccharidoses, osteosclerosis, and 
pycnodysostosis).127 During the following years, a further 32 genes were identified that 
cause craniosynostosis (16 in multiple patients and 16 in single patients). An overview of 
these genes is given in Tables 10.1 and 10.2. Most of the genes are involved in previously 
described pathways: Sonic hedgehog pathway, WNT-signalling, NOTCH/EPH pathway, 
the RAS/MAPK pathway, Indian hedgehog, Retinoic acid and/or the STAT3 pathway. 
However, more and more mutations are being identified in genes that are involved 
in brain development or that are shown to be mutated in intellectual disability and/or 
behavioural anomalies. In these cases, craniosynostosis does not occur in all affected 
individuals. 
Mutations have also been identified in genes that were previously shown to be 
pathogenic in mouse models (FUZ, BCL11B) and in SMAD6 (an inhibitor of BMP), with 
striking incomplete penetrance.341 Genotypes of a common variant near BMP2 explain 
nearly all the phenotypic variation in these kindreds.341 This interaction of rare and 
common variants has implications for variant filtering using frequencies. 
The phenotypes associated with these newly identified mutations are less specific 
and some are very rare. This, in combination with the increasing number of potential 
genetic causes, indicates the importance of next generation sequencing. 
Craniofacial clefting
As craniofacial clefts are very rare and aetiologically heterogeneous342 only a subset 
of genetic causes are known, varying from homeobox gene mutations to mutations 
in genes involved in vesicle trafficking. Strikingly, an overlap is seen with the genetic 
causes of craniosynostosis. First EFNB1 was identified to cause CFNS, a phenotype 
comprising of both craniosynostosis and frontonasal dysplasia.63 Recently, localized 
TWIST1 mutations were shown to cause a severe form of frontonasal dysplasia 
(Sweeney-Cox syndrome).142 In contrast, TWIST1 haploinsufficiency is known to cause 
Saethre-Chotzen syndrome.138,139 Both EFNB1 and TWIST1 are involved in the NOTCH/
EPH pathway. Although few genetic causes of craniofacial clefting in humans are 
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known, several mouse models have been described that suffer from severe craniofacial 
clefting. One of these is the brachyrrhine mouse, which exhibits frontonasal dysplasia 
and renal hypoplasia.343 Linkage analysis has mapped the mutation in the brachyrrhine 
mouse to a critical region that contains only one gene, Six2.343 Direct sequencing of the 
gene has not identified any mutations,343 but expression of the gene was reduced.343 
Therefore, it is likely that a regulatory sequence upstream or downstream of the Six2 
gene is involved.343 The identification of a patient with a deletion of the SIX2 gene and 
its surrounding noncoding DNA, exhibiting frontonasal dysplasia344 is further evidence 
that regulatory elements may play a key role in the occurrence of craniofacial clefting, 
and underlining the importance of whole genome sequencing in these disorders (see 
table 10.3 for an overview). 
Facial dysostosis
Recently, Terrazas et al. gave an overview of the aetiology of the most well-known 
facial dysostoses (Treacher Collins syndrome, Acrofacial Dysostosis-Cincinnati type, 
Mandibulofacial Dysostosis with Microcephaly, Nager, and Miller syndrome).345 Many 
other subtypes are known (as reviewed by Wieczorek et al. in 2013).11 Since 2013, new 
genetic causes have been identified, and some subtypes have been shown to be allelic 
(see table 10.4 for an overview). However, the genetic cause of several subtypes remains 
unknown. Lehalle et al. mention that many facial dysostoses are caused by spliceosomal 
defects (hence called spliceosomopathies), whilst others are caused by ribosomal 
dysfunction (ribosomopathies).289 It would be of great interest to further screen the 
genes of these pathways.
Next generation sequencing
For years dideoxy sequencing was the gold standard for genetic testing. More recently, 
whole exome sequencing has been adopted as a standard approach within genetic 
research. Clinical implementation, however, needs robust data and high quality,346 
therefore questions arise about which method should be used in the clinic.  
In particularly, the reduced sensitivity of whole exome sequencing at certain 
regions (especially GC-rich),347 is a major concern.348 The quality of the data depends 
on the sequencing platform used, as well as on the sensitivity of the bioinformatic 
pipeline.349 This has been demonstrated by Gilissen et al. in 2014,143 who reanalysed 
whole exome sequencing parent-patient trios that had been described by De Ligt et 
al. in 2012.350 Using more sensitive analysis pipelines they revealed many additional de 
novo variants.143  
To achieve better capture performance, clinical laboratories have developed 
custom gene panels.346 Recently published studies show that these gene panels are 
generally sequenced much deeper than whole exome sequencing and whole genome 
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sequencing.346 As gene-panels are hypothesis-driven, they can be designed with care 
to provide consistent coverage of the targets if the number of candidates is limited. 
However, as new disease genes are being discovered at a fast pace, gene panels need to 
be updated frequently.351
The major advantage of whole genome sequencing is the possibility identifying 
non-coding pathogenic variations. Whole genome sequencing has the potential to 
detect all types of genomic variants, including structural variants.143 whole genome 
sequencing is also expected to be more powerful for detecting potential disease-causing 
mutations within whole exome sequencing regions 352 as it has a more even coverage, 
no strand bias, and a higher proportion of transcripts covered completely.143,346,349 
However, a comparison of two whole genome sequencing platforms for 56 genes 
concluded that current whole genome sequencing platforms are unable to cover 10-
19% of genes to acceptable standards for SNV discovery.346,353 A comparison of whole 
exome sequencing and whole genome sequencing for variant calling showed that both 
whole exome sequencing as well as whole genome sequencing were unable to identify 
all variants.346,354 Moreover, whole exome sequencing is still considerably cheaper than 
whole genome sequencing and analysis time still seriously limits implementation of 
whole genome sequencing in routine diagnostics.349 Currently, little benefit can be 
expected from the identification of deep-intronic de novo variants since these are still 
very difficult to interpret351 and validate.143 Whole exome sequencing is unlikely to 
miss confident calls made by whole genome sequencing, provided that the position is 
covered by whole exome sequencing.349 For these reasons, whole exome sequencing 
remains the preferred choice for diagnostic laboratories for now. However, with 
sequencing costs further declining and techniques and analysis improving, whole 
genome sequencing has the potential to entirely replace whole exome sequencing.348
Future directions of craniofacial genetics
Multiplex ligation-dependent probe amplification (MLPA)
Using next generation sequencing, we have identified gross rearrangements in TCF12 
causing TCF12-related craniosynostosis. Previous to this, dideoxy sequencing has 
been used to identify mutations in TCF12. Gross rearrangements, however, cannot be 
identified by this sequence technology, but they can be identified using MLPA. Instead 
of preparing an in-house MLPA kit, negotiation with MRC Holland (MRC Holland BV, 
Amsterdam, NL) has been undertaken to develop an MLPA kit for TCF12 including the 
genes ZIC1 and ERF. In this way a certified test can be performed in a diagnostic setting 
both in a prospective and a retrospective way.
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Incidental findings
Patient material used in our whole genome sequencing study was send to us from 
several physicians and/or laboratories situated in several countries. When starting, 
discussions were on-going concerning communicating incidental findings. A consensus 
had not been reached; each country, each university and even each department in 
our own hospital had different views on this subject. Therefore we have chosen not 
to communicate the incidental findings. We plan to offer parents and patients the 
possibility to opt open. In this way, we can test preferences concerning incidental 
findings, as well as meeting the recommendations of the ACMG.336
Next generation sequencing
This thesis has shown that next generation sequencing contributes to genetic testing of 
patients with craniofacial malformations. With whole exome sequencing, all genes are 
tested in a single experiment, increasing the chance of identifying the genetic cause, 
especially if the mutation is located in a gene that otherwise would not have been 
tested (for example in the case of an atypical presentation or rarely associated gene). 
Hence, next generation sequencing increases the efficiency of identifying the genetic 
causes of craniofacial malformations, as it has been shown to do for other rare diseases, 
intellectual disability143 and cardiovascular diseases.434
Moving from gene-specific testing to next generation sequencing can lead to a 
reduction of costs. In patients with syndromic craniosynostosis for example, FGFR2, 
FGFR3 and TWIST1 are routinely screened and an array has been performed routinely. 
By increasing the numbers of genes that are tested, these costs can rise even further. 
Although the costs of massively-parallel sequencing are high (originally US $2.7 billion 
during the Human Genome Project), they are decreasing. Furthermore, the competition 
for the breakthrough leading to the 1000-dollar genome is still on. Therefore, it seems 
cost-effective to switch to next generation sequencing. 
It has been hypothesized that next generation sequencing data can be re-used for 
other diagnostics, for example to test the response to certain medication (prevention 
of severe side effects and avoidance of ineffective therapy),435 to screen for hereditary 
cancer, carrier testing,436 and instead of blood type testing, possibly leading to a cost 
reduction and efficiency gain. Also, stored data can be reused as reference material for 
other indications. However, the increased amount of data produced by next generation 
sequencing leads to higher storage costs, therefore, time will tell if genetic data is stored 
and re-used or if resequencing is performed.
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Whole genome sequencing
As more and more genes are found to be involved in the occurrence of congenital 
craniofacial malformations, and the associated phenotypes become less specific, the 
focus shifts from single-gene tests to multiplex testing of all genes (i.e. next generation 
sequencing). In case of whole genome sequencing, the complete genome is tested. 
To date, we have sequenced (whole genome) 317 DNA samples of patients with 
craniofacial malformations and their family members, comprising one sextet, two 
quintets, eleven quartets, seventy-eight trios, six duos and eleven singletons. Based 
on clinical appearance, samples were expected to be affected or not-affected. Eighty 
probands had craniosynostosis, eleven had a form of craniofacial clefting, two had a 
combination of craniosynostosis and craniofacial clefting, three had facial dysostosis, 
two had another facial phenotype and eleven were sent by another craniofacial centre 
and their exact phenotype was unknown (see table 10.5 for an overview). Appropriate 
genes and, if indicated, metabolic tests were tested with negative results prior to 
sequencing. 
Filtering of the data was based on inheritance pattern, frequency, the predicted 
effect of the mutation and using lists of genes of interest (manually curated lists 
of genes that were mentioned in literature, were associated with a “craniofacial” 
phenotype in the Mouse Genome Database [Mouse Genome Informatics website, The 
Jackson Laboratory, Bar Harbor, Maine, USA] and POSSUMweb database [Pictures of 
Standard Syndromes and Undiagnosed Malformations, Murdoch Children’s Research 
Institute, Royal Children’s Hospital, Melbourne, Australia], that did not have a loss-of-
function mutation in the Exome Variant Server [Exome Variant Server, NHLBI GO Exome 
Sequencing Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/)], as well 
as all genes that had a de novo mutation in DDD). Variants were classified according 
to ACMG guidelines into Benign, likely Benign, variant of unknown significance, Likely 
Pathogenic, and Pathogenic.147 All putatively causative variants were confirmed by an 
independent sequencing technology.
When a previously described mutation was observed it was assumed to be 
pathogenic. If a mutation was observed in a previously described gene with a phenotype 
similar to the proband in question, the phenotype of the patient was re-evaluated for 
the syndrome (like the ANKRD11 mutation). If candidate mutations were found in the 
same gene in more than one case with a similar phenotype, this was suggestive of a 
pathogenic effect. Therefore, all 317 samples were checked for the repeated occurrence 
of mutations in candidate genes. To confirm pathogenicity, candidate genes were 
screened in our patient cohort and an additional cohort in Oxford. If possible, the 
biological consequence of a candidate was validated. 
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Using the above-mentioned gene lists and various filtering techniques we 
identified mutations in 30 out of 109 proband samples. Fourteen mutations were 
identified in “core craniofacial genes” (BMP2/SMAD6, TCF12 deletion (3x), TCF12 (2x), 
ERF (2x), TWIST1, IL11RA (2x), MSX2, ZIC1, TXNL4A), four in genes that were only rarely 
associated with craniosynostosis, craniofacial clefting or facial dysostosis (ANKRD11, 
IDS, KRAS, JAG1) and one known disease gene for which a causal relationship with 
craniosynostosis, craniofacial clefting or facial dysostosis was currently unknown 
(AHDC1). In eight patients, mutations were identified in novel genes (TLK2 (2x), 
BCL11B, PRRX1, LUZP1, FUZ, CDK8, ZFHX4). In three, a chromosomal rearrangement was 
identified (del1p31.3, UPD chromosome 5, del10p13). Hence, our overall success rate 
in identifying pathogenic mutations was 30/109 (27.5%), compared to 37.5% when a 
combined approach (whole exome and whole genome sequencing) was performed on 
samples with craniosynostosis exclusively.4 
Novel causative gene identification
Using next generation sequencing, we have identified a number of interesting candidate 
genes. Currently, validation of these genes is ongoing by using mouse-models and also 
resequencing the genes in patient cohorts. The confirmation of the pathogenicity of 
these genes cannot be established without our close (international) collaborations. 
Also, these collaborations are essential to be able to identify novel genetic causes in the 
unsolved cases where these strategical partnerships offer the possibility to have large 
test and validation cohorts. 
Additional strategies to identify even more novel genetic causes are: 1. identifying 
mosaic causes (mosaicism has been seen in craniofrontonasal syndrome203 and ZIC1-
related craniosynostosis65 for example), 2. searching for complex causes (as shown in 
the SMAD6/BMP2 case341), 3. searching in regulatory elements (as shown by the SIX2 
case344), 4. using pathway analysis to identify other causative genes (as shown by the 
ribosomopathies and spliceosomopathies that underlie many facial dysostoses289), 5. 
studying epigenetic factors (differentially methylated sites have been associated with 
non-syndromic cleft lip and/or palate97 for example).
Best care
A molecular diagnosis has implications for genetic counselling and for clinical 
management. With respect to genetic counselling, an accurate recurrence risk can be 
given. Concerning clinical management, one could think of preventive measures like 
early hearing tests in patients with a P250R mutation in FGFR3 (Muenke syndrome) 
at a younger age. Also, therapy can be adjusted to the genetic diagnosis. Nowadays, 
patients with Muenke syndrome undergo a fronto-orbital advancement, while patients 
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with Apert and Crouzon syndrome undergo occipital remodelling. Moreover, because 
of the mild phenotype of TCF12-related craniosynostosis, an adjusted protocol is used 
in these patients (unpublished data). Hence, personalized medicine seems within reach.
 
Therapy
Due to the prenatal onset, true treatment options remain poor. However, Shukla et 
al. were able to reverse coronal synostosis in mice by intraperitoneal injection of the 
pregnant mother437, Wang et al. ameliorated the associated skin disorder in Beare-
Stevenson mice 438 and the late onset of craniosynostosis in ERF-related craniosynostosis 
seems to provide a therapeutic goal. In mice with Treacher-Collins syndrome, p53-
inhibition 439,440 or dietary supplementation with N-acetylcysteine 441 (an antioxidant) 
substantially ameliorated the phenotype. Additionally, with the introduction of CRISPR/
Cas9, treatment of congenital craniofacial malformations seems within reach.442 
Obviously, designing therapy requires detailed knowledge of the development of the 
head and neck and the involved genetic pathways. Improving this knowledge has been 
the aim of this thesis as it can lead to a future with improved diagnostic and therapeutic 
strategies.
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Summary
In this era of rapidly developing next generation sequencing, the aim of this thesis is to 
study the genetic alterations that cause congenital craniofacial malformations with a 
special emphasis on the use of next generation sequencing.
 
Chapter 1 is an introduction to craniofacial genetics. It describes the subdivision of 
craniofacial malformations in: 
1. Craniosynostosis: the premature fusion of calvarial sutures.
2. Craniofacial clefts: a disturbed bone outgrowth or a fusion defect of various 
embryologic facial prominences.
3. Facial dysostosis: underdevelopment of structures derived from the first and 
second pharyngeal arches.  
To gain a better understanding of these malformations, knowledge of the anatomy 
of the human head and face and its embryological development is essential. The 
embryological development is driven by the genetic code, which is written in DNA. 
Errors in the DNA can occur during mitosis (normal cell division), but also during meiosis 
(the formation of germ cells). These errors can lead to heritable diseases. Until now, most 
of the identified causes of heritable craniofacial malformations are dominant. However, 
more and more causes are identified that are showing a recessive mode of inheritance. 
And even polygenic causes are implied. So besides the current targeted gene specific 
tests, new clever sequencing and analyses techniques are needed that test all genes 
and modes of inheritance at the same time. Next generation sequencing provides the 
answer to this. One of these next generation sequencing techniques is whole genome 
sequencing, offered by Complete Genomics for example, studying the complete human 
genome. Using whole genome sequencing, a huge amount of data is produced that 
need to be filtered cleverly to identify the genetic cause of a craniofacial malformation. 
Knowing the precise molecular diagnosis is essential for genetic counselling, especially 
concerning recurrence risk for the parents and inheritance for the proband. Also, the 
molecular diagnosis has implications for clinical management.
Therefore, the following aims were defined for this thesis:
1. Identify new genetic causes in genes that have been previously associated with 
craniofacial malformations.
2. Use next generation sequencing to identify novel genetic causes in genes that 
have not previously been associated with craniofacial malformations.
3. Study the use of next generation sequencing as a diagnostic tool in patient cohorts.
The first part of this thesis studies genes that have been previously associated with 
craniofacial malformations. We focus predominantly on mutations in FGFR2, a Fibroblast 
Growth Factor Receptor, that cause Crouzon syndrome if mutated. 
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Chapter 2 describes the identification of a novel missense mutation in FGFR2 
(c.812G>T, p.(Gly271Val)) in two individual patients with Crouzon syndrome. The first 
patient had bicoronal and sagittal suture synostosis and exorbitism directly after birth. 
The second patient was first referred at the age of 20 years with mild retrusion of the 
forehead, exorbitism, mild orbital dystopia, and maxillary hypoplasia. No information 
was available regarding the presence of craniosynostosis. In addition, a de novo 
mutation in FGFR2 (c.1851G>C, p.(Leu617Phe)) was described that had been identified 
once before. This mutation occurred in a patient with sagittal suture synostosis, 
bilateral undescended testes, OSA and maxillary hypoplasia. In the same chapter, the 
results of a sequencing study of FGFR2 are described. In 124 patients with syndromic 
craniosynostosis, all coding exons and exon/intron junctions of FGFR2 have been 
analysed. By expanding the analysis, two previously described mutations have been 
identified and four unclassified variants, that are considered non-pathogenic. Hence, 
new mutations are still identified in FGFR2.   
Chapter 3 describes the identification of apparently synonymous variants in FGFR2 
(c.1083A>G, p.(Pro361Pro) and c.1083A>T, p.(Pro361Pro)) in two families. The mutation 
carriers in both families exhibit features of mild Crouzon syndrome. The synonymous 
variants occur at the donor splice site of exon IIIc of FGFR2. Due to these variants the 
use of a cryptic splice site in exon IIIc is expected that leads to an in-frame deletion of 17 
amino acids. Amplification and sequencing of cDNA from the patients shows the use of 
the cryptic splice donor within exon IIIc in the mutant allele and also complete skipping 
of exon IIIc. These results demonstrate that these sequence changes are pathogenic 
mutations.  
In the first part of this thesis we have also focused on EFNB1. It has been 
demonstrated that mutations in this gene cause craniofrontonasal syndrome (CFNS). 
Chapter 4 studies the phenotype of 23 patients with a pathogenic mutation in EFNB1 
by a cross-sectional observational study. Patients with CFNS have consistent features 
like hypertelorism, a certain degree of longitudinal ridging and/or splitting of nails of at 
least one digit or toe, a certain degree of webbed neck and a clinodactyly of one or more 
toes. Also, abnormal facial proportions have been observed in all patients (relatively 
small upper face compared to the width of the face, short nose, and a relatively long 
upper lip).
 
The second part of this thesis studies the identification of novel genetic causes of 
craniofacial malformations using next generation sequencing and describes the 
phenotype of these malformations. 
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Chapter 5 discusses the identification of mutations in TCF12 as a frequent cause 
of coronal craniosynostosis by whole exome sequencing. Dideoxy sequencing of 340 
samples, has led to the identification of another 35 heterozygous mutations. Analysis 
of the phenotype of the index patients shows that mutations predominantly occur in 
patients with coronal synostosis. The clinical features are suggestive of Saethre-Chotzen 
syndrome. And most of the patients have a benign clinical course. Analysis of the family 
members of the index patients has led to the identification of another 35 mutation-
positive individuals. Only 16 of them have craniosynostosis or other suspicious clinical 
features, indicating a substantial non-penetrance. TCF12 encodes a class I E protein that 
heterodimerises with class II basic Helix-Loop-Helix proteins such as TWIST1. Functional 
analysis has shown that TCF12 and TWIST1 act synergistically in a transactivation assay, 
but this effect is lower in the presence of TCF12 missense mutations. Mouse models 
have shown that mice heterozygous for both Tcf12 and Twist1 suffer from severe coronal 
synostosis. This suggests that the total quantity of TCF12/TWIST1 heterodimers plays an 
important role in coronal suture development. So if a patient suffers from coronal suture 
synostosis and gene-specific testing of FGFR3 and TWIST1 is negative, TCF12 should be 
tested.  
TCF12-related craniosynostosis can also be caused by small heterozygous loss-
of-function mutations in TCF12. The identification of large intragenic rearrangements 
causing TCF12-related craniosynostosis is described in Chapter 6. Using whole genome 
sequencing, three large (84.9, 8.6 and 5.4 kb) intragenic exon deletions are identified 
in TCF12. Deletion-specific PCRs have confirmed these deletions. The deletions co-
segregate with the disorder and non-penetrance has been shown (as has been described 
in chapter 5). One of the deletions lies 3’ of the region that encodes the bHLH domain. 
cDNA analysis of this deletion indicates skipping of exon 20. This patient is the first 
patient described with increased intracranial pressure and synostosis of all vault sutures 
(except for the metopic suture). In parallel, a heterozygous tandem duplication (11.3 kb) 
has been identified that includes exons 19 and 20 of TCF12. Analysis of the cDNA reveals 
two relatively weak fragments, indicating splicing from exon 20 to the duplicated exon 
19 in one fragment and an additional neo-exon in the other. Analysis of the normal 
sequences of the rearrangements indicates nonhomologous end joining as the most 
likely cause. Since 4 of 108 (3.7%) individuals with coronal synostosis and previously 
negative genetic testing have deletions in TCF12, screening for larger rearrangements 
in TCF12 seems essential, if TCF12-related craniosynostosis is suspected. 
Chapter 7 discusses the identification with next generation sequencing of five 
gain-of-function mutations in ZIC1 that are associated with coronal craniosynostosis 
and learning disabilities. All mutations identified in ZIC1 are located in the highly 
conserved C-terminus of the protein. Four nonsense mutations have arisen de novo 
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(post-zygotically in one case) and one missense mutation has been identified in a family 
consisting of six affected individuals in three generations. Analysis of the phenotype 
shows bicoronal synostosis with severe brachycephaly, sometimes lambdoid synostosis, 
and mild to severe learning disabilities. Also, progressive scoliosis is seen. CT and MRI 
brain scans show agenesis of the corpus callosum, dilated lateral ventricles, peaked 
tentorium, hypoplastic pons, cerebellum with prominent cerebellar folia and enlarged 
foramen magnum. Functional analysis of ZIC1 indicates escape from nonsense-mediated 
decay and suggests a gain-of-function mechanism. Also, the function of Xenopus zic1 
has been studied by injecting several truncated constructs, leading to disrupted en-2 
expression. Using in situ hybridisation, a transient zone of Zic1 expression is identified 
in the supraorbital region that overlap with En1. This indicates an early instructive role 
for Zic1 in the supraorbital regulatory centre that constitutes the zone from which cells 
migrate and populate the coronal suture. Combining these results, it seems likely that 
the coronal synostosis phenotype might be attributable to alteration of EN1 expression 
in the supraorbital regulatory centre. If coronal suture synostosis in combination with 
learning disabilities is seen, ZIC1 should be tested. 
Lastly, chapter 8 focuses on the identification by whole genome sequencing of 
mutations in TXNL4A as a cause of Burn-McKeown syndrome (BMKS) and choanal atresia. 
A patient with clinical features of BMKS and her parents have been analysed by whole 
genome sequencing, identifying a splice-site mutation and a 34 base pair promoter 
deletion in TXNL4A. Analysis of the cDNA indicates that the allele carrying the splice-
site mutation is not expressed, while the expression of the allele carrying the promoter 
deletion has been reduced. Dideoxy-sequence analysis of a cohort of 19 patients with 
clinical features of BMKS and 17 patients with isolated choanal atresia identified the 
same splice-site mutation and promoter deletion in a patient with BMKS. Additionally, 
a homozygous promoter deletion has been identified in a patient with isolated choanal 
atresia and another homozygous promoter deletion has been identified in two cousins 
with BMKS. This demonstrates the importance of screening for mutations in TXNL4A in 
patients with (mild) clinical features of BMKS.
 
The third part of this thesis studies the use of next generation sequencing as a diagnostic 
tool in patient cohorts. 
Chapter 9 describes the use of next generation sequencing (both exome and 
whole genome sequencing) in craniosynostosis. Subjects with craniosynostosis have 
been enrolled where previous molecular genetic testing has been negative. A total of 
40 cases and, if available, parental samples, have been enrolled. Thirty-seven samples 
have been exome sequenced and 3 samples by whole genome sequencing. Data have 
been analysed based on all likely modes of inheritance and for variants in 57 genes 
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recurrently mutated in craniosynostosis. Variants have been confirmed by dideoxy 
sequencing. Mutations have been identified in 15 of the 40 cases (37.5%); 13 mutations 
in confirmed disease genes and at least two in novel disease-associated genes. Many 
of the mutations are found in genes that are rarely associated with craniosynostosis. 
In some of these cases, achieving a precise molecular diagnosis has had immediate 
implications for genetic counselling and for clinical management.  
Therefore, it seems worthwhile to apply next generation sequencing. As shown 
by the findings of mutations in at least two likely novel craniosynostosis-genes, an 
additional benefit of this strategy is that new disease loci may be identified.
 
Taking these findings together we may conclude that: 
1. Novel mutations are still found in genes known to be associated with craniofacial 
malformations.
2. Using next generation sequencing, more genes are associated with craniofacial 
malformations.
3. The use of next generation sequencing is appropriate not only in genetic research 
but also as a diagnostic tool.
Improving the knowledge concerning craniofacial genetics can lead to a future with 
improved diagnostic and therapeutic strategies.
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Nu next generation sequencing zich heel snel ontwikkelt, is het doel van dit proefschrift 
om de genetische oorzaken van aangeboren schedel- en aangezichtsafwijkingen verder 
te onderzoeken en dan in het bijzonder door middel van next generation sequencing.
Hoofdstuk 1 geeft een introductie in de craniofaciale genetica. Het beschrijft de 
onderverdeling van aangeboren schedel- en aangezichtsafwijkingen in: 
1. Craniosynostose: het te vroeg sluiten van de schedelnaden.
2. Schedel- en aangezichtsspleten (clefts): waarbij sprake is van bijvoorbeeld een 
verstoorde bot uitgroei of een mislukte fusie van verschillende embryologische 
prominentia.
3. En faciale dysostose: waarbij sprake is van een onderontwikkeling van de structuren 
die hun oorsprong vinden in de eerste en tweede kieuwboog. 
Om een beter begrip te krijgen van deze aandoeningen, is kennis van de normale 
anatomie en de embryologische ontwikkeling van het hoofd en aangezicht essentieel. 
De embryologische ontwikkeling wordt aangestuurd door DNA. Foutjes in het 
DNA kunnen ontstaan tijdens de mitose (de normale celdeling), maar ook tijdens 
de meiose (de vorming van kiemcellen). Deze foutjes kunnen leiden tot erfelijke 
aandoeningen. Tot nu toe zijn de meeste geïdentificeerde oorzaken van schedel- en 
aangezichtsaandoeningen dominant, echter meer en meer worden ook recessief 
overervende oorzaken geïdentificeerd en er wordt zelfs gespeculeerd over polygene 
oorzaken. Dus naast de huidige gen specifieke diagnostiek, waarbij slechts 1 gen per 
test wordt onderzocht, zijn sequencing en analyse technieken nodig, die alle genen en 
overervingsmanieren in 1 keer kunnen testen. Met next generation sequencing kan dit. 
Een van deze next generation sequencing technieken is whole genome sequencing, 
een techniek waarbij het gehele genoom wordt onderzocht in 1 test. Deze techniek 
wordt onder andere aangeboden door Complete Genomics. Door middel van whole 
genome sequencing worden grote hoeveelheden data geproduceerd die op een 
slimme manier gefilterd moeten worden om de genetische oorzaak van bijvoorbeeld 
schedel- en aangezichtsaandoeningen te kunnen identificeren. 
Als de exacte moleculaire oorzaak bekend is, kunnen patiënten beter gecounseld 
worden, vooral over het herhalingsrisico voor de ouders en de erfelijkheid voor de 
patiënt. Ook kan de moleculaire diagnose gevolgen hebben voor de behandeling. 
De volgende doelen zijn gesteld voor dit proefschrift:
1. Identificeren van nieuwe genetische oorzaken in genen die eerder al geassocieerd 
zijn met schedel- en aangezichtsaandoeningen.
2. Door middel van next generation sequencing nieuwe genetische oorzaken 
identificeren in genen die nog niet geassocieerd zijn met schedel- en 
aangezichtsaandoeningen.
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3. Het gebruik van next generation sequencing voor de genetische diagnostiek van 
schedel- en aangezichtsaandoeningen bestuderen in een patiënten cohort.
Het eerste gedeelte van dit proefschrift gaat over genen die eerder al geassocieerd 
zijn met aangeboren schedel- en aangezichtsafwijkingen. We focussen met name op 
mutaties in FGFR2, een Fibroblast Growth Factor Receptor. Indien hier een mutatie in 
optreedt, kan het klinisch beeld van Crouzon syndroom ontstaan. 
Hoofdstuk 2 beschrijft de identificatie van een nieuwe missense mutatie in 
FGFR2 (c.812G>T, p.(Gly271Val)) in twee patiënten met Crouzon syndroom die geen 
familie van elkaar zijn. De eerste patiënt heeft sinds zijn geboorte synostose van beide 
coronanaden, synostose van de sagittaal naad en exorbitisme. De tweede patiënt is 
pas op latere leeftijd doorverwezen (20 jaar) met milde retrusie van het voorhoofd, 
exorbitisme, milde orbitale dystopie en hypoplasie van de maxilla. Het is onduidelijk of 
eerder sprake is geweest van craniosynostose. Daarnaast wordt een de novo mutatie in 
FGFR2 (c.1851G>C, p.(Leu617Phe)) beschreven die 1 keer eerder is aangetoond. Deze 
mutatie komt voor bij een patiënt met synostose van de sagittaal naad, niet-ingedaalde 
testes, OSAS en hypoplasie van de maxilla. In hetzelfde hoofdstuk, worden de resultaten 
gepresenteerd van een sequencing studie van FGFR2 waarbij alle coderende exonen en 
ook de exon/intron overgangen worden geanalyseerd in het DNA van 124 patiënten 
met syndromale craniosynostose. Door deze uitbreiding van de analyse, zijn twee 
mutaties gevonden en vier (niet-pathogene) unclassified variants. Kortom, er worden 
nog steeds nieuwe mutaties geïdentificeerd in FGFR2. 
Hoofdstuk 3 beschrijft de identificatie van twee ogenschijnlijk synonieme 
varianten in FGFR2 (c.1083A>G, p.(Pro361Pro) en c.1083A>T, p.(Pro361Pro)) in patiënten 
met milde kenmerken van Crouzon syndroom. De varianten liggen ter plaatse van 
de donor splice site van exon IIIc van FGFR2. Door analyse van het cDNA van de twee 
patiënten wordt aangetoond dat het gehele exon IIIc wordt overgeslagen (exon 
skipping), wat aannemelijk maakt dat deze varianten de pathogene mutaties zijn.
Naast FGFR2 kijken we in het eerste deel van dit proefschrift ook naar EFNB1. 
Eerder is aangetoond dat mutaties in dit gen kunnen leiden tot het craniofrontonasaal 
syndroom (CFNS). Hoofdstuk 4 bestudeert het fenotype van 23 patiënten met een 
pathogene mutatie in EFNB1 door middel van een cross-sectioneel observationeel 
onderzoek. Patiënten met CFNS kunnen kenmerken vertonen zoals hypertelorisme, 
longitudinale ribbels op de nagels of zelfs gespleten nagels van minstens 1 vinger of 
teen, enige webbing van de nek en clinodactylie van 1 of meer tenen. Daarnaast blijken 
de proporties van het aangezicht afwijkend in alle patiënten (waarbij het bovenste deel 
van het gezicht relatief klein is in vergelijking met de breedte van het gezicht, de neus 
korter is en er een relatief lange bovenlip bestaat).
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Het tweede deel van dit proefschrift beschrijft de identificatie door middel van 
next generation sequencing van nieuwe genetische oorzaken van schedel- en 
aangezichtsafwijkingen en het fenotype van deze aandoeningen. 
Hoofdstuk 5 beschrijft de ontdekking, door middel van whole exome sequencing, 
van mutaties in TCF12 als een frequente oorzaak van synostose van de corona naden. 
Door daarna dideoxy sequencing van TCF12 te verrichten op 340 andere DNA monsters 
zijn nog eens 35 mutaties in TCF12 gevonden. Analyse van het fenotype van de index 
patiënten toont aan dat er vooral sprake is van synostose van de corona naden. De 
klinische kenmerken lijken enigszins op Saethre-Chotzen syndroom. Verder hebben 
de meeste patiënten een redelijk goede kliniek. Analyse van de familieleden van de 
index patiënten heeft geleid tot de identificatie van nog eens 35 mutatie-positieve 
personen. Slechts 16 van hen hebben craniosynostose of andere verdachte kenmerken, 
wat verminderde penetrantie aannemelijk maakt. TCF12 codeert voor een klasse 
I E eiwit dat heterodimeren vormt met klasse II basic Helix-Loop-Helix eiwitten zoals 
TWIST1. Een transactivatie assay toont dat TCF12 en TWIST1 synergistisch werken, maar 
dat dit synergistische effect lager is wanneer er missense mutaties zitten in TCF12. Een 
muizenmodel toont aan dat muizen die zowel heterozygoot zijn voor een mutatie 
in Tcf12 als in Twist1 ernstige coronale synostose hebben. Dit alles suggereert dat de 
totale hoeveelheid heterodimeren van TCF12/TWIST1 een belangrijke rol speelt in de 
ontwikkeling van coronale synostose. Als een patiënt coronale synostose heeft en gen-
specifieke testen voor mutaties in FGFR3 en TWIST1 negatief zijn, dan moet TCF12 getest 
worden. 
Waar in hoofdstuk 5 wordt beschreven dat TCF12-gerelateerde craniosynostose 
veroorzaakt kan worden door kleine heterozygote loss-of-function mutaties in TCF12, 
wordt in hoofdstuk 6 de identificatie van grote rearrangements in het TCF12-gen als 
oorzaak van TCF12-gerelateerde craniosynostose beschreven. Door middel van whole 
genome sequencing zijn drie grote intragene exon deleties gevonden (84.9, 8.6 en 5.4 
KB). De deleties zijn bevestigd door middel van deletie-specifieke PCRs. De deleties co-
segregeren met de aandoening, terwijl verminderde penetrantie ook wordt gezien (net 
als in hoofdstuk 5). Een van de deleties ligt 3’ van de regio die codeert voor het bHLH 
domein. cDNA analyse toont aan dat deze deletie skipping van exon 20 veroorzaakt. De 
patiënt met deze deletie is de eerste patiënt met TCF12-gerelateerde craniosynostose 
en verhoogde intracraniële druk en synostose van alle schedelnaden (behoudens 
de metopica naad). Tevens wordt een heterozygote tandem duplicatie (11.3 KB) 
beschreven die zowel exon 19 als 20 dupliceert. cDNA analyse toont twee relatief zwakke 
fragmenten, wat doet suggereert dat zowel sprake is van splicing van exon 20 naar het 
gedupliceerde exon 19 en dat het andere fragment bestaat uit een neo-exon. Analyse 
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van de sequenties van de rearrangements doet vermoeden dat nonhomologous end 
joining de meest waarschijnlijke oorzaak is. Aangezien 4 van de 108 (3.7%) personen 
met coronale synostose en negatieve gen-specifieke testen, deleties hebben in TCF12, 
lijkt screening voor grote rearrangements in TCF12 essentieel, wanneer gedacht wordt 
aan TCF12-gerelateerde craniosynostose. 
Hoofdstuk 7 beschrijft de identificatie door middel van next generation 
sequencing van vijf mutaties in ZIC1 die geassocieerd zijn met corona naad synostose 
en leerproblemen. Alle mutaties bevinden zich in het zeer geconserveerde C-terminus 
van het eiwit. Vier nonsense mutaties zijn de novo en 1 missense mutatie komt voor in 
een familie van zes aangedane personen in drie generaties. Analyse van het fenotype 
toont synostose van de corona naden met ernstige brachycephalie, soms is er tevens 
sprake van synostose van de lambdoid naden en patiënten kunnen milde tot ernstige 
leerproblemen hebben. Ook wordt progressieve scoliose gezien. Op de CT en MRI 
hersenscans wordt agenesie van het corpus callosum gezien, gedilateerde zijventrikels, 
een hoger en piekend tentorium, een hypoplastische pons, een cerebellum met 
prominente cerebellaire folia en een verwijd foramen magnum. Functionele analyse 
van ZIC1 impliceert dat er geen nonsense mediated decay optreedt en dat er sprake 
is van een gain-of-function mechanisme. De functie van Xenopus zic1 is bestudeerd 
door middel van het injecteren van verschillende getrunceerde constructen, waardoor 
en-2 expressie wordt verstoord. Door middel van in situ hybridisatie, wordt in de 
supra orbitale regio overlap gezien van de gebieden waar Zic1 en En1 tot expressie 
komen. Dit suggereert een rol voor Zic1 tijdens de vroege ontwikkeling in het supra 
orbitale regulatie centrum van waaruit de cellen migreren die uiteindelijk de corona 
naden bevolken. Deze resultaten tezamen impliceren dat de synostose van de corona 
naden mogelijk toe te schrijven is aan een verandering in de expressie van EN1 in het 
supra orbitale regulatie centrum. Bij patiënten met synostose van de corona naden en 
leerproblemen dient getest te worden voor mutaties in ZIC1.   
Het laatste hoofdstuk van dit deel, hoofdstuk 8, beschrijft de vondst van mutaties 
in TXNL4A als een oorzaak van Burn-McKeown syndroom (BMKS) en choanen atresie. 
Het DNA van een patiënte met klinische kenmerken van BMKS en dat van haar ouders 
is geanalyseerd middels whole genome sequencing. Zodoende zijn een splice site 
mutatie en een promoter deletie van 34 basenparen in TXNL4A ontdekt. Analyse van 
het cDNA toont dat het allel met de splice site mutatie niet tot expressie komt en dat de 
expressie van het allel met de promoter deletie verminderd is. Door middel van dideoxy 
sequencing van een cohort van 19 patiënten met klinische kenmerken van BMKS en 17 
patiënten met geïsoleerde choanen atresie zijn dezelfde splice site mutatie en promoter 
deletie gevonden in een patiënt met BMKS. Tevens, is een homozygote promoter deletie 
gevonden in een patiënt met geïsoleerde choanen atresie en een andere homozygote 
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promoter deletie in het DNA van een neef en een nicht met milde kenmerken van 
BMKS. Deze bevindingen tonen aan dat het belangrijk is om te screenen voor mutaties 
in TXNL4A in patiënten met (milde) klinische kenmerken van BMKS.
 
Het derde deel van dit proefschrift beschrijft het gebruik van next generation sequencing 
in de genetische diagnostiek van patiënten met schedel- en aangezichtsaandoeningen. 
In hoofdstuk 9 wordt het gebruik van next generation sequencing beschreven 
(zowel exome sequencing als whole genome sequencing) bij patiënten met 
craniosynostose en negatieve gen-specifieke testen. In totaal is het DNA van 40 patiënten 
geïncludeerd en, indien beschikbaar, ook het DNA van hun ouders. Zevenendertig 
monsters zijn gesequenced middels exome sequencing en drie middels whole genome 
sequencing. De data zijn geanalyseerd voor alle mogelijke overervingspatronen en 
voor varianten in de 57 bekende craniosynostose genen. De gevonden varianten zijn 
bevestigd met dideoxy sequencing. Er zijn mutaties gevonden in 15 van de 40 index 
patiënten (37,5%); 13 mutaties zijn gevonden in bekende genen en ten minste twee 
mutaties zijn gevonden in nieuwe genen. Veel van de mutaties zijn gevonden in genen 
die slechts af en toe geassocieerd zijn met craniosynostose. In enkele gevallen, heeft 
de ontdekking van de exacte moleculaire diagnose consequenties gehad voor de 
genetische counseling en de behandeling. Al met al lijkt het zeker de moeite waard om 
next generation sequencing in te zetten. Een bijkomend voordeel van next generation 
sequencing is dat er ook nieuwe craniosynostose genen gevonden kunnen worden.
Samenvattend kan gesteld worden dat:
1. Er nog steeds nieuwe mutaties worden gevonden in genen die reeds geassocieerd 
zijn met schedel- en aangezichtsaandoeningen.
2. Er door middel van next generation sequencing, steeds meer genetische oorzaken 
van schedel- en aangezichtsaandoeningen worden gevonden.
3. En dat next generation sequencing geschikt is voor zowel genetisch onderzoek als 
voor de genetische diagnostiek.
Meer inzicht in de craniofaciale genetica kan leiden tot een gouden toekomst met 
verbeterde diagnostiek en daarmee ook verbeterde behandelmogelijkheden.
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Supplementary Figure 2.1. Sequence electropherogram of Patient 1. A: normal sequence. B: 
mutated sequence.
Supplementary Figures
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Supplementary Figure 2 Selected cDNA studies on subjects heterozygous for TCF12 mutations. 
(a) Family #22 (c.1468-20T>A). At the top are shown the normal splice junctions between exons 16 
and 17 of TCF12 (exon sequence is in upper case and intron sequence in lower case). The T>A 
point mutation (shown in red in sequence at bottom) lies within the intron, 20 nucleotides upstream 
Nature Genetics: doi: 10.1038/ng.253114845-goos-layout.indd   256 13/11/2017   19:20
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Supplementary Figure 5.2. Selected cDNA studies on subjects heterozygous for 
TCF12 mutations. A: family #22 (c.1468-20T>A). At the top are shown the normal splice 
junctions between exons 16 and 17 of TCF12 (exon sequence is in upper case and intron 
sequence in lower case). The T>A point mutation (shown in red in sequence at bottom) 
lies within the intron, 20 nucleotides upstream of the normal acceptor splice site: this is 
predicted to create a cryptic acceptor with a higher score (0.99) than the normal acceptor 
(0.96) using the Splice Site Prediction by Neural Network program (www.fruitfly.org/
seq_tools/splice.html). The use of the cryptic site was confirmed by cDNA sequencing 
(using primers in exons 16 and 18/19), demonstrating a low level of the neo-exon (dotted 
box) which contains a premature stop codon (underlined in the intron sequence). 
B: family #5 (c.822C>G). This substitution creates a synonymous change and locates 4 
nucleotides before the end of exon 9 (vertical red dotted line). The normal exon 9 donor 
site is unusually weak (score 0.09 using Splice Site Prediction by Neural Network), and 
the score is little changed by the substitution (score 0.06). However sequencing of cDNA 
generated by primers in exons 9 and 11 showed that the mutant allele is virtually absent 
from the normal cDNA (arrow), this was confirmed by restriction digestion using SmlI, 
which cuts only the wild type allele, showing only a small proportion of undigested 
product in the patient sample (U, uncut; II-1, patient; C, normal control). 
C: family #19 (c.1349delC). This mutation creates a frameshift within exon 16. The gel 
shows the result of digestion of the exon 13/14-18 cDNA product with restriction 
enzyme Cac8I, which cuts only the wild type allele at the site of mutation. Note the lower 
amount of mutant (white arrowhead) compared with wild type (white arrow) fragment, 
suggesting that the mutant transcript is unstable; also note the similar proportions of 
mutant allele in the affected child III-1 and his unaffected mother II-1. C = control, U = 
uncut. 
D: family #1 (c.526+1G>A). This mutation disrupts the highly conserved first intronic 
nucleotide following exon 7, and is therefore predicted to abolish splicing at this site. 
This is the only mutation occurring upstream of the alternatively transcribed exon 9A, so 
we wished to establish its effect on splicing. When using primers located in exons 5 and 
9/10 for cDNA amplification, a low level of an additional smaller fragment was present 
in samples from the 3 mutation carriers in this family (left panel: I-1 and II-2, blood; III-
1, fibroblasts), but not in a normal fibroblast control (C); N = negative water control. 
DNA sequencing of this smaller fragment (right panel) demonstrated that it results from 
skipping of exon 7, predicted to create an out-of-frame translation product. 
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Supplementary Figure 3 Relative prevalence of mutations in TCF12 and other genetic diagnoses 
in craniosynostosis. The dataset comprizes all children (n = 402) born in the period 1998-2006, 
managed at a single craniofacial unit (Oxford), and requiring at least one major craniofacial 
procedure. Ninety-eight children had a proven genetic diagnosis, including four with TCF12
mutations.
All other cases 
(76%)
FGFR2 (28%)
FGFR3
(19%)
TWIST1
(16%)
Chromosomal (13%)
Other 
(10%)
ERF
(5%)
EFNB1
(4%)
TCF12 (4%)
Proven genetic 
(24%)
Nature Genetics: doi: 10.1038/ng.2531
Supplementary Figure 5.3. Relative prevalence of mutations in TCF12 and other genetic 
diagnoses in craniosynostosis. The dataset comprises all children (n = 402) born in the period 
1998-2006, managed at a single craniofacial unit (Oxford), and requiring at least one major 
cra iofacial procedur . N n ty- ight children h d a proven genetic iagnosis, inclu in  f ur with 
TCF12 mutations.
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Supplementary Figure 4 Structural and functional analysis of missense mutations in the 
bHLH domain of TCF12. (a) Comparative amino acid sequence analysis of the bHLH 
domains of the three human class I proteins (TCF12, TCF4 and TCF3; the latter is 
frequently termed E2A with E12/E47 alternative spliceforms), the unique homologs in 
Drosophila melanogaster (Da- daughterless) and Caenorhabditis elegans (HLH-2), and 
Nature Genetics: doi: 10.1038/ng.2531
Supplementary Figure 5.4. Structural and functional analysis of missense mutations in the 
bHLH domain of TCF12. A: comparative amino acid sequence analysis of the bHLH domains 
of the three human class I proteins (TCF12, TCF4 and TCF3; the latter is frequently termed E2A 
with E12/E47 alt rnative splicef rms), the unique homologs in Drosophila melanogaster (Da-
daughterless) and Caenorhabditis elegans (HLH-2), and human class II proteins TWIST1 and 
NEUROD1. The two missense mutations observed in TCF12 (p.Leu624Pro and p.Gln638Glu) are 
indicated in red. B: structure of a bHLH class I/II heterodimer (murine E47/NeuroD1) bound to 
DNA, visualized in Protein Workshop (PDB accession no. 2QL2). The side chains of the residues 
corresponding to p.Leu624 and p.Gln638, both of which are conserved between TCF12 and Tcf3, 
are highlighted. Substitutions at these buried residues are predicted to abrogate dimerization. 
C: analysis of transactivation with 1 μg of TCF12 and/or TWIST1 wild-type or mutant proteins as 
shown, using reporters either including (+) or omitting (-) three E-box DNA-binding motifs. Results 
are shown as mean±SEM of 3 experiments and normalized to the output from transfecting both 
TCF12 and TWIST1 with the E-box reporter. 
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Supplementary Table 2.1 Primers and methods used for sequencing all coding exons 
and exon/intron junctions of FGFR2. Accession number reference sequence used is 
NM_000141.4. 
Amplicon
5’ → 3’ Product size 
(bp)Forward primer Reverse primer
Exon03B CACTTGGGCTGGAGTGATTT AGCCCCATTTACAATGCAAG 428
Exon04 CCATTTGCAGAGCAAGAACA GCCTGGCATCCAATTACAA 495
Exon05 CCTGGGTTGTTGACTTTGCT CTGTGCAGCAACACTGGTTT 361
Exon06 TTACTCATGGAGGGGAAGCTGT AAAAATGTAGGGCTGGGCATC 590
Exon07 TTCTTGCCTCCTTCAGCTTC TTGGGGAAATGATGCTTCTC 596
Exon08 AGGCTTTTCTGGCATGAGGT CCTCTCTCAACTCCAACAGGA 393
Exon10 TCAGTGTTGCTCCGTGTCTC AAAAGGGGCCATTTCTGATAA 413
Exon11B GCCTTTTGGTTCCTTTGGTT GAAGTCGATGGCATCAAAGC 392
Exon12 GTTTCTGACTTCTGCCAGCC CCTGCTGACATCATCACACC 402
Exon13 AGCCGTTCCACCAGTAATTG ACCGAAAACTTCTCAACCCC 467
Exon14 TGTTTCAACTAAGTCTTTGGCAAC GTGCTCTGGGAGCAGGATCT 296
Exon15 AAAAATGTTTTGCTGAATTGC CGAGGGCTTGATCTAGCAAA 368
Exon16 CCGGCCACACTGTATTTCTT TCTCAACATTGACGGCCTTT 357
Exon17 CAGCTCTTAAACAGGGCATAGC GCCACTAAAGAAGGAAGAAAGG 247
Exon18 ATCCCCGTGTCATCATCATT CCAGAGAGCTTCAGCCATTC 459
Exon19 AAGTCAAAGTGCCTTTCGGA GGGGATGTCCCTCTGTCTTT 530
Exon21A AGCGGGTTATTTAGGTCCGT TCCACTGCTCCAGAAACCTT 759
 Methods Primers were developed for Sanger sequence analysis. PCR amplification was carried out in 
a total volume of 25 µl, containing 10x PCR buffer (Invitrogen, Life Technologies Ltd, Paisley, 
UK), 50 mM MgCl2 (Invitrogen), 100 mM dNTP, 10 µM forward primer, 10 µM reverse primer, 
Platinum Taq DNA polymerase (Invitrogen), 100 ng genomic DNA. (Exon 03B 20 µM forward 
primer and 20 µM reverse primer.) PCR conditions were: 94°C for 2 min; followed by 30 cycles 
of 30 s at 94°C, 30 s at 60°C and 90 s at 72°C; followed by 10 min at 72°C, and 5 min at 20°C. 
PCR products were purified using Agencourt AMPure (Agencourt. Beckman Coulter Inc., 
Brea, CA, USA). Direct sequencing of both strands was performed using Big Dye terminator 
version 3.1 (Applied Biosystems, Foster City, CA, USA). Dye terminators were removed using 
Agencourt CleanSeQ (Agencourt) and loaded on an ABI 3130XL Genetic Analyzer (Applied 
Biosystems). The sequences were analysed using SeqPilot version 4.1.2 build 507 (JSI Medical 
Systems Gmbh, Kippenheim, Germany).
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Supplementary Table 5.6. Antibodies used for immune function tests. 
Commercial source and catalogue number
Antibody BD Bioscience eBioscience Cambridge Bioscience
CD3 APC 555335
CD3 FITC 555332
CD3 PE-Cy5 555334
CD3 PE-Cy7 557851
CD4 APC 555349
CD4 FITC 555346
CD4 PE-Cy5 555348
CD19 APC-Cy7 557791
CD14 APC 555399 17-0149-73
CCR7 FITC 561675
CD45RO PE-Cy5 555494
CD62 APC 561916
CD62L APC-Cy7 304813
CD16 PE 555407
CD56 PE 555514
CD56 PE-Cy7 557747
CD25 APC-Cy7 557753
IgD FITC 555778
IgM PECy5 551079
CD10 FITC 347503
CD27 PE 555441
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NVPC spring meeting 2012 0.2
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NVPC autumn meeting 2011 0.2
NVSCA 2011
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2. Teaching activities
Lecturing Year ECTS
Anatomy of the upper extremities 2012-2015 0.5
Microsurgery 2012-2015 3.5
Dysmorphology 2012-2014 1
Tendon repair 2013 0.1
Macroscopic suture techniques 2012 0.1
Supervision of students Year ECTS
Supervision master thesis M. van Pelt 2015 3
Supervision (tutor) of freshmen Medical School 2014 1
Supervision minor students 2013 1
3. Organizing activities
Conferences and meetings Year ECTS
Autumn meeting NVSCA 2014 2
Esser Course “To the base of the thumb” 2012-2013 2
Administrative activities Year ECTS
General board member Promeras (PhD association Erasmus University Medical 
Centre)
2011-2014 2
Author of the booklet “Starting your PhD at Erasmus MC” 2
General board member PNN (Dutch PhD association) 2012-2014 2
General board member EPAR (PhD association Erasmus University) 2011-2013 1
* In case the seminar, workshop or conference was visited without presenting a paper, ECTS are given in this 
table
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